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1.1 Calcium: a universal, intracellular second messenger
Calcium (Ca2+) is a highly versatile intracellular signal that can regulate many different cel-
lular functions like cell growth and differentiation, gene expression, apoptosis and necrosis, 
cell motility and muscle contraction (Berridge, 1993; Berridge et al., 2000; Carafoli et al., 
2001). To achieve this versatility, the Ca2+-signalling system operates in many different ways 
to regulate cellular processes (Fig. 1.1, (Berridge et al., 2003)). Changes in Ca2+ levels can 
occur in microseconds or hours such as in gene transcription or cell proliferation. The level 
of intracellular Ca2+ is determined by a balance between the on reactions that introduce Ca2+ 
into the cytoplasm and the off reactions through which the Ca2+-signal is removed by the 
combined action of buffers, pumps and exchangers (Fig. 1.1). 
Figure 1.1: Ca2+-signalling dynamics and homeostasis. During the on reactions, stimuli induce both the 
entry of external Ca2+ and the formation of second messengers that release internal Ca2+ that is stored within 
the endoplasmic reticulum (ER/SR). Most of this Ca2+ (shown as red circles) is bound to buffer, whereas a 
small proportion binds to the effectors that activate various cellular processes that operate over a wide tem-
poral spectrum. During the off reactions, Ca2+ leaves the effectors and buffers and is removed from the cell 
by various exchangers and pumps. The Na+/Ca2+ exchanger (NCX) and the plasma-membrane Ca2+-ATPase 
(PMCA) extrude Ca2+ to the outside, whereas the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps 
back into the ER. Mitochondria also have an active function during the recovery process in that they sequester 
Ca2+rapidly through a uniporter, and this then released more slowly back into the cytosol to be dealt with by the 
SERCA and the PMCA. Ins(1,4,5)P3R, inositol-1,4,5-triphosphate receptor; RYR, ryanodine receptor. From 
Berridge et al., 2003.
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During the on reaction, a small proportion of the Ca2+ binds to different effectors that are 
responsible for stimulating numerous Ca2+-dependent processes (Fig. 1.1). 
The Ca2+-binding sites of the majority of proteins involved in transducing Ca2+-signals have 
a structural motif in common, a lelix-loop-helix, termed the EF-hand. The term EF-hand 
motif was introduced by Kretzinger and is based on the first three-dimensional structure 
of parvalbumin, the founding member of this family (Kretsinger and Nockolds, 1973). EF-
hand proteins exhibit both high selectivity for Ca2+ and the ability to respond rapidly and 
efficiently to modest (hundred-fold) changes in Ca2+ concentration. Part of the EF-hand pro-
tein members, for example parvalbumin, act intracellulary as so called Ca2+-buffer proteins 
whereas other family members act as so called Ca2+-sensor proteins. Prominent examples for 
the latter are the S100 proteins (Donato, 1999; Nelson and Chazin, 1998). This  diversity in 
function for a single family of proteins is intriguing and has prompted to further studies.
1.2 Cardiac excitation-contraction coupling
Cardiac excitation-contraction coupling represents the process from electrical excitation of 
the myocyte to contraction of the heart. The ubiquitous second messenger Ca2+ plays essenti-
al role in cardiac electrical activity and is a direct activator of the myofilaments which cause 
contraction. During the cardiac action potential, Ca2+ enters the cell through depolarization-
activated Ca2+-channels (L-Type voltage-operated channels). This inward Ca2+ current (ICa), 
contributes to the action potential plateau (Fig 1.2 (Bers, 2002)). Ca2+ entry in term,  triggers 
Ca2+-release from the sarcoplasmic reticulum (SR). This process is commonly known as 
Ca2+-induced Ca2+-release process, CICR (Roderick et al., 2003). 
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Figure 1.2: Ca2+transport in ventricular myocytes. Inset shows the time course of an action potential (AP, 
black), Ca2+-transient (blue) and contraction (red) measured in rabbit ventricular myocyte at 37°C. NCX, Na+/
Ca2+-exchanger; ATP, ATPase; PLB, phospholamban; SR, sarcoplasmic reticulum. From Bers, 2002.
The combination of Ca2+ influx and release from the SR raises the free intracellular Ca2+ con-
centration ([Ca2+]
i
), allowing Ca2+ to bind to the myofilament protein troponin C, which then 
switches on the contractile machinery.  For relaxation to occur [Ca2+]
i
 must decline, allowing 
Ca2+ to dissociate from troponin. The four pathways  resonsible for Ca2+ transport out involve 
the SR Ca2+-ATPase (SERCA), sarcolemmal Na+/Ca2+-exchange (NCX), sarcolemmal Ca2+-
ATPase or mitochondria Ca2+ uniport (Figure 1.2).
1.3 S100 proteins
S100 is a multigenic family of low molecular weight (Mr beween 9 and 13 kDa) Ca2+-bin-
ding proteins of the EF-hand type. The EF-hand was devised by Kretsinger and Nockolds 
over 30 years ago as a graphical description of the Ca2+-binding motiv observed in parvalbu-
min ((Fig. 1.3 (Kretsinger and Nockolds, 1973)). 
Figure 1.3: A symbolic representation of the EF-hand motif.
Helix E winds down the index fingers, whereas helix F winds up the 
thumb of a right hand. When Ca2+-ion binds, helix F moves from the 
closed (apoprotein, light grey) to the open (holoprotein, dark grey) con-
formation. From Lewit-Bentley and Rety, 2000.
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The first member of the S100 family was discovered in 1965 as an unfractioned bovine brain 
mixture of S100B and S100A1, called ʻS100  ʼbecause of its solubility in a 100% satured 
ammonium sulfate solution (Moore, 1965). Several years later bovine brain S100 protein 
was shown to consist of two distinct, but strictly related proteins, S100A1 and S100B which 
termed out not to be brain-specific (Isobe and Okuyama, 1978; Isobe and Okuyama, 1981). 
The nomenclature of S100 proteins is given by the gene location within the cluster on chro-
mosome 1q21 and is designed by consecutive Arabic numbers placed behind the stem sym-
bol S100A, for example S100A1. In contrast, S100 genes from other chromosomal regions 
should carry the stem symbol S100 followed by a single letter, like S100B that is localized 
on chromosome 21q22.
An S100 protein is characterized by the presence of two Ca2+-binding motifs of the EF-hand 
type interconnected by an intermediate region often referred to as the hinge region (Fig. 
1.4).
Figure 1.4: Schematic representation of the secondary structure of an S100 protein. Each Ca2+-binding 
loop (L1 and L2, in the N- and C-terminal half, respectively) is flanked by α-helices (helices I and II, and he-
lices III and IV for L1 and L2, respectively).  A linker region (hinge region, H) connects helix II-III. Helix IV 
is followed by a C-terminal extension. From Donato et al., 2001.
In each Ca2+-binding motif of the EF-hand type, a Ca2+-binding loop is flanked by α-heli-
ces, resulting in the characteristic helix-loop-helix arrangement. The C-terminal EF-hand 
contains the classical Ca2+-binding motif with a canonical Ca2+-binding loop, common to 
all EF-hand proteins. This Ca2+-binding motif has a typical sequence signature of 12 amino 
acids (Fig 1.5) and is flanked by helices III and IV. The N-terminal EF-hand is different from 
the classical EF-hand motif, the Ca2+-binding loop is unconventional, longer and rearranged, 
and is characteristic for S100 proteins. Therefore, this EF-hand with a 14-amino-acid con-
sensus sequence motif, which is flanked by helices I and II, is called the ʻS100-specific  ʼor 
ʻpseudo-EF-hand  ʼ(Fig 1.5 (Heizmann and Cox, 1998; Marenholz et al., 2004)). 
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Canonical 
EF-hand
S100 EF-hand
Figure 1.5: Schematic representation of the secondary structure of an S100 protein. Each Ca2+-binding 
loop (L1 and L2, in the N- and C-terminal half, respectively) is flanked by α-helices (helices I and II, and he-
lices III and IV for L1 and L2, respectively).  A linker region (hinge region, H) connects helix II-III. Helix IV 
is followed by a C-terminal extension. From Marenholz et al., 2004.
Hence, the two Ca2+-binding sites in an S100 protein bind Ca2+ with different affinities, a hig-
her affinity in the case of the C-terminal site and a much lower affinity in the case of the N-
terminal site (Donato, 1986). The highest sequence identity among S100 members is found 
in the Ca2+-binding sites. The hinge region and the C-terminal extension display the least ex-
tent of sequence identity, suggesting the possibility that these two regions might play a role 
in the specification of biological activity of individual S100 proteins (Heizmann and Cox, 
1998). In some cases, such as S100A1 and S100B, some conserved residues are found
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at the same positions in the hinge region and the C-terminal extension, which explains in 
part the large overlap of the regulatory roles attributed to these two S100 members (Donato, 
1999).
Within cells, most of S100 proteins exist as homodimers in which the two monomers are 
related by a two-fold axis of rotation and are held together by non-covalent bonds (Fig. 
1.6A (Donato, 2001)). This has been demonstrated for S100A1, S100A1, S100A6, S100A7, 
S100A8, S100A10, S100A11, S100A12 and S100B, by nuclear magnetic resonance (NMR) 
spectroscopy, X-ray crystallography, or multiple anomalous wavelength dispersion (Drohat 
et al., 1996; Drohat et al., 1998; Kilby et al., 1996; Moore, 1965; Moroz et al., 2000; Potts et 
al., 1995; Rety et al., 2000; Rety et al., 1999; Rustandi et al., 2002; Sastry et al., 1998). Only 
a single member of the S100 family, calbindin 3, occurs as a monomer.
A B
Figure 1.6: Structure of Ca2+-free (A) and Ca2+-loaded (B) S100B
2
 dimer (taken as an example of S100 
dimer). One S100B monomer is in yellow and the other is in blue. Helices are indicated by Roman numerals 
(I-IV in one monomer, and Iʼ-IV  ʼ in the other monomer. Binding of Ca2+ to each S100B monomer cause a 
reorientation of helix III relative to all other helices with consequent reorientation of the hinge region and the 
(H) (compare A with B). These changes result in the exposure to the solvent of a surface defined by residues 
(in magenta) in helices III and IV, the hinge region and the C-terminal extension. Ca2+ ions are represented by 
light-pink dots within Ca2+-binding loops (L1, L2 in one monomer, and L1ʼ, L2  ʼin the other monomer). Note 
that the Ca2+-loaded S100B
2
 dimer is more extended than the Ca2+-free dimer (B). From Donato, 2001.
Dimerization of S100 proteins seems important for their biological activites. Structural in-
formation (Fig. 1.6) suggests that upon Ca2+-binding, helix III becomes perpendicular to 
helix IV as a consequence of a remarkable change of the interhelical angle between these 
two helices (Drohat et al., 1998; Smith and Shaw, 1998). Due to this change, the hinge region 
swings out. As a result of these structural changes, a cleft forms in each monomer, which is 
defined by residues in the hinge region, helices III and IV and the C-terminal extension, 
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and is buried in monomeric apo S100. Residues defining this cleft are believed to be im-
portant for the Ca2+-dependent recognition of S100 target proteins. However, one member, 
S100A10, does not undergo Ca2+-dependent conformational changes as it is in a permanent 
ʻCa2+-on  ʼstate (Gerke and Weber, 1985; Rety et al., 1999).  
It is generally accepted that within cells, S100 proteins regulate the activity of effector pro-
teins (target proteins). Because this regulation is modulated by Ca2+, S100 proteins are also 
considered Ca2+-sensor proteins. One exception to this paradigm is the monomeric calbindin 
D9k for which no target protein has identified. Instead, calbindin D9K buffers cytosolic Ca2+ 
and is thus is a Ca2+ modulator protein.
S100 proteins exhibit cell- and tissue-specific expression and have been linked to Ca2+-
dependent regulation of a variety of S100 isoform-specific intracellular activities such as 
protein phosphorylation, enzyme activity, cell proliferation and differentiation, dynamics 
of cytoskeletal constituents, structural organization of membranes, intracellular Ca2+-home-
ostasis and inflammation (Donato, 2003; Heizmann and Cox, 1998; Zimmer et al., 1995). 
In addition growing evidence indicates that members of the S100 protein family also exert 
extracellular effects on their target cells (Donato, 2003; Most et al., 2003a). Although S100 
proteins apparently lack the classic signaling sequences required for secretion, some S100 
proteins seem to reach the extracellular space through secretory pathways that neither in-
volve the common endoplasmic reticulum/Golgi nor the alternative interleukin-1 route 
(Rammes et al., 1997). The number of downstream functions affected by extracellular S100 
proteins is increasing. For instance, S100B, S100A4 and S100A12 have been shown to pro-
mote differentiation of embryonic neurons (Mikkelsen et al., 2001; Novitskaya et al., 2000; 
Selinfreund et al., 1991). Some extracellular activities of S100 proteins such as S100A12 
and S100B are apparently mediated through interaction with the multiligand receptor for 
advanced glycation end products (RAGE)(Hofmann et al., 1999; Huttunen et al., 2000). In 
addition S100 proteins play an important role in the pathology of diseases, like in neoplasias, 
neurodegenerative disorders, inflammatory diseases and cardiomyopathies (Ehlermann et 
al., 2000; Most et al., 2003a; Most et al., 2004; Sheng et al., 1994; Wicki et al., 1997).
Chapter 1: Introduction
8
1.4 S100 A1
S100A1 is the most abundant S100 protein isoform in striated muscle (Donato, 2003; Kato 
and Kimura, 1985). Based on the observation that cardiac-restricted S100A1 overexpression 
enhances Ca2+-cycling and cardiac contractility performance in vitro and in vivo (Most et 
al., 2001; Most et al., 2003b;Most et al, 2004; Remppis et al., 2002; Remppis et al., 2004), 
S100A1 has been earmarked as a novel positive inotropic intracellular regulator of heart 
function. These effects are primarily attributed to improved cardiac sarcoplasmic reticulum 
(SR) Ca2+-handling. A recent study also provided evidence that S100A1 improves SR Ca2+-
fluxes and contractile force in skeletal muscle (Most et al., 2003c). In contrast to conventio-
nal positive inotropic agents, S100A1-mediated chronic cardiac inotropic actions in normal 
myocardium are independent of β-adrenergic signaling, with no alteration of heart rate or 
signs of myocardial hypertrophy or fibrosis (Most et al., 2003b). In addition, S100A1-defi-
cient mice showed an impaired cardiac-contractility response to hemodynamic stress (Du et 
al., 2002). Consistently, S100A1 has been found to be downregulated in human and animal 
models of heart failure (Remppis et al., 1996; Tsoporis et al., 2003).
Furthermore, S100A1 stimulates the sarcomeric, myosin-associated giant kinase twit-
chin in a Ca2+-dependent manner in vitro (Heierhorst et al., 1996). Twitchin is a member of 
a family of giant protein kinases involved in regulation of muscle contraction and the me-
chanoelastic properties of the sarcomere in invertebrates. Titin, the corresponding protein in 
vertebrates, was recently shown to interact with S100A1 (Yamasaki et al., 2001). S100A1 
was proposed to provide a mechanism to free the thin filaments from titin and reduce titin-
based tension before active contraction (Yamasaki et al., 2001). 
Similar to other S100 protein members, S100A1 also exhibits extracellular functions (Dona-
to, 2003; Most et al, 2003a). Although no evidence for its secretion has been offered so far, 
S100A1 induces neurite extension activity and also exhibits a pro-survival effect on neurons 
(Donato, 2003; Huttunen et al., 2000). Moreover, it has been shown that S100A1 is released 
into the extracellular space in considerable amounts during ischemic myocardial injury via 
an unknown mechanism (Kiewitz et al., 2000).
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In the current thesis, the molecular mechanisms of S100A1 on cardiac function have been 
examined. Analysis of the internalization of S100A1 revealed a novel pro-survival pathway 
of extracellulary added S100A1 (Chapter 2). Furthermore, restoring S100A1 protein expres-
sion by adenoviral gene transfer can rescue defective contractile performance of failing my-
ocardium in vitro and in vivo (Chapter 3). In addition, we were able to gain insight into the 
mechanism through which S100A1 differentially modulates sarcolemmal and sarcoplasmic 
Ca2+-handling in ventricular cardiomyocytes depending on the subcellular location of this 
protein (Chapter 4). Last but not least, we identified new target proteins of S100A1, all of 
which are involved in energy metabolism. S100A1 directly interacts with the F
1
-ATPase in a 
Ca2+-dependent manner and is able to increase the ATP content of neonatal rat cardiomyocy-
tes (Chapter 5). Overall, this work presents new knowledge on the cardiac regulator protein 
S100A1 and provides insight into the molecular mechanisms of this protein.
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2.1 Abstract
S100A1 is a Ca2+-binding protein of the EF-hand type, which belongs to the S100 pro-
tein family. It is specifically expressed in myocardium at high levels and is considered to 
be an important regulator of cardiac contractility. Since S100A1 protein is released into the 
extracellular space during ischemic myocardial injury, we examined the cardioprotective 
potential of extracellular S100A1 protein on ventricular cardiomyocytes in vitro. In this re-
port we show that extracellularly added S100A1 protein is endocytosed into the endosomal 
compartment of neonatal ventricular cardiomyocytes via a Ca2+-dependent clathrin-media-
ted process. S100A1-uptake protects neonatal ventricular cardiomyocytes from 2-deoxyglu-
cose and oxidative-stress induced apoptosis in vitro. S100A1-mediated anti-apoptotic effects 
involve specific activation of the extracellular signal-regulated kinase 1/2 pro-survival pa-
thway, including activation of phospholipase C, protein kinase C, mitogen-activated protein 
kinase kinase 1 (MEK1) and ERK 1/2. In contrast, neither transsarcolemmal Ca2+-influx via 
the L-type channel, nor protein kinase A activity seem to take part in the S100A1-mediated 
signaling pathway. In conclusion, this study provides evidence for S100A1 protein serving 
as a novel cardioprotective factor in vitro. These findings warrant speculation that injury-
dependent release of S100A1 protein from cardiomyocytes may serve as an intrinsic mecha-
nism to promote survival of myocardium in vivo.
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2.2 Introduction
S100A1, a low-molecular weight (Mr 10.000) Ca2+-binding protein belongs to a multige-
nic family (21 members) of non-ubiquitous Ca2+-modulated proteins to form an important 
sub-class of EF-hand proteins. Importantly, S100 proteins exhibit cell- and tissue-specific 
expression and have been linked to Ca2+-dependent regulation of a variety of S100 iso-
form-specific intracellular activities such as protein phosphorylation, enzyme activity, cell 
proliferation and differentiation, dynamics of cytoskeletal constituents, structural organiza-
tion of membranes, intracellular Ca2+-homeostasis and inflammation (for reviews see (1-3)). 
S100A1 is the most abundant S100 protein isoform in striated muscle and has been identified 
as a novel positive inotropic intracellular regulator of cardiac as well as skeletal muscle Ca2+-
homeostasis and contractility (4-8). 
However, growing evidence indicates that members of the S100 protein family also exert ex-
tracellular effects on their target cells (3). Although S100 proteins apparently lack signaling 
sequences required for secretion, some S100 isoforms seem to follow secretory pathways 
that involve neither the classical endoplasmic reticulum/Golgi nor the alternative interleu-
kin-1-like route (9). For instance, S100A8 and S100A9, expressed at high concentrations 
by myelomonocytic cells, are secreted by a novel tubulin-dependent pathway and then exert 
important roles in the regulation of inflammatory processes (9). Similarly, extracellular func-
tions for S100B, which is is secreted by astrocytes, have been extensively described (10). 
After secretion, S100B appears to exert both trophic and pro-survival effects on neurons via 
activation of the Ras/mitogen-activated protein (MAP) kinase pathway (11,12). Neurotro-
phic effects have also been reported for extracellular S100A4 and S100A12 protein based 
on the activation of the extracellular signal-regulated protein kinase (ERK1/2) signaling 
pathway (13,14). 
It has been shown that S100A1 protein is released into the extracellular space in conside-
rable amounts during ischemic myocardial injury via an unknown mechanism (15). Based 
on these observations, we raised the hypothesis that extracellular S100A1 protein may exert 
protective effects on myocardial cells. To address this question, the current study focuses on 
the characterization of extracellular effects of S100A1 protein on cardiac myocytes and 
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related molecular mechanisms in vitro. Indeed, our study identifies S100A1 protein as a 
novel cardioprotective factor since we could demonstrate for the first time that extracellular 
S100A1 protein can protect cardiomyocytes from apoptosis based on Ca2+-dependent clath-
rin-mediated endocytotic uptake resulting in a specific activation of the pro-survival ERK1/2 
signaling pathway. 
2.3 Experimental Procedures
Reagents
Monodansylcadaverine (M-4008), chlorpromazine (C-8138) and verapamil (V-4629) were 
purchased from Sigma while myr-PKI (476485), calphostin-c (208725), U-73122 (662035), 
and PD98095 (513000) were obtained from Calbiochem. Myr-FRCRCF was custom-made 
by Eurogentec (Belgium) as prviously described (16,17). Anti-RAGE Ab was obtained from 
Chemicon (MAB5328).       
Expression and purification of human recombinant S100A1 protein
Expression and purification of human recombinant S100A1 protein in E.coli was performed 
as previously described (6). After dialysis against PBS (pH 7.4), aliquots of purified S100A1 
were stored at -80°C. Coupling of S100A1 with tetramethyl-rhodamine (Rh-S100A1) was 
carried out by Eurogentec. 
Cell culture
Isolation of neonatal ventricular cardiomyocytes (NVCM) was performed as previously de-
scribed (18). NVCM were cultured for 3 days either on plastic culture dishes, glass cover-
slips or cell-locatesʻ (Eppendorf) in DME media (Biochrom) supplemented with penicil-
lin/streptomycin (100U/ml), L-glutamine (2 mM) and 0.5% FCS Gold (PAA Laboratories 
Gmbh) (standard medium) at 37°C in a 95% air-5% CO2 humidified atmosphere. To induce 
apoptosis, 2-day old cultures were either incubated in glucose-free standard medium or DME 
media containing 2-deoxyglucose (3mM) or H2O2 (100 µM), respectively, for an additional 
18 h. NVCM were treated with 1 µM human recombinant S100A1 where indicated. 
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Indirect Immunofluorescence and Phase contrast images 
3-day old NVCM grown on glass coverslips were incubated with Rh-S100A1 (1 µM) as 
indicated, washed three times with PBS (pH 7.4), fixed in 4% paraformaldehyde and perme-
abilized with 0.2% Triton X-100 in PBS. Following three PBS washes, coverslips were in-
cubated in 0.1% bovine serum albumine for 30 min to block nonspecific sites. Subsequently, 
cells were labeled with either anti-α-actinin (Sigma, 1/3000), anti-transferrin (Sigma, 1/500) 
or anti-caveolin-3 (Santa Cruz, 1/500) antibodies. Following incubation of the primary an-
tibody for 1 h in the dark, coverslips were washed four times with PBS and then the cor-
responding ALEXA Fluor 488-conjugated secondary antibody (Molecular Probes, 1/800) 
was added for 1 h. After several washes with PBS, coverslips were mounted in Mowiol. 
Confocal images (CLSM) were obtained using a 100x oil objective on a Leica TCS SP laser 
scanning confocal microscope. Digitized confocal images were processed by Leica software 
and Adobe Photoshop. For phase contrast images, an inverse microscope (Olympus IX 70) 
equipped with a SensiCam CCD camera of PCO, was used. Images were subsequently pro-
cessed with TILLvisION4.01 software (Tillphotonics).
Trypan Blue Exclusion, Cytochrome c Release, Caspase-3 Activity and MTT assay 
The fraction of dead cells was determined by counting trypan blue stained cells on cell-loca-
te slides. Viable NVCM were tested for electrical excitability by field stimulation. On each 
cell-locate slide, a total number of at least 150 cells were inspected. Cytochrome c release 
and caspase-3 activity were assessed by Quantikine“ M Mouse Cytochrome c Immunoassay 
(R&D Systems, Cat.Nr. MCTC0) and Caspase-3 Colorimetric Assay (R&D Systems, Cat.
Nr. BF3100), respectively, as outlined by the manufactures protocol. MTT assay based on 
reduction of tetrazolium salt 3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) was purchased from Trevigen (4890-25-K) and carried out according to the manuf-
actures protocol. 
Western Blot and MAPK Activity  
Western blots using specific antibodies were performed to assess protein levels of 
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phosphorylated/non-phosphorylated MAP kinases p44/42 (ERK1/2; Cell Signaling # 
9101/9102), p38 (Cell Signaling # 9211/9212), p54/46 (SAPK/JNK; Cell Signaling # 
9251/9252), cardiac actin (Biogene Ac1-20.4.2) and S100A1 protein (SA 5632, Eurogen-
tec). Cell cultures were rinsed in PBS and scraped off the dish in lysis buffer (PBS pH 7.4, 
SDS 2%, 2 mM EGTA/EDTA) containing a mixture of 1% v/v phosphatase inhibitors (Sig-
ma; Phosphatase inhibitor cocktail I/II) and protease inhibitor (1 tablet/5ml) (Roche; Mini 
complete EDTA free protease inhibitor). To determine Rh-S100A1-uptake, NVCM were 
first washed extensively with EGTA/EDTA buffer (PBS, pH 7.4, 2 mM EGTA/EDTA) and 
then lysed. Blots were developed with the Avidix chemiluminescence detection system (Tro-
pix, Applied Biosystems, Foster City, CA) and quantified by densitometry. 
Statistical analyses
Data are presented as mean ± SEM. Unpaired student´s t-test and a two way repeated ANO-
VA analysis were performed to test for differences between groups. A value of  P < 0.05 was 
accepted as statistically significant.
2.4 Results
Ca2+-dependent clathrin-mediated endocytosis of extracellular S100A1 protein in 
NVCM
Before studying the effect of extracellularly added S100A1 protein on NVCM, the purity 
of human recombinant S100A1 protein was analyzed by SDS-PAGE and the specificity of 
S100A1 was confirmed by western blots probed with an custom-made antibody that specifi-
cally recognizes human S100A1 (SA5632) (data not shown) as recently described (6).
Incubation of NVCM with 1 µM rhodamine-conjugated recombinant S100A1 protein (Rh-
S100A1) for 5, 30 and 120 min in the presence of 2 mM extracellular Ca2+ ([Ca2+]
e
) resulted 
in a vesicular accumulation of the protein in the cytosol as shown by CLSM (Fig. 2.1). Con-
sistent with a cytosolic distribution of internalized S100A1 protein, images taken at the level 
of the nucleus revealed nuclear exclusion of Rh-S100A1. Simultaneous indirect immunoflu-
orescence labeling of Rh-S100A1 treated NVCM with an anti-α-actinin antibody 
21
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revealed regular striated Z-line pattern typical of cardiomyocytes. Despite a reported inter-
action of S100A1 protein with the Z-line component capZ (19), internalized Rh-S100A1 
protein seemed not localize to the Z-lines. 
Figure 2.1: Localization of internalized Rh-S100A1 protein in NVCM.  (A,D,G) In 3–day old cardiomy-
ocyte cultures, rhodamine-coupled S100A1 (Rh-S100A1, red) is detected intracellularly five minutes after 
its addition to the culture medium. The overall intracellular distribution of Rh-S100A1 is similar 30 and 120 
min after addition to the culture medium. (B,E,H) To identify cardiomyocytes, the same cultures were immu-
nostained with an anti-α-actinin/Alexa Fluor 488-anti-mouse antibody (green), which reveals a distinct striated 
pattern. (C,F,I) Merged images confirming the uptake of Rh-S100A1 by NVCM. Bar, 10 µm.
This suggests that internalized and endogenous S100A1 protein are present in distinct cellu-
lar compartments probably serving dual functions in the cardiomyocyte. To further examine 
the specificity of S100A1-uptake, parallel NVCM cultures were incubated with correspon-
ding concentrations of rhodamine alone. However, in these Rh-treated cells, we did not 
detect any dye uptake (data not shown). In contrast to NVCM cultured in Ca2+-containing 
standard medium, a vesicular accumulation of Rh-S100A1 protein was not observed in cells 
that were kept in Ca2+-free medium containing 2 mM EGTA (Fig. 2.2, B-G). This absence 
indicates that the uptake of exogenous S100A1 is dependent on Ca2+. Analysis of homoge-
nates from control NVCM and cells treated with S100A1 in the presence and absence of 
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Ca2+ by anti-S100A1 western blotting further confirmed the Ca2+-dependence of S100A1 
internalization (Fig 2.2A). Moreover, if NVCM cultures were incubated for 20 min with 
anti-S100A1 antibody (SA 5632) prior to the addition of recombinant S100A1, uptake of 
S100A1 protein was also be inhibited (Fig. 2.2H). As expected for a specific inhibition, the 
antibody-mediated ʻclearing  ʼ was dose-dependent and thus, an unspecific cellular uptake 
of the protein driven by the rhodamine tag could be excluded. In contrast, despite previous 
reports that have identified RAGE as a potential S100 protein receptor, intracellular uptake 
of S100A1 could not be prevented by a 30 min preincubation with an anti-RAGE antibody 
(10µg/ml) that recognizes the ligand-binding domain of the receptor (MAB5328; data not 
shown) (11,20). 
Figure 2.2: Ca2+-dependence of S100A1 internalization. (A) Western blot of homogenates of untreated (con-
trol) and S100A1-treated NVCM in the presence of 2 mM Ca2+ (upper panel) or 2 mM EGTA (middle panel) 
probed with an antibody that is specific for human S100A1. Addition of 2 mM EGTA to the medium prevents 
cellular uptake of Rh-S100A1. Probing with an antibody that recognizes cardiac actin (bottom panel) demons-
trates that protein loading in individual lanes was comparable. (B) Fluorescence image showing the cellular 
uptake of exogenously added Rh-S100A1 (red) in the presence of 2 mM [Ca2+]
e
 after 30 min. Immunostaining 
with an anti-α-actinin antibody (C) reveals the striated pattern typical for cardiomyocytes. (D) Merged image 
of Rh-S100A1 and Alexa Fluor 488-anti-actinin in the presence of 2 mM [Ca2+]
e
. Bar, 10 µm. (E) Internaliza-
tion of Rh-S100A1 does not occur in the presence of 2 mM EGTA. (F) Immunostaining of Rh-S100A1-treated 
NVCM in the presence of 2 mM EGTA with an anti-α-actinin/Alexa Fluor 488-anti-mouse antibody. (G) Mer-
ged image of (E) and (F) reveals only the striated pattern typical for cardiomyocytes, but without Rh-S100A1-
uptake. Bar, 10 µm. (H) Western blot of homogenates prepared from S100A1-treated (1µM) NVCM cultures 
that were incubated with different amounts of anti-S100A1 antibody (SA 5632, v/v %). Uptake of extracellular-
ly added S100A1 is inhibited by SA 5632 in a dose-dependent manner. The band representing human S100A1 
is no longer detected if SA 5632 is present in the culture medium at 2% (v/v).
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To gain insight into the pathway of S100A1 internalization, Rh-S100A1 treated NVCM 
were labeled with an anti-caveolin-3/Alexa Fluor 488-anti-mouse antibody (Fig. 2.3), which 
is a marker for the caveolin-mediated uptake (21). Merging corresponding rhodamine and 
Alexa Fluor 488 confocal images clearly showed that the caveolin-3 staining pattern is 
distinct from that of Rh-S100A1 vesicles (Fig. 2.3C). In contrast, immunolabeling of Rh-
S100A1 treated NVCM with an anti-transferrin antibody, which is a marker for the endo-
somal compartment revealed that Rh-S100A1 vesicles colocalize with transferrin and are 
therefore part of the endosomal compartment (Fig. 2.3, D-F) (22,23). 
Figure 2.3:  Colocalization of internalized Rh-S100A1 with the endosomal compartment. (A) Vesicu-
lar accumulation of Rh-S100A1 in the cytoplasm. (B) Immunostaining of Rh-S100A1-treated NVCM with 
an anti-caveolin-3/Alexa Fluor 488-anti-mouse antibody, which outlines the caveolin-mediated pathway. (C) 
Overlay of (A) and (B) shows no colocalization. (D) Vesicular accumulation of Rh-S100A1 in the cytoplasm. 
(E) Labeling of the endosomal compartment in Rh-S100A1-treated NVCM with an anti-transferrin/Alexa Flu-
or 488-anti-mouse antibody. (F) Overlay of (A) and (B) reveals colocalization of Rh-S100A1 and transferrin. 
Bar, 5 µm. 
To substantiate that a clathrin-mediated uptake rather than a caveolin-dependent process 
is involved in S100A1 internalization, we examined the effects of two inhibitors of clathrin-
mediated endocytosis, monodansylcadaverine (MDC) and chlorpromazine (CPZ) (24,25), 
on the uptake of S100A1. As illustrated by western blots of homogenates of cells incubated 
with S100A1 in the presence of inhibitors, that were probed with an anti-human S100A1 
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antibody (Fig. 2.4A), MDC and CPZ resulted in a dose-dependent inhibition of S100A1 in-
ternalization. Consistently, CLSM images of NVCM incubated with S100A1 in the presence 
of MDC revealed an absence of Rh-S100A1-uptake (Fig. 2.4B). 
Figure 2.4: Clathrin-mediated endocytosis of S100A1 in NVCM. (A) Western blots of homogenates of 
S100A1-treated NVCM incubated in the presence of monodansylcadaverine (MDC; upper panel) and chlor-
promazine (CPZ; lower panel), respectively. Internalized S100A1 is detected with an anti-human S100A1 
specific antibody (SA 5632) whereas an anti-cardiac actin antibody was used to normalize amounts of protein 
loaded in individual lanes (bottom panel). Inhibition of S100A1-uptake via the clathrin-mediated pathway by 
MDC and CPZ is dose-dependent. (B) Fluorescence image of Rh-S100A1-treated (1 µM) NVCM incubated 
with standard medium containing 50 µM MDC. Vesicular accumulation of Rh-S100A1 in the cytoplasm is not 
detected if clathrin-mediated endocytosis is blocked by MDC. (C) Immunolabeling of the same coverslip with 
an anti-a-actinin/Alexa Fluor 488-anti-mouse antibody confirms the presence of cardiomyocytes. Bar, 10 µm. 
In conclusion, our data strongly suggest that extracellular S100A1 protein is internalized 
and routed for the endosomal compartment of NVCM via a Ca2+-dependent, clathrin-medi-
ated endocytotic pathway. Because RAGE apparently does not mediate internalization of 
extracellular S100A1 protein in NVCM in our experimental setting, S100A1 protein may be 
endocytosed by another, yet to be identified receptor.
Activation of the ERK1/2 signaling pathway by endocytosed S100A1
Since signaling proteins of the mitogen-activated protein kinase (MAPK) pathways in 
particular have been linked to the endosomal compartment (for review see (25)), we next 
investigated whether endocytotic uptake of S100A1 protein might affect MAPK activity in 
NVCM. For this purpose, western blots of homogenates were probed with antibodies that 
specifically recognize either the unposphorylated or the phosphorylated form of the respec-
tive protein. Figure 2.5A shows that addition of 1 µM S100A1 to NVCM in the presence of 
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2 mM [Ca2+]
e
 resulted in a specific increase of p44/42 (ERK1/2) phosphorylation (3.8-fold, 
upper panel) compared to control cells.
Figure 2.5: Extracellular S100A1 addition specifically increases levels of phosphorylated ERK1/2 (P-
p44/42). (A) The effects of extracellularly added S100A1 (1 µM) on the levels of unphosphorylated and phos-
phorylated p44/42 (ERK1/2; top), p55/46 (SAPK/JNK; middle) and p38 (bottom) are shown by Western blots 
of cell extracts from untreated (control) and S100A1-treated cardiomyocytes (+S100A1; 1µM) probed with 
specific antibodies. Top, Ca2+-mediated uptake of S100A1 leads to a 3.8±0.3-fold increase in p44/42 phospho-
rylation (P-p44/42; middle panel) compared to control (P<0.01, n=3), whereas the levels of unphosphorylated 
p44/42 (upper panel) remain constant. Inhibition of  S100A1-uptake by 2 mM extracellular EGTA (lower 
panel) prevents ERK1/2 activation. Middle and bottom, p54/46 and p38 phosphorylation state are not affected 
by endocytosed S100A1. (B) Time-dependence of S100A1-induced activation of p44/42 phosphorylation (P-
p44/42). The increase in p44/42 phosphorylation coincides with an increased level of internalized S100A1 over 
time. Maximal S100A1-uptake and P-p44/42 levels are reached after 10 min. (C) Dose-dependent activation 
of ERK1/2 phosphorylation. NVCM were incubated with increasing amounts of S100A1 (0.01-10 µM) for 30 
min. A significant (P<0.01) increase of P-p44/42 is detected at 1 µM and 10 µM S100A1 stimulation. 
Consistently, if S100A1-uptake is prevented by the presence of 2 mM EGTA (see Fig. 
2.2 A), S100A1-mediated activation of ERK1/2 was absent. In contrast, the extent of phos-
phorylation of SAPK/JNK (p54/46, middle panel) and p38 (lower panel) following Ca2+-de-
pendent S100A1-uptake was comparable to that of control cells (Fig. 2.5A). Incubation of 
NVCM with S100A1 protein (1 µM) in the range of 1 to 30 min showed a time-dependence 
of ERK1/2 activation (Fig. 2.5B), while a 30 min application of increasing concentrations 
of extracellular S100A1 protein (0.01-10 µM; Fig. 2.5C) resulted in a dose-dependent en-
Chapter 2: S100A1-dependent anti-apoptotic signaling 
26
Figure 2.6: Effects of S100A1 on the signaling pathway upstream of ERK1/2. (A) Western blot of extracts 
from cells treated with S100A1 in the presence of 50 µM MDC, probed with specific antibodies, S100A1-
uptake as well as S100A1-mediated increase of ERK1/2 phosphorylation is inhibited. (B) Addition of incre-
asing amounts of MEK1 inhibitor PD98095 (2, 4, 10 µM) to S100A1-stimulated NVCM. Western blots of 
homogenates show that S100A1-uptake is not affected by PD98095, whereas the levels of phosphorylated 
ERK1/2 are reduced in a dose-dependent manner. (C) Effects of PLC, PKC and PKA inhibition on S100A1-
mediated activation of ERK1/2 phosphorylation. In the presence of PLC inhibitor U-73122 levels of P-p44/42 
are significantly reduced. A similar effect is observed by inhibition of PKC with calphostin-c. In contrast, 
inhibition of PKA by myr-PKI has no effect on the levels of P-p44/42. Probing the Western blot with an anti-
S100A1 antibody shows that S100A1 endocytosis (internalized S100A1) is not influenced by the inhibitors of 
PLC, PKC and PKA. (D) Effects of transsarcolemmal Ca2+-influx on ERK1/2 phosphorylation. Simultaneous 
inhibition of L-type Ca2+-channel (5 µM verapamil) and NXC (10 µM myr-FRCRCF) leads to a reduction of 
P-p44/42 levels in untreated (control) cells and S100A1-treated cells by approximately 40%. Both S100A1-
uptake (internalized S100A1) and S100A1-mediated activation of ERK1/2 are not significantly perturbed. 
Equal protein loading in individual lanes was confirmed by comparable levels of cardiac actin.
hancement of ERK1/2 phosphorylation. Concomitantly, the concentration of endocytosed 
S100A1 protein increased (Fig. 2.5, B and C). Inhibition of S100A1 endocytosis by 50 
µM monodansylcadaverine effectively abrogated the S100A1-mediated increase in ERK1/2 
phosphorylation (Fig. 2.6 A). Furthermore, S100A1-mediated activation of ERK 1/2 could 
be prevented by preincubation with PD98095 (2-10 µM) (Fig. 2.6B), a specific inhibitor of 
MEK1 (26,27). 
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Since extracellular neurotrophic effects of S100A4 protein on rat hippocampal neurons 
depends on phospholipase C (PLC), which has also been linked to the endosomal compart-
ment, we investigated the influence of PLC inhibition by U-73122 (5 µM) on S100A1-me-
diated ERK1/2 activation (13,25). As illustrated in Figure 2.6 C, it appears that inhibition of 
PLC completely prevented the S100A1-induced enhancement of ERK1/2 phosphorylation. 
Because receptor-mediated activation of PLC is known to subsequently enhance protein 
kinase C (PKC) activity, we next tested whether S100A1-mediated enhancement of ERK1/2 
activity requires activation of PKC. Interestingly, in the presence of calphostin-c (0.5 µM), 
a potent inhibitor of PKC (13), S100A1-induced enhancement of ERK1/2 phosphorylation 
was abrogated (Fig. 2.6C). Since activation of cAMP-dependent protein kinase (PKA) has 
also been linked to ERK1/2 signaling, we likewise explored the effect of PKA inhibition 
on S100A1-dependent ERK1/2 activation by a cell permeable specific PKA inhibitor (28). 
However, preincubation of NVCM with myristolated PKA inhibitor 14-22 amide (myr-
PKI, 5 µM) for 30 min, did not affect S100A1-mediated enhancement of ERK1/2 activity 
(Fig. 2.6C). This finding suggests that the modulation of the ERK1/2 signaling pathway by 
S100A1 does not involve PKA.
Transsarcolemmal Ca2+-influx has been shown to be another modulator of ERK1/2 sig-
naling (28). Because exogenous addition of S100A1 protein to immature cardiomyocytes 
has been shown to increase L-type Ca2+-channel (dihydropyridine receptor, DHPR) activity 
and thus Ca2+-influx (29), we explored the effect of extracellularly added S100A1 protein on 
ERK1/2 signaling in response to inhibition of transsarcolemmal Ca2+-influx. For this purpo-
se, DHPR was blocked with verapamil (5 µM) and the sodium-calcium exchanger (NCX) 
with a cell-permeable specific NCX inhibitor, myr-FRCRCF (10 µM), In both cases, the in-
hibitors slightly reduced the extent of ERK1/2 phosphorylation in control cells as well as in 
S100A1-treated cardiomyoctyes, but did not perturb the S100A1-uptake and S100A1-medi-
ated activation of ERK1/2 phosphorylation (S100A1 vs. control +3.2±0.4-fold, n=3, P<0.01; 
S100A1 vs. control (verapamil/myrFRCRCF) +2.8±0.2-fold, n=3, P<0.01) (Fig. 2.6D).
Taken together, our results strongly support the notion that endocytosed S100A1 protein 
specifically increases ERK1/2 activity via the PLC-PKC-MEK1 pathway. In contrast, PKA 
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and transsarcolemmal Ca2+-influx did not appear to be involved in S100A1-mediated activa-
tion of ERK1/2.
S100A1 inhibits NVCM apoptosis via ERK1/2 signaling
Previous studies which have demonstrated that ERK1/2 activation is associated with 
protection from apoptosis in cardiomyocytes (26,30-33), prompted us to examine whether 
S100A1-induced ERK1/2 signaling may exert cardioprotective effects on cardiomyocytes. 
To assess if S100A1 addition provides protection from apoptotic stimuli, NVCM were in-
cubated in 2-deoxyglucose- containing (2-DOG) glucose-free medium for 18h as described 
previously (26) and in 2-DOG containing the MEK1 inhibitor PD98095. Figure 2.7 shows 
corresponding phase contrast images of NVCM cultured in standard medium in comparison 
to cells cultured in 2-DOG. Addition of S100A1 to NVCM cultured in standard medium 
did not significantly alter cell morphology (Fig. 2.7, A and B). Apoptosis is induced when 
NVCM were cultured in 2-DOG rather than standard medium (Fig. 2.7C)  and cells display 
a rounded morphology. In the presence of S100A1 (Fig. 2.7D), the rounding up of 2-DOG 
was prevented and cell morphology is similar to that of untreated cells cultured in standard 
medium (Fig. 2.7A). The S100A1-induced protection from apoptosis abolished in the pres-
ence of the MEK1 inhibitor PD98095 (Fig. 2.7F). 
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Figure 2.7: Antiapoptotic effect of S100A1 protein on NVCM. (A-F) Phase contrast images of NVCM under 
different culture conditions. (A) Untreated cells in standard culture medium (containing glucose) (control). (B) 
Addition of S100A1 (1 µM) to NVCM in standard medium does not significantly alter their morphology. (C) 
NVCM cultured for 18 h in medium containing the apoptosis inducing 2-deoxyglucose (2-DOG; 3 mM) without 
S100A1 display a rounded morphology. (D) If S100A1 is added to the cells, cells cultured in 2-DOG extend 
cellular processes and assume a morphology similar to that of control cells (A). (E) Untreated cells cultured as 
in (C) but in the presence of the MEK1 inhibitor PD98095 do not spread. (F) In the presence of PD98095, 2-
DOG induced apoptosis is not overcome by S100A1 addition. Bar, 50 µm. (G) Anti-apoptotic effect of S100A1 
involves the ERK1/2 pathway. Compared to control NVCM (standard medium, no S100A1; 100%), only 28 ± 
3.6% of cells (n = 5) cultured in 2-DOG were viable and able to contract. When cells were treated with S100A1 
(1 µM) the survival rate of 2-DOG-induced apoptotic cells is ~2-fold higher (79 ± 5.6%, * P<0.01) compared 
to control cells. Addition of 10 µM PD98095 abolishes the S100A1-induced rescue (30 ± 5.8% survival, n=5, 
** P<0.01). (H) S100A1 treatment reduces apoptosis-related mitochondrial cytochrome c release by ~2.5-fold 
(S100A1 17±1.1% vs. untreated 61±2.3%, n=5, * P<0.01, data are expressed as % cytosolic cytochrome c 
from total cytochrome c (tcytc), tcytc was estimated at approximately 230 ng per 106 cells). This reduction 
is blocked by 10 µM PD98095 (S100A1-treated 17±1.1% vs. S100A1-treated/PD98095 50.4±2.1%, n=5, ** 
P<0.01). (I) Apoptosis-related caspase-3 activity is reduced ~1.8-fold by S100A1 treatment (S100A1-treated 
0.37±0.08 vs. untreated 1.05±0.1, n=5, * P<0.01). The antiapoptotic effect of S100A1 treatment is effectively 
inhibited by 10 µM PD98095 (S100A1-treated 0.37±0.08 vs. S100A1-treated/PD98095 1.05±0.046, n=5, ** 
P<0.01). (J) In comparison to untreated NCVM, S100A1 treatment prevents the 2-DOG-mediated decrease 
in mitochondrial dehydrogenase activity (S100A1-treated 1.4±0.2 vs. untreated 0.6±0.1, n=5, * P<0.01). This 
anti-apoptotic effect is inhibited by 10 µM PD98095 (S100A1-treated 1.4±0.2 vs. S100A1-treated/PD98095 
0.4±0.1, n=5, ** P<0.01).    
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Viability of NVCM was assessed by trypan-blue exclusion and electrical field stimulation 
(Fig. 2.7G). Addition of 1 µM S100A1 protein did not affect viability of cells under standard 
culture conditions (S100A1-treated 117±8, vs. untreated 119±8, each n=5 cell locates, P=n.
s.). However, compared to untreated NVCM (100%), only ~30% of cells cultured in 2-DOG 
were viable and able to contract. When cells were treated with S100A1 (1 µM) the survival 
rate of 2-DOG-induced apoptotic cells was ~2-fold higher. Consistent with the morphologi-
cal data, S100A1-mediated rescue from apoptosis was effectively abolished by the presence 
of the MEK1 inhibitor PD98095 (10 µM). 
As additional indicators of apoptosis, mitochondrial cytochrome c release, caspase-3 and 
mitochondrial dehydrogenase activity were quantified under different culture conditions 
(Fig. 2.7, H-J). If S100A1 was added to cells cultured in 2-DOG medium, the cytochrome c 
release and caspase-3 activity was reduced by ~2.5-fold and ~1.8-fold, respectively (Fig. 2.7 
H and I). Again, the S100A1-mediated protection from apoptosis was effectively prevented 
by addition of 10 µM PD98095. The presence of the inhibitor also blocked a nearly ~1.3-
fold higher preservation of mitochondrial dehydrogenase activity in S100A1-treated cells 
compared to untreated NVCM (Fig. 2.7J). In line with these results the pretreatment of cul-
tured cardiomyocytes with S100A1 similarly inhibited oxidative-stress-induced apoptosis 
by H
2
O
2
 (100µM) in our experimental setting (data not shown).
In summary, these results demonstrate that addition of S100A1 protein to cultured ne-
onatal ventricular cardiomyocytes protects them via activation of  ERK1/2 signaling from 
apoptotic stimuli. 
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2.5 Discussion
To date, the multigene family of Ca2+-binding proteins of the EF-hand type known as 
S100 proteins has grown to 21 members that are differentially expressed in a large number of 
cell types. Individual S100 proteins are viewed as cell-specific proteins, which are implica-
ted in the Ca2+-dependent regulation of a variety of activities in the cell (3). Recent evidence 
indicates that S100 proteins, once secreted or released into the extracellular space, may also 
exert specific effects on their target cells. For instance, extracellular S100A8 and S100A9 se-
creted by a novel tubulin-dependent pathway have been ascribed important functions in the 
regulation of inflammatory processes (9). In addition, secreted S100B, S100A4 and S100A12 
have been shown to exert a neurotrophic effect on neurons (11,13,14). In the case of S100B, 
the trophic effects on neurite outgrowth were accompanied by an increased expression of the 
anti-apoptotic protein Bcl-2 (11). Since S100A1 is also released into the extracellular space 
following ischemic myocardial injury (15), we undertook this study addressing the question 
whether extracellular S100A1 may exert protective effects on cardiac cells.
Our data for the first time provide evidence that extracellular addition of S100A1 protein 
can protect neonatal ventricular cardiomyocytes from apoptosis in vitro via specific activa-
tion of the ERK1/2 signaling pathway. By coupling human recombinant S100A1 protein 
with rhodamine we were able to trace the uptake of S100A1 into the cytosolic compartment 
of cultured NVCM. Indirect immunofluorescence staining and uptake experiments under 
different culture conditions revealed that S100A1 protein is internalized via a Ca2+-depen-
dent clathrin-mediated endocytotic pathway. Interestingly, our results suggest that the cell 
surface receptor for advanced glycosylated end products (RAGE), which has been reported 
to interact with S100B (11,20), does not seem to be involved in the endocytosis of S100A1 
in NVCM. Therefore, another cell surface receptor is likely to be responsible for S100A1 
uptake in NVCM. Recently, internalization of S100A1 protein into embryonic murine cardi-
omyocytes has been shown to be associated with a decrease in membrane capacitance (29). 
With regard to the current study, this decrease in membrane capacitance is likely to reflect 
endocytotic vesicles forming at the plasma membrane, which then pinch off as clathrin-coa-
ted vesicles and eventually fuse with the endosomal compartment. 
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A growing body of evidence indicates that several signaling proteins involved in receptor 
tyrosine kinase (RTK) and G-protein coupled receptor (GPCR) signal transduction, e.g., 
PLC, Ras, Raf, MEK1 and ERK1/2, are located in endosomes from where they transduce 
signals to the cytosol and nucleus (25). In hippocampal neurons, it has been shown that 
the extracellular addition of S100A4 protein activates the ERK1/2 signaling pathway (13). 
Correspondingly, our data obtained from western blots probed with antibodies that speci-
fically recognize unphosphorylated or phosphorylated forms of ERK1/2, together with the 
western blot data obtained when known upstream constituents of the MAPK signaling pa-
thway were inhibited (Fig. 2.8), demonstrate that internalized S100A1 protein specifically 
activates ERK1/2 in cardiomyocytes both in a time- and dose-dependent manner. Hereby, 
internalization of S100A1 protein represents an important prerequisite for the activation of 
ERK1/2 since prevention of S100A1 endocytosis, both in Ca2+-free medium and in the pre-
sence of inhibitors of clathrin-mediated endocytosis, resulted in a lack of enhanced ERK1/2 
phosphorylation. In contrast, kinases involved in other signaling pathways, such as p38 and 
SAPK/JNK (p54/46), are not affected. 
Figure 2.8: Model of S100A1 
involvement in ERK1/2 si-
gnaling. The model suggests 
endocytosis of extracellular 
S100A1 by NVCM via an 
unknown receptor. Inhibitors 
of the S100A1-mediated pa-
thway are shown in red while 
markers are given in blue. 
PLC, phospholipase C; PKC, 
phosphokinase C; MEK1, 
MAPkinase kinase1; ERK1/2, 
extracellular signal-regulated 
kinase 1/2; MDC, monodan-
sylcadaverine; CPZ, chlorpro-
mazine.
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By using several specific inhibitors of intracellular signal transduction constituents (see 
Fig. 2.8), we could identify that S100A1-mediated activation of ERK1/2 signaling involves 
activation of PLC and PKC, which have been closely linked to the endosomal compartment 
(25). A stimulation of ERK1/2 activation by PKC has been previously reported (34). Based 
on our collective findings, we have developed a model of how S100A1 participates in the 
ERK1/2 signaling cascade (Figure 2.8). As depicted by the model, our data further provide 
evidence that sarcolemmal Ca2+-influx mediated by the L-type channel does not participa-
te in the S100A1-mediated enhancement of ERK1/2 phosphorylation. These findings are 
in contrast to work by Gomez and coworkers, which shows that glucagon-like peptide 1 
(GPL-1)-mediated activation of ERK1/2 requires Ca2+-influx through L-type channel in a 
mouse pancreatic β-cell line (28). Moreover, in their experimental system, inhibiting PKA 
activity diminished GPL-1-mediated ERK1/2 activation, whereas inhibition of PKA showed 
no significant effect on the S100A1-mediated ERK1/2 activation in NVCM. In addition, an 
unchanged phosphorylation state at serine16 in phospholamban in NVCM after addition of 
S100A1 revealed no evidence for enhanced PKA activity in our experimental setting (data 
not shown). From these differences we conclude that S100A1-mediated ERK1/2 activation 
follows a different signaling pathway than GPL-1. Taken together our results strongly sup-
port the notion that internalized S100A1 protein is routed to the endosomal compartment 
where it specifically activates the ERK1/2 signaling pathway. 
Since an activation of the ERK1/2 signaling pathway by different means has been re-
ported to protect cardiomyocytes from apoptosis (26,30,32,33,35), we evidently examined 
whether S100A1 treatment had a similar effect on the viability of neonatal cardiomyocytes 
in response to the apoptosis inducing agent 2-deoxyglucose. Indeed, our data show that 
S100A1 protein dramatically enhances the survival of cardiomyocytes in response to 2-
DOG. S100A1-treated cells at the same time display a reduced release of mitochondrial 
cytochrome c, a diminished caspase-3 activity and maintain their mitochondrial dehydro-
genase activity. In accordance, the pretreatment of cultured cardiomyocytes with S100A1 
similarly inhibited oxidative-stress-induced apoptosis by H
2
O
2
 (100µM) in our experimental 
setting (data not shown) further corroborating the cytoprotective effect of S100A1 protein. 
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Consistent with the S100A1 signaling pathway outlined in Figure 2.8, these pro-survival pa-
rameters are effectively blocked if MEK1 is inhibited by PD98095. Taken together, the data 
of our study provide convincing evidence that the antiapoptotic effect of S100A1-uptake in 
vitro is brought about by enhanced ERK1/2 signaling. The results of the present study pro-
vide the basis for the working model shown in Figure 2.8, which illustrates the downstream 
signaling pathways involved in the antiapoptotic actions of extracellular S100A1 on cardi-
omyocytes. In conclusion, our study identifies extracellular S100A1 protein as a novel anti-
apoptotic factor that enhances survival of neonatal cardiomyocytes in vitro via activation of 
the PLC-PKC-MAP kinase kinase1-ERK1/2 pathway.
The mechanism by which a considerable amount of S100A1 is released into the extracel-
lular space during ischemic myocardial injury is yet unknown. Since other S100 proteins 
are secreted either by a Ca2+- or tubulin-dependent pathway, one might consider a similar 
mechanism for myocardial S100A1 release. Based on these considerations, we hypothesize 
that in vivo, S100A1 extrusion from myocardial cells under pathological conditions might 
promote the survival of the surrounding myocardium. Because S100A1 protein levels are 
reduced in heart failure (36) and S100A1 gene-deletion resulted in progressive deterioration 
of cardiac function in vivo (8), S100A1 protein deficiency may not only result in impaired 
contractility of the failing heart, but may also contribute to an enhanced susceptibility of 
injured or failing cardiomyocytes to apoptosis. Undoubtedly, elucidating the detailed mole-
cular mechanism of myocardial S100A1 release is now imminent, as are studies that provide 
insight into the pathophysiological relevance of the cardioprotective effect of S100A1 pro-
tein on cardiac cells in vivo. 
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3.1 Abstract
Cardiac-restricted overexpression of the Ca2+-binding protein S100A1 has been shown to 
lead to increased myocardial contractile performance in vitro and in vivo. Since decreased 
cardiac expression of S100A1 is a characteristic of heart failure, we tested the hypothesis 
that S100A1 gene transfer could restore contractile function of failing myocardium. Adeno-
viral S100A1 gene delivery normalized S100A1 protein expression in a post-infarction rat 
heart failure model and reversed contractile dysfunction of failing myocardium in vivo and 
in vitro. S100A1 gene transfer to failing cardiomyocytes restored diminished intracellular 
Ca2+-transients and sarcoplasmic reticulum (SR) Ca2+-load mechanistically due to increased 
SR Ca2+-uptake and reduced SR Ca2+-leak. Moreover, S100A1 gene transfer decreased ele-
vated intracellular Na+-concentrations to levels seen in non-failing cardiomyocytes, reversed 
reactivated fetal gene expression and restored energy supply in failing cardiomyocytes. In-
tracoronary adenoviral-mediated S100A1 gene delivery in vivo to the post-infarcted failing 
rat heart normalized myocardial contractile function and Ca2+-handling providing physio-
logic significance to results found in myocytes. Thus, the present study demonstrates that 
restoration of S100A1 protein levels in failing myocardium by gene transfer may be a novel 
therapeutic strategy for the treatment of heart failure. 
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3.2 Introduction
Heart failure (HF) remains a leading cause of mortality in the developed world (1) and 
this, in part, reflects a lack of therapies targeted to the underlying molecular defects that lead 
to chronic ventricular dysfunction.  Although other systems contribute, there is substantial 
evidence for abnormal intracellular Ca2+-handling being a key component of the impaired 
contractile performance of the failing heart (2). This defect has been linked to abnormal 
levels of Ca2+-sensor and regulatory proteins in failing myocardium (3) and restoring di-
minished key protein levels may therefore represent a strategy to reverse the defect. In this 
regard, S100A1, a low-molecular weight (Mr 10,000) Ca2+-binding protein is especially in-
teresting with respect to cardiovascular disease.  S100A1, a member of the multigenic S100 
family, is the most abundant S100 protein isoform in the heart (4) and has been found to be 
down-regulated in human and animal models of heart failure (5, 6). Importantly, S100A1 has 
previously been identified as a novel positive inotropic regulator of heart function based on 
the observation that cardiac-restricted S100A1 overexpression enhances Ca2+-cycling and 
cardiac contractile performance in vitro and in vivo (7-10). These effects were mainly due 
to improved cardiac sarcoplasmic reticulum (SR) Ca2+-handling and a recent study also pro-
vided evidence that S100A1 can improve SR Ca2+-fluxes and contractile force in skeletal 
muscle (11).
In contrast to conventional positive inotropic agents, S100A1-mediated chronic cardiac 
inotropic actions in normal myocardium were independent of β-adrenergic signaling with no 
alteration of heart rate or signs of myocardial hypertrophy or fibrosis (8).  In support of these 
results, S100A1-deficient hearts display severe inotropic and lusitropic defects shown both 
by impaired contractile reserve and rapid progressive deterioration of contractile function 
in response to acute and chronic hemodynamic stress, respectively (12). Thus, the loss of 
S100A1 protein in human heart failure may indeed contribute to the Ca2+-dysregulation and 
deterioration of contractile strength. Interestingly, S100A1 has most recently been shown to 
inhibit programmed cell death of ventricular cardiomyocytes (13), a process that can signi-
ficantly contribute to the development and progression of HF. 
Most of the data to date showing positive myocardial functional effects with S100A1 
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overexpression has either been seen in a transgenic mouse model or adenoviral-mediated 
gene delivery to cultured ventricular cardiomyocytes or engineered heart tissue from non-
failing hearts and not in the context of HF. Therefore, it is not known whether restoration of 
S100A1 protein expression in the failing heart in vivo may improve contractile performance 
and prove to be therapeutic. In this study, we tested this hypothesis using adenoviral-medi-
ated myocardial S100A1 gene delivery to an experimental rat HF model. Our translational 
approach demonstrates that S100A1 gene transfer can normalize S100A1 protein levels and 
restore contractile function of failing myocardium in vitro and in vivo primarily through a 
normalization and restoration of myocyte Ca2+-homeostasis. 
3.3 Methods 
Generation of S100A1 adenovirus
To construct the adenovirus containing both the human S100A1 and GFP cDNA (AdS100A1), 
we used the method described by He et al. (21). An adenovirus containing GFP only (AdGFP) 
served as a control.  The titers of stocks used for these studies measured by plaque assays 
were 2x1011 plaque forming units/ml (pfu/ml) for AdS100A1 and 3¥1011 pfu/ml for AdGFP. 
Aliquots were stored at –80°C. 
Experimental rat HF model 
All animal procedures and experiments were peformed in accordance with corresponding 
institutional guidelines. 10-12 weeks old Sprague-Dawley rats of either sex (n=30) were 
sedated with pentobarbital (65mg/kg IP), intubated and further anesthetized with isoflurane 
(2% v/v) during mechanical ventilation.  Hearts were exposed by median sternotomy, fixed 
by an apical suture, and a liquid-nitrogen cooled cryoprobe with a diameter of 7 mm was 
applied for three freeze-thaw cycles on the free LV anterior wall.  The chest was then closed 
and animals were transferred back to their cages receiving appropiate analgesia.  Four ani-
mals in the cryoinfarction group died during surgery. Sham-operated control animals (n=9) 
underwent a similar procedure except application of the cryoprobe.  Hearts of six cryoin-
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farcted animals were sectioned transaxially and size of the infarcted LV area was estimated 
to 32±3% by triphenyltetrazolium chloride (TTC) staining (Figure 1A) (22). There were no 
differences in infarct size between any subsequent groups (data not shown).
Cardiac catheterization and in vivo intracoronary myocardial adenovirus delivery 
12 weeks after surgery closed-chest cardiac catheterization was performed both in anesthe-
tized (Xylazine 5mg/kg BW, Ketamine 100mg/kg BW) sham-operated and cryoinfarcted 
animals as described (8). A 2.5 F Millar catheter was inserted into the left main carotid 
artery and advanced into the LV. In vivo basal and isoproterenol-stimulated hemodynamic 
analysis (Bemon32/Amon32 Version 3.2.) included heart rate (beats/min), maximal (LVdP/
dtmax) and minimal (LVdP/dtmin) first derivate of LV pressure, LV end-diastolic pressure 
(LVEDP) and maximal LV systolic ejection pressure (LVESP).  Isoproterenol (6µg/kg/min) 
was administered via the jugular vein and data were aquired when functional parameters 
reached a stable plateau.  Afterwards, in vivo cardiac gene delivery was performed as pre-
viously described by the Hajjar group (15, 23).  Animals were divided in three groups either 
receiving 200 µl AdS100A1 (1x1010 pfu; n=8) or AdGFP (1x1010 pfu; n=8) in solution via a 
22-G catheter advanced from the apex of the LV to the aortic root.  The third failing group 
(n=8) received saline injection only.  The aorta and the main pulmonary artery were clamped 
distal to the site of the catheter and the solution injected.  The clamp was maintained for 10 
sec when the heart pumped against a closed isovolumic system allowing the adenovirus to 
circulate down the coronary arteries and perfuse the heart.  In each group one animal died 
during this procedure.  After removal of air and blood, the chest was closed, and animals 
were extubated and transferred back to their cages.  Seven days after gene transfer, in vivo 
cardiac function was reevaluated as described above via the right main carotid artery.  After 
cardiac catheterization, same animals were used for isolation of ventricular cardiomyocy-
tes. Transfection efficieny was monitored by GFP fluorescence (510 nm) in cryosectioned 
hearts (20 µm sections, 40-fold magnification).  To confirm specificity of the GFP emission 
both the same offset for suppressed background of non-transfected hearts excited at 488 nm 
was applied to adenovirally transfected hearts (Figure 3.5A-F) and additional measurements 
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were taken below and above the GFP excitation spectrum (data not shown).  
Cardiomyocyte isolation and in vitro gene transfer
Adult LV cardiomyocytes were obtained using a collagenase digestion method as described 
in detail elsewhere (9). Adenoviral transfection (5 pfu/cell) of isolated ventricular cardiomy-
ocytes from saline-treated failing hearts (n=4) was carried out in HEPES-modified medium 
199 (M199) and cells were maintained in M199 for 24 hours at 37°C, 95%O2/5%CO2. 
Cardiomyocytes used for contractility, Ca2+ and Na+ measurements were plated with a den-
sity of 30.000 cells/cm2 on laminin-coated glass dishes.  For analysis of mRNA and protein 
expression and energetic metabolites, cardiomyocytes were plated with a density of 150.000 
and 300.000 cells/cm2, respectively. 
Indirect Immunofluorescence
Imaging of adenoviral treated ventricular cardiomyocytes was carried out as described pre-
viously with minor modifications (13).  Briefly, adenoviral transfection (5 pfu/cell) of isolated 
cells was carried out on coated glass coverslips.  After 24 hrs cells were fixed, permeabilized 
and labeled with anti-S100A1 (SA 5632, Eurogentec; 1/300), anti-SERCA2 (Alexis; 1/500) 
or anti-RyR2 (Alexis; 1/500) antibodies, followed by the corresponding Cy3-conjugated 
(Jackson Immuno Research Lab; 1/3000) and Cy5-conjugated (Jackson Immuno Research 
Lab; 1/400) secondary antibodies.  Confocal images were obtained using a 40x objective on 
a Leica TCS SP laser scanning confocal microscope. Digitized confocal images were pro-
cessed by Leica software and Adobe Photoshop.
Cardiomyocyte contractility
Contractile properties of isolated ventricular cardiomyocytes were obtained by video-edge-
detection as described previously (7). Analysis of in vivo and in vitro transfected cardio-
myocytes was carried out immediately after isolation and 24 hrs following adenoviral gene 
transfer, respectively.  Analysis of steady state twitches at 2 Hz field stimulation, 37°C and 2 
mM extracellular Ca2+-concentration ([Ca2+]
e
) was performed by custom designed software 
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written in LabView (version 5.0, National Instruments). 
Intracellular Ca2+-transients and SR Ca2+-load
Calibration and assessment of intracellular Ca2+-transients and SR Ca2+-load in field-stimu-
lated ventricular cardiomyocytes was performed as described in details elsewhere (8). As-
sessment of Ca2+-handling properties in isolated, FURA-2AM loaded in vivo and in vitro-
transfected cardiomyocytes was carried out immediately after isolation and 24 hrs following 
adenoviral gene delivery, respectively.  Steady state transients at 2 Hz field stimulation, 
37°C and 2 mM [Ca2+]
e
 were analyzed by T.I.L.L Vision software (version 4.01).  To avoid 
interference with FURA-2 and GFP emission, FURA-2 emision was assessed both in non-
transfected and GFP-transfected cells and GFP emission interference (+5%) was subtracted 
prior to calibration.    
COS-1 cell culture and adenoviral transfection
COS-1 cells were maintained in DMEM supplemented with 10% FCS, penicillin/streptomy-
cin (100 units/ml) and glutamine (2 mM) at 37°C in a 95% air/5% CO2 humidified atmos-
phere and grown to 80% confluency. Infections of cultured cells with recombinant adenovi-
rus were performed with a multiplicity of 100 viral particles per cell in serum free medium 
for 6 hours. Cells were either co-infected with S100A1 and SERCA2a adenovirus or each 
virus alone. Cells were further grown in supplemented DMEM for 48 hours and harvested 
for preparation of microsomal fractions and western blot analysis in ice-cold PBS (pH 7.4) 
supplemented with protease inhibitors (1tablet/5 ml) (Roche Applied Science; Mini Com-
plete EDTA free protease inhibitors).    
Ca2+-ATPase measurements
Cardiac SR vesicles and microsomal fractions from in vitro adenoviral treated failing cardi-
omyocytes and COS cells, respectively, were prepared by density-gradient centrifugation as 
previously described (n=3 different preparations) (8, 24). COS microsomal fractions were 
prepared in the presence of CaCl
2 
(1 mM) to prevent depletion of overexpressed S100A1 
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protein. SR Ca2+-ATPase activity was assessed by the use of a pyruvate/NADH coupled 
enzymatic reaction (19). 
SR Ca2+-leak assay
Ca2+-leak from SR vesicles derived from in vivo adenoviral treated and control hearts (n=3 
in each group) was assessed by the use of the Ca2+-indicator Fluo-3 as described previously 
(25).  S100A1 recombinant human protein and S100A1 peptides (N-terminal; N: amino acid 
2-16; hinge region; H: amino acid 42-54; C-terminal; C: amino acids 75-94) were obtained 
as described elsewhere (11).   
[3H]-Ryanodine binding
[3H]-Ryanodine binding experiments were performed from terminal SR vesicle preparations 
prepared from rat left ventricular myocardium as described (8, 26). Briefly, membranes were 
incubated at 37°C with 6 nM [3H]ryanodine (Perkin Elmer) in 300 µl of 20 mM PIPES, 
pH 7.1, 150 mM KCl, 0.5 mM MgCl
2
, 15 mM NaCl, EGTA 3 mM, 10 mM caffeine, 1% 
phosphatase inhibitors (Sigma; inhibitor mix I/II), protease inhibitors (1tablet/5 ml) (Ro-
che Applied Science; Mini Complete EDTA free protease inhibitors) and the indicated free 
Ca2+-concentrations either in the presence or absence of 1 µM human recombinant S100A1 
protein. Nonspecific binding was determined using 1000-fold excess of unlabeled ryanodi-
ne. After 60 min, aliquots of the samples were diluted in 10 volumes of ice-cold water and 
placed on Whatman GF/B filters preincubated with 2% polyethyleneimine in water. Filters 
were washed three times with 5 ml of ice-cold 20 mM PIPES, pH 7.1, 150 mM KCl, 15 mM 
NaCl. Radioactivity remaining on the filters was determined by liquid scintillation counting 
to obtain bound [3H]ryanodine.       
Western Blotting
Western blots to assess protein levels of S100A1 protein (Sigma, S-2407), SERCA2 (Biomol 
SA209-0100), NCX (ABR MA3-926), CSQ (calbiochem 208915), cardiac actin (Progen 
Ac1-20.4.2), PLB (upstate 05-205), Ser16-PLB (upstate 07-052) and GFP (clontech, #837 
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1-1) were done with samples of in vitro (n=3) or in vivo (n=7) adenovirally treated myocar-
dium as wells as transfected COS cells (n=3) as described elsewhere (8). S100A1 protein 
(Mr 10000) from cellular extracts was enriched by sequential size exlusion centrifugation 
columns (Amicon; Microcon YM-50 and -3).
 
Co-immunoprecipitations
Co-immunoprecipitation for S100A1 with SERCA2 and RyR2 was investigated in crude 
membrane preparations from in vitro adenoviral-treated failing cardiomyocytes as described 
previously (8, 27). Interaction of S100A1 with SERCA2 was also tested in cell lysates from 
adenovirally transfected COS cells. To exclude unspecific binding anti-S100A1 (SA 5632) 
preincubated with the blocking peptide (hinge, S100A1 amino acids 42-54) was used as a 
control. Samples were processed by western blot as described above with minor modifica-
tions. Co-immunprecipitated samples for S100A1-SERCA2 and S100A1-RyR2 were stai-
ned with an anti-S100A1 (SA 5632, custom-made by Eurogentec), anti-SERCA2 (Biomol, 
SA209-0100) and anti-RyR2 (ABR, MA-3-925) antibody, followed by a corresponding pair 
of Alexa-Fluor 680 (Molular Probes) and IRDye 800CW (Rockland) coupled secondary 
antibodes, respectively. Proteins were visualized with an LICOR infrared imager (Odyssey) 
and pictures were processed by Odyssey v1.2 infrared imaging software. 
  
RNA Isolation, Reverse Transcription and Quantitative Real-Time PCR
Total RNA isolation, reverse transcription and real-time RT-PCR was carried out for rat at-
rial natriuretic factor (ANF; forward primer 5ʼ-CCCGACCCAGCATGG-3ʼ, reverse primer 
5ʼ-CAACTGCTTTCTGAAAGGGGTG-3ʼ; annealing temperature 60°C), NCX (forward 
primer 5ʼ-GCTCATATTACTGTAAGAAAGGGGTG-3ʼ, reverse primer 5ʼ-GGCGGCG-
CTTCCCA-CAATGG-3ʼ; annealing temperature 61°C), a-sk-actin (forward primer 5ʼ-
CAGCTCTGGCTCCCAGCACC-3ʼ, reverse primer 5ʼ-AATGGCTGGCTTTAATGCTT-
CA-3ʼ; annealing temperature 60°C) from in vitro (n=3) and in vivo (n=7) adenoviral treated 
failing cardiomyocytes by the use of an ABI Prism 7000 Sequence Detection System and 
the Platinum“ SYBR“ Green qPCR SuperMix-UDG (Invitrogen) as described elsewhere 
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(10). 18s rRNA signals were used for normalization (forward primer 5ʼ-TCAAGAACG-
AAAGTCGGAGG-3ʼ, reverse primer 5ʼ-GGACATCTAAGGGCATCAC-3ʼ; annealing 
temperature 60°C).  After amplification, a melting curve acquired by heating the product 
to 95°C, cooling to and maintaining at 55°C for 20 sec, then slowly (0.5°C/sec) heating to 
95°C was used to determine the specificity of PCR products, which were then confirmed by 
gel electrophoresis. 
Measurement of intracellular Na+-concentrations
Calibration and assessment of intracellular Na+-concentration ([Na+]
i
) of cardiomyocytes 
(n=3 different preparations) was accomplished 24 hrs following adenoviral delivery by the 
use of the Na+-fluorescent dye SBFI-AM as previously described (28). Analysis of [Na+]
i 
was 
performed at rest and 2 Hz at 37°C and 2 mM [Ca2+]
e
 with T.I.L.L Vision software (version 
4.01).  
Assessment of high energetic phosphates 
Phosphocreatine (PCr) and adenosine triphosphate (ATP) levels were measured in cellular 
homogenates 24 hrs after adenoviral treatment (n=3 different preparations) as described pre-
viously (29).
Statistics
Data are generally expressed as mean±SEM.  An unpaired two-tail studentʼs t-test and two-
way repeated measures ANOVA were performed for statistical comparisons.  For all tests, a 
P value of <0.05 was considered as significant.
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3.4 Results
Characterization of experimental heart failure model
12 weeks after surgery, cryoinfarcted animals (n=24) (Figure 3.1A) developed post-in-
farction HF shown by marked LV enlargement (Figure 3.1B) and depressed in vivo basal 
and β-adrenergic stimulated cardiac function compared with sham-operated control animals 
(sham-OP, n=9) (Table 3.1).
Figure 3.1: Post-infarct heart failure 
model. (A) Representative TTC-stai-
ned cross-sections of a sham-operated 
(left panel) and a cryoinfarcted (right 
panel) rat heart 6 hrs after surgery. 
Transmural cryoinfarcted myocardi-
um emerges as brown tissue with a 
grey-white border zone (right panel). 
Bar, 5mm. (B) Representative mid-
ventricular cross-sections of a sham-
operated (left panel) and cryoinfarcted 
(right panel) rat heart 12 weeks after 
surgery. Bar, 1mm. (C) Representative 
images of a freshly isolated LV cardi-
omyocyte from a non-failing (left pa-
nel) and failing heart (right panel) 12 
weeks after surgery. Note the marked 
increase in end-diastolic length in F. 
Bar, 25µm. 
C
Similarly, isolated LV cardiomyocytes from cryoinfarcted hearts displayed evidence of HF 
with significant depression of contractility and Ca2+-cycling (Table 3.2) as well as a marked 
increase in end-diastolic cell length (EDL) (31%) (Figure 3.1C) compared with non-failing 
cardiomyocytes obtained from sham-operated rats. Quantitative RT-PCR analysis indicated 
a significant increase in mRNA levels for ANF (42-fold), NCX (2.7-fold) and α-sk-actin 
(10-fold) in failing cardiomyocytes (Figure 3.2A). 
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Table 3.1
Figure 3.2. Reactivated fetal gene expression and abnormal abundance of Ca2+-regulatory proteins in 
failing myocardium. (A) Reactivated fetal gene expression (ANF, NCX and α-sk-actin) in failing rat cardi-
omyocytes (F) versus non-failing sham-operated hearts (NF). (n=6; * P<0.01 F vs. NF).  Results were obtai-
ned from 5 different hearts in each group 12 weeks after surgery. (B) Abnormal protein expression in failing 
cryoinfarcted rat hearts. (Left) Representative results of Western blots for NCX, SERCA2, CSQ, S100A1 and 
PLB from pooled fractions of failing (F) cryoinfarcted rat hearts (F; n=5) and non-failing (NF; n=5) sham-
operated control hearts 12 weeks after surgery. (Right) Average change (n-fold) in protein expression in failing 
(F) cryoinfarcted hearts relative to the sham-operated group (NF). (n=7; * P<0.01 F vs. NF).  Data are given 
as mean±SEM.
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Moreover, failing cardiomyocytes exhibited a significant decrease in protein levels for 
S100A1 (4.1-fold), SERCA2 (1.9-fold) and PLB (1.2-fold) compared with non-failing cardi-
omyocytes (Figure 3.2B).  NCX protein in failing cardiomyocytes was up-regulated (2-fold) 
while CSQ was unchanged compared with non-failing cells (Figure 3.2B).  These results 
show that chronic cryoinfarcted rat hearts have the typical biochemical and functional alte-
rations of failing myocardium. 
S100A1 gene transfer restores S100A1 protein levels in failing ventricular cardiomyo-
cytes in vitro 
To assess the impact of cardiac S100A1 gene transfer on failing ventricular cardiomyo-
cytes in vitro, we treated adult cardiomyocytes isolated from post-infarcted failing rat hearts 
with a S100A1 adenovirus (AdS100A1). Incubation of failing cardiomyocytes either with 
AdS100A1 (MOI 5 pfu/cell) or AdGFP (MOI 5 pfu/cell) resulted in a nearly 100% infection 
rate in both groups as indicated by the expression of the GFP reporter (Figure 3.3A). Analysis 
of S100A1 protein expression 24 hrs following gene transfer revealed restoration of S100A1 
protein in failing cardiomyocytes (F) to levels observed in non-failing cardiomyocytes (NF) 
(F; 0.9±0.3, NF; 4.2±0.4, F-AdS100A1; 3.9±0.5, P=n.s. NF vs. F-AdS100A1, P<0.05 F-
Table 3.2
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AdS100A1 vs. F, n=4) (Figure 3.3B).  Data are given as relative arbitrary units normalized 
to CSQ that did not change among the different groups nor did α-cardiac actin. In contrast, 
AdGFP-treated failing myocytes continued to have diminished expression of S100A1 (F-
AdGFP; 0.8±0.3, Figure 3.3B). The increased S100A1 protein seen 24 hrs after AdS100A1 
treatment did not change aberrant protein expression of SERCA2 (NF; 4.2±0.4, F; 2.1±0.3, 
F-AdGFP; 2.2±0.4, F-AdS100A1; 2.4±0.2, n=4), NCX (NF; 0.7±0.1, F; 1.4±0.2, F-AdGFP; 
1.6±0.3, F-AdS100A1; 1.5±0.3, n=4) or PLB (NF; 1.1±0.1, F; 0.7±0.2, F-AdGFP; 0.6±0.1, 
F-AdS100A1; 0.6±0.2, n=4) compared with either AdGFP-treated or untreated failing car-
diomyocytes (Figure 3.3B). 
Figure 3.3: S100A1-mediated rescue of contractile dysfunction in vitro. (A) Efficiency of adenoviral-me-
diated gene transfer in failing cardiomyocytes. Representative transmission (left) and GFP emission images 
(right) from failing cells 24 hrs after adenoviral infection. (upper panel, left) F-AdGFP transmission, (upper 
panel, right) F-AdGFP 510-nm emission, (lower panel, left) F-AdS100A1 transmission, (lower panel, right) F-
AdS100A1 510-nm emission. Bar, 100 µm. (B) Restoration of S100A1 protein levels in failing cardiomyocytes 
24 hrs after S100A1 gene transfer. Representative results of Western blots for SERCA2, NCX, CSQ, cardiac 
actin, GFP, PLB and S100A1 from homogenates both of untreated non-failing (NF) and failing (F) cells and 
Ad-GFP and Ad-S100A1 transfected failing cardiomyocytes. Note that GFP is only expressed in adenoviral 
treated failing cells. Data are shown from two different representative preparations (animal 82 and 93). (C) 
Rescue of contractile function in failing cardiomyocytes (F) after adenoviral S100A1 gene transfer. 
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Original tracings of fractional shortening (FS%, shown as downward deflection) from a representative non-
failing (NF, upper panel, left), failing (F, upper panel, right) and AdGFP-infected (F-AdGFP, lower panel, left) 
and AdS100A1-infected (F-AdS100A1, lower panel, right) failing cardiomyocyte. (D) Normalization of frac-
tional shortening (FS%; upper panel), rate of cellular shortening (-dl/dt; µm/msec; middle panel) and rate of 
cellular relengthening (+dl/dt; µm/msec; lower panel) in failing cells after S100A1 gene addition. (n=40 cells 
from four different preparations in each group; * P<0.01 NF vs. F and F-AdGFP, ** P<0.01 F-AdS100A1 vs. 
F and F-AdGFP, P=n.s. NF vs. F-AdS100A1). Data are presented as mean±SEM.
Adenoviral S100A1 gene delivery rescues contractile function of failing ventricular 
cardiomyocytes in vitro
Figure 3.3C shows representative steady-state twitches from untreated non-failing (NF) 
and failing cardiomyocytes (F) (upper panel) and AdGFP- and AdS100A1-treated failing 
cells (lower panel). Recordings were obtained at 2Hz, 37°C and 2 mM [Ca2+]
e
 24 hrs after 
gene transfer.  S100A1 gene delivery significantly increased fractional shortening (FS%) (%: 
NF; 10.8±0.49, F; 5.8±0.37, F-AdGFP; 5.1±0.27, F-AdS100A1; 10.5±0.39), the rate of cell 
shortening (-dL/dt) (-µm/msec: NF; 0.82±0.05, F; 0.41±0.03, F-AdGFP; 0.39±0.03, F-Ad-
S100A1; 0.89±0.05) and relenghtening (+dL/dt) (+µm/msec: NF; 0.75±0.05, F; 0.29±0.03, 
F-AdGFP; 0.27±0.02, F-AdS100A1; 0.67±0.04) in failing cardiomyocytes to levels obser-
ved in non-failing cells (Figure 3.3D).  AdGFP treatment did not improve contractility of 
failing cells (Figure 3.3D).
S100A1 gene delivery normalizes Ca2+-handling in failing ventricular cardiomyocytes 
in vitro
Figure 3.4A displays representative steady-state Ca2+-transients obtained under basal 
conditions from non-failing (NF) and failing cardiomyocytes (F) 24 hrs after AdGFP or 
AdS100A1 treatment.  S100A1 gene transfer significantly increased the Ca2+-transient amp-
litude (nM) in failing cardiomyocytes to a degree observed in non-failing control cells (nM: 
NF; 326±23, F; 231±14, F-AdGFP; 225±33, F-AdS100A1; 300±25), whereas, infection 
with AdGFP did not improve decreased Ca2+-transient amplitudes (Figure 3.4B). In addition, 
AdS100A1-treated cells showed a significant accelerated decay of Ca2+-transient as assessed 
by the decay-constant t (data not shown). Moreover, S100A1 gene transfer also significantly 
reduced the elevated diastolic Ca2+-overload ([Ca2+]
i
) observed in AdGFP-treated and untre-
ated failing cells (nM: NF; 208±13, F; 322±25, F-AdGFP; 310±34, F-AdS100A1; 247±16) 
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(Figure 3.4C). Application of the SERCA2 inhibitor cyclopyazonic acid (10µM) abrogated 
the gain in function found in AdS100A1-treated failing myocytes (data not shown).
Figure 3.4: Normalization of Ca2+-transients and SR Ca2+-load after S100A1 gene delivery in failing car-
diomyocytes (A) Original tracings of Ca2+-transients (shown as upward deflection) from a representative non 
failing (NF), failing (F), AdGFP-infected (F-AdGFP) and AdS100A1-infected (F-AdS100A1) failing cardio-
myocyte. (B) Normalization of Ca2+-transient amplitude (nM) and (C) significant decrease in diastolic [Ca2+] 
(nM) in failing cells after AdS100A1 treatement. (n=40 cells from four different preparations in each group). 
(D) Original tracings of cytosolic Ca2+-rise in response to acute caffeine application (10mM) in the presence of 
Ni2+ (5mM) (shown as upward deflection) from a representative non-failing (NF), failing (NF) and AdGFP-
infected (F-AdGFP) and AdS100A1-infected (F-AdS100A1) failing cells. (E) Normalization of SR Ca2+-load 
estimated from the caffeine-induced cytosolic Ca2+-rise (nM) in failing cells after AdS100A1 gene transfer. 
(n=40 cells from four different preparations in each group). * P<0.01 NF vs. F and F-AdGFP, ** P<0.01 F-
AdS100A1 vs. F and F-AdGFP, P=n.s. NF vs. F-AdS100A1. Data are presented as mean±SEM.
Figure 3.4D provides representative original tracings of cytosolic [Ca2+]
i
 rise for untreated 
non-failing (NF), failing cells (F), AdGFP- and AdS100A1-treated failing cardiomyocytes in 
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response to rapid application of caffeine (10mM) and Ni2+ (5mM) serving as a measure for 
the SR Ca2+-load.  S100A1 gene delivery significantly augmented the amplitude of the caf-
feine-mediated rise in [Ca2+]
i
 to levels observed in non-failing control (nM: NF; 787±33, F; 
469±44, F-AdGFP; 449±29, F-AdS100A1; 709±19) (Figure 3.4E) indicating restoration of 
SR Ca2+-content in failing cells by S100A1. In contrast, infection of failing cardiomyocytes 
with AdGFP did not improve diminished SR Ca2+-load (Figure 3.4E). 
S100A1 interacts with SERCA2 and enhances SR Ca2+-ATPase activity in vitro
Subcellular location of adenovirally expressed S100A1 in failing cardiomyocytes was 
investigated by confocal laser scanning microscopy. Anti-S100A1 immunolabelling of 
AdS100A1-treated failing cardiomyocytes revealed a fine granular network-like distribution 
for S100A1 (blue) throughout the cell that was periodically enhanced nearly every 2µm. 
(Figure 3.5B, see 3-fold magnified inlet). A similar pattern was obtained for SERCA2 (red) 
(Figure 3.5C).  Superimposing of both images revealed substantial colocalization of S100A1 
and SERCA2 (violet) (Figure 3.5D). This finding was further corroborated by Ca2+-depen-
dent co-immunoprecipitation for S100A1 with SERCA2 in the presence of 1 mM Ca2+ (Fi-
gure 3.5E). Lower free Ca2+ (1µM) also supported this interaction (data not shown). Inte-
restingly, co-immunoprecipitations carried out for SERCA2 and PLB revealed no apparent 
alteration of the PLB/SERCA2 interaction by S100A1 (data not shown). 
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Figure 3.5: S100A1 interacts with SERCA2 and increases activity of the SR Ca2+-pump in failing myocar-
dium. (A) Nomarski image of an AdS100A1 treated failing cardiomyocyte.  Immunolabeling of (B) S100A1 
(blue) and (C) SERCA2 (red) in the same cell. (D) Overlay of G and H depicts co-localization of SERCA2 
and S100A1 (violet). Bar, 20µm. (E) Ca2+-dependent co-immunoprecipitation of SERCA2 (red) and S100A1 
(green). Samples were immunoprecipated with anti-SERCA2 antibody and co-stained for S100A1. Controls 
were carried out with A/G-Sepharose beads (A/G-Beads) only. (F) Enhancement of Ca2+-dependent Ca2+-AT-
Pase activity in homogenates of AdS100A1-treated failing cardiomyocytes. (G) Co-incubation of F-AdGFP 
homogenates with human recombinant S100A1 protein (rhS100A1) and S100A1 peptides enhances SERCA2 
activity. Experiments were carried out at pCa 6.2. (n=6). * P<0.01 NF vs. F, ** P<0.01 F-AdS100A1 and F-
AdGFP + S100A1 protein or peptides vs. F-AdGFP.  Pooled cardiomyocyte samples were obtained from four 
different preparations in each group.  Data are presented as mean±SEM.
SERCA2 activity was measured in SR preparations derived both from AdS100A1- and 
AdGFP-treated failing cells as well as non-failing cardiomyocytes by the use of a pyruva-
te/NADH coupled reaction at pCa 6.2. SERCA2 activity in AdGFP-treated failing cells (F-
AdGFP) was significantly decreased compared with non-failing control (NF) (Figure 3.5F). 
However, SR preparations from AdS100A1 myocytes had significantly improved Ca2+-de-
pendent SERCA2 activity (µmol/min/mg protein: NF; 0.175±0.03, F-AdGFP; 0.07±0.01, 
F-AdS100A1; 0.121±0.02) (Figure 3.5F). Further in accordance with these data, incubation 
of SR vesicles isolated from F-AdGFP myocytes with recombinant human S100A1 protein 
showed a similar increase in SERCA2 activity (Figure 3.5G). Testing of distinct regions of 
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S100A1 using oligopeptides revealed that the S100A1-mediated increase in SERCA2 activi-
ty is through the carboxyl terminal domain (S100A1-C) of the protein (Figure 3.5G).
S100A1 interacts with SERCA2 and increases SR Ca2+-ATPase activity in COS cells
Co-expression of S100A1 and SERCA2 in COS cells was carried out to confirm the 
impact of S100A1 on SR Ca2+-handling seen in myocardial tissue. COS cells were incuba-
ted with 100 viral particles per cell to achieve 100% transfection (data not shown). Figure 
3.6A shows representative western blot images for adenovirally overexpressed SERCA2 and 
S100A1 protein in COS cell lysates. Staining for ß-actin served as a control for equal protein 
loading. Assessment of Ca2+-ATPase activity in COS microsomal fractions were carried out 
in the presence of 600 nM free Ca2+-concentration (pCa 6.2). As displayed in Figure 3.6B 
(left panel) co-expression of S100A1 enhanced Ca2+-ATPase activity of SERCA2 by 44%. 
Notably, the S100A1 mediated increase in SERCA2 activity could be prevented by addition 
of an anti-S100A1 antibody (10 µl SA 5632) whereas application of the antibody preincu-
bated with an S100A1 blocking peptide (S100A1 amino acids 42-54) did not abrogate the 
S100A1-mediated effect. Thapsigargin (10–6 M) completely abolished the ATPase activity 
both in SERCA2 and S100A1/SERCA2 overexpressing COS cells confirming specificity of 
the measurements. Likewise co-expressed S100A1 protein, addition of 1 µM of human re-
combinant S100A1 protein also significantly increased the Ca2+-ATPase activity in SERCA2 
overexpressing COS cells (Figure 3.6B, right panel).
Co-immunoprecipitations carried out for adenovirally expressed S100A1 and SERCA2 
confirmed the Ca2+-dependent interaction of both molecules observed in myocardium.  
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Figure 3.6: S100A1 interacts with SERCA2 and increases activity of the SR Ca2+-pump in COS cells. (A) 
Representative Western Blots given for adenovirally expressed S100A1 and SERCA2 in COS cells. ß-actin 
staining served as leading control. (B) (Left panel) Enhanced Ca2+-dependent ATPase activity in SERCA2 ex-
pressing COS cells by co-expressed S100A1 protein. Expression of S100A1 alone did not alter Ca2+-dependent 
ATPase activity in COS cells. Note that addition of anti-S100A1 antibody (SA 5632) abrogated the S100A1 
mediated increase in Ca2+-dependent ATPase activity. (Right panel) Increased Ca2+-dependent ATPase activity 
in SERCA2 expressing COS cells following application of human recombinant S100A1 protein (1µM). Appli-
cation of anti-S100A1 antibody (SA 5632, 10µl) abrogated the S100A1 mediated enhancement of Ca2+-depen-
dent ATPase activity. Application of the SERCA2 inhibitor thapsigargin (10-6 M) abolished Ca2+-dependent 
ATPase activity in AdSERCA2 infected COS cells. Experiments were carried out at pCa 6.2. (n=3). * P<0.01 
vs. AdSERCA2, ** P<0.01 vs. AdS100A1/AdSERCA2. Data are presented as mean±SEM. (C) Ca2+-depen-
dent co-immunoprecipitation of SERCA2 (red) and S100A1 (green). Samples were immunoprecipated with 
anti-S100A1 antibody and co-stained for SERCA2. Controls were carried out with an anti-S100A1 antibody 
preincubated with an blocking peptide. 
As shown in Figure 3.6C, S100A1 co-immunoprecipates SERCA2 only in the presence of 
1 µM free Ca2+-concentration but not in the presence of EGTA. S100A1 also co-precipitates 
with SERCA2 in the presence of 1 mM Ca2+ (data not shown). Specificity of this finding was 
confirmed by testing the S100A1 antibody preincubated with an S100A1 blocking peptide 
that neither precipated S100A1 protein nor co-precipated SERCA2.  
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S100A1 interacts with the RyR2 and reduces the SR Ca2+-leak
Since S100A1 has been shown to interact with RyR in striated muscle (14), we investiga-
ted whether adenoviral expressed S100A1 might associate with the SR Ca2+-release channel 
in failing cardiomyocytes. Figure 3.7 shows representative confocal images for S100A1 
(blue) (Figure 3.7B) and RyR2 (red) (Figure 3.7C) in myocytes after AdS100A1 treatment. 
Merging the corresponding pictures revealed partial colocalization for S100A1 with the 
RyR2 (violet) (Figure 3.7D, see 3-fold magnified inlet).
Figure 3.7: S100A1 interacts with RyR2 and reduces the SR Ca2+-leak in failing myocardium. (A) No-
marski image of an AdS100A1-transfected failing cardiomyocyte. Immunolabelling of (B) S100A1 (blue) and 
(C) RyR2 (red) in the same cell. (D) Overlay of B and C depicts colocalization of S100A1 and RyR2 (violet). 
Bar, 20µm. (E) Ca2+-dependent co-immunoprecipitation of RyR2 (green) and S100A1 (red). Controls were 
carried out with A/G-Sepharose beads (A/G-Beads) only. (F) Typical tracings of the time course (upper panel) 
and averaged values (%) (lower panel) of the SR Ca2+ leak in non-failing (NFCs), failing (FCs) and AdGFP- 
and AdS100A1-transfected failing myocardium. Arrow indicates addition of thapsigargin (+TG; 1µM) (n=4). 
* P<0.01 NFCs vs. FCs and FCs-AdGFP, ** P<0.01 FCs-AdS100A1 vs. FCs and FCs-AdGFP, P=n.s. NFCs 
vs. FCs-AdS100A1. Data are presented as mean±SEM.
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As shown in Figure 3.7E, Ca2+-dependent (1mM) co-immunoprecipitation of S100A1 with 
RyR2 in failing cells provides further evidence for the association of both proteins. This was 
also evident with lower Ca2+ (1µM, data not shown). Since S100A1 gene transfer resulted in 
restored SR Ca2+-content and decreased diastolic [Ca2+]
i
, we investigated whether S100A1 
might affect the SR Ca2+-leak in failing myocardium. Figure 3.7F (upper panel) shows the 
representative time course of the Ca2+-leak from SR vesicles derived from non-failing as 
well as AdGFP- and AdS100A1-treated failing myocardium in the presence of thapsigargin 
(+TG, 1µM) after Ca2+-uptake induced by MgATP. In contrast to non-failing SR vesicles, 
a prominent Ca2+-leak was observed in non-treated and AdGFP-treated failing myocardium 
that was significantly reduced after AdS100A1 treatment.
S100A1 modulates activity of the cardiac SR Ca2+-release channel     
The influence of S100A1 on RyR2 activity was further investigated in S100A1-depleted 
cardiac SR vesicle preparations. RyR2 activity was indirectly measured by assessment of 
Ca2+-dependent RyR2 [3H]-ryanodine binding in the presence and absence of 1 µM human 
recombinant S100A1. As depicted in Figure 3.8, S100A1 modulates RyR2  [3H]-ryanodine 
binding in a biphasic manner. Applied S100A1 apparently reduced [3H]-ryanodine binding 
and RyR2 open probability, respectively, at least in the presence of 150 nM. However, in 
the presence of increasing Ca2+ concentrations, S100A1 enhanced [3H]-ryanodine binding 
implicating increased activity of the RyR2. Thus, decreased RyR2 activity at diastolic Ca2+-
concentrations might account at least in part for the S100A1-caused decrease in the SR Ca2+-
leak whereas enhanced RyR2 activity at supra-diastolic Ca2+-concentrations might contribu-
te to the S100A1-mediated increase in Ca2+-transient amplitude in normal (7, 8) and even 
failing cardiomyocytes. 
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Figure 3.8: S100A1 modulates RyR2 activity in biphasic manner. Control SR vesicles show a Ca2+-de-
pendent increase of [3H]-ryanodine binding in the presence of 0.5 mM Mg2+ and 10 mM caffeine. Addition 
of 1µM S100A1 protein decreased [3H]-ryanodine at 150 nM free Ca2+ concentrations while ≥ 300 nM free 
Ca2+ S100A1 increased [3H]-ryanodine binding to the cardiac SR Ca2+-release channel. Data are presented as 
mean±SEM and expressed as counts per minute (CPM). Experiments (n=3) were carried out in triplicates.  
Fetal gene expression in failing ventricular cardiomyocytes in vitro is reversed 
after AdS100A1 treatment
As assessed by quantitative real-time PCR, normalization of S100A1 protein levels in 
failing cardiomyocytes significantly suppressed increased mRNA expression of ANF (Fi-
gure 3.9A) (arbitrary units: NFCs; 1, FCs; 42±06, FCs-AdGFP; 37±07, FCs-AdS100A1; 
24±05) and essentially normalized NCX mRNA (Figure 3.9B) (arbitrary units: NFCs; 1, 
FCs; 2.7±0.5, FCs-AdGFP; 2.9±0.3, FCs-AdS100A1; 1.23±0.2) within 24 hrs, whereas 
AdGFP infection revealed no alterations of these genes.
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Figure 3.9. Effect of adenovirally expressed S100A1 on fetal gene expression and Na+-handling in failing 
cardiomyocytes. (A) Average relative mRNA expression for ANF (upper panel) and (B) NCX (lower panel). 
18S rRNA signals were used for normalization. (n=6) (C) Normalization of [Na+]
i
 in FCS following S100A1 
gene transfer. (n=40 cells from four different preparations; FCs [open triangles], FCs-AdGFP [filled triangles], 
NFCs [open squares], FCs-AdS100A1 [filled squares]. * P<0.01 compared with NFCs; **P. Data <0.01 com-
pared with FCs and FCs-Ad GFP; P=NS, NFCs vs. FCs-AdS100A1. Data are presented as mean±SEM.
AdS100A1 treatment normalizes intracellular Na+-concentration in failing ventricular 
cardiomyocytes in vitro
We next addressed the impact of S100A1 gene-transfer on disturbed intracellular Na+-
handling in failing cardiomyocytes by the measurement of the Na+-fluorescent indicator 
SBFI-AM.  Steady state [Na+]
i
 was found to be significantly increased both in untreated 
and AdGFP-treated failing cardiomyocytes compared with non-failing control (NFC) both 
under rest (mM: FCs 16.12±0.36, FCs-AdGFP 16.12±0.36, NFCs 11.21±0.41) and electrical 
stimulation (2Hz) (mM: F 20.21±0.49, FCs-AdGFP 20.24±0.68, NFCs 15.04±0.39) (Figure 
3.9C). However, S100A1 gene transfer decreased elevated [Na+]
i
 in failing cardiomyocy-
tes under both conditions to levels observed in non-failing cells (mM: rest FCs-AdS100A1 
10.67±0.49, 2Hz FCs-AdS100A1 13.80±0.47) (Figure 9C). 
Improved contractile reserve in failing ventricular cardiomyocytes after AdS100A1 
treatment in vitro 
AdS100A1 infection significantly improved the blunted β-adrenergic contractile response 
of failing cardiomyocytes compared with AdGFP-treated and untreated failing cells (Figure 
3.10A).  However, phosphorylation of PLB serine-16, reflecting cAMP-dependent protein 
kinase (PKA) activity was unchanged in AdS100A1-infected failing cardiomyocytes com-
C
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pared to controls (Figure 3.10B). Note that treatment of non-failing cells with isoproterenol 
resulted in a visible higher amount of PLB Serine-16 phosphorylation than in failing cardi-
omyocytes. 
Figure 3.10: Adenoviral S100A1 gene delivery improves contractile reserve and normalizes energy sup-
ply in FCs. (A) Improved β-adrenergic stimulated contractility due to S100A1 gene addition in failing car-
diomyocytes. (n=30 cells from three different preparations. (B) Representative Western blots for total PLB 
(upper panel) and phosphorylated PLB (PLB-P Serine-16, lower panel) levels in NFCs, FCs, FCs-AdGFP, and 
FCs_AdS100A1-infected FCs under basal conditions and in response to isoproterenol (Iso, 10–6 M). (C) Nor-
malization of PCr/ATP ratio in FCs following S100A1 gene addition. Average results for PCr/ATP ratio of each 
experimental group. (n=4). * P<0.01 compared with NFCs, ** P<0.01 compared with FCs and FCs-AdGFP, 
P=NCS, NFCs vs. FCs-AdS100A1. Data are presented as mean±SEM.    
AdS100A1 gene transfer rescues high energetic phosphate production in failing ventri-
cular cardiomyocytes in vitro
High energetic phosphates in non-failing and failing cardiomyocytes were determined by 
high performance liquid chromatography.  Figure 3.10C shows that the ratio of total amounts 
of phosphocreatine (PCr) to adenosine triphosphate (ATP) was significantly lower in fai-
ling than in non-failing cardiomyocytes indicating impaired energy production. Importantly, 
AdS100A1 treatment recovered the PCr/ATP ratio to values of non-failing cells (arbitrary 
units: NFCs; 2.43±0.1, FCs; 1.39±0.1, FCs-AdGFP; 1.48±0.2, FCs-AdS100A1; 2.4±0.1). 
A B
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Cardiac AdS100A1 gene transfer restores S100A1 protein levels in failing hearts in 
vivo
Having shown that S100A1 gene transfer normalized function of failing ventricular car-
diomyocytes in vitro, we next adressed the question whether in vivo intracoronary adeno-
viral-mediated S100A1 delivery might restore contractile function of failing rat hearts. We 
applied a catheter-based adenoviral delivery technique that has previously been shown to 
achieve global and relatively homogenous transgene expression throughout rat myocardium 
(15). Figure 3.11 shows representative confocal Nomarski and GFP fluorescence images 
of midventricular cyrosections of sham-OP (A/B) as well as AdS100A1 (C/D) and AdGFP 
(E/F) treated post-infarct rat hearts, respectively. To assess the amount of gene expression in 
these hearts 7 days after AdS100A1 (n=7) and AdGFP (n=7) intracoronary gene transfer, we 
analyzed cardiac S100A1 and GFP protein levels by Western blotting. As shown in Figure 
3.11G, infection with AdGFP did not alter downregulated S100A1 protein compared with 
failing saline-treated hearts (n=7) (arbitrary units: F-AdGFP 0.7±0.2, F-saline; 0.6±0.3, P=n.
s. F-AdGFP vs. F-saline, n=4), whereas delivery with AdS100A1 resulted in normalized car-
diac S100A1 protein compared with sham-operated non-failing hearts (n=9) (F-AdS100A1; 
2.2±0.3, sham-OP; 2.5±0.4, P=n.s. F-AdS100A1 vs. sham-OP, P<0.05 F-AdS100A1 vs. F-
AdGFP and F-saline, n=4).  The data are given as relative arbitrary units normalized to un-
changed CSQ for each group.  Note that GFP protein expression was only detected in treated 
hearts  (Figure 3.11G). 
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Figure 3.11: Intracoronary adenoviral S100A1 gene delivery rescues contractile dysfunction in vivo. (A-F) Repre-
sentative corresponding Nomarski and GFP-fluorescence images from midventricular cyrosections of non-failing (A/B) 
and AdS100A1- (C/D) and AdGFP-treated (E/F) failing myocyardium. Magnification 40-fold. (G) Cardiac S100A1 gene 
transfer reconstitutes S100A1 protein levels in failing myocardium in vivo.  Representative Western blot of S100A1, CSQ 
and GFP expression in sham-operated non-failing, saline-treated failing, and adenovirally-treated (AdGFP/AdS100A1) fai-
ling myocardium. (H-L) Restoration of basal cardiac contractile performance after AdS100A1 gene transfer in vivo. (M-O) 
Preserved gain-in-function of AdS100A1-treated failing hearts in vivo after isoproterenol stimulation. Saline- and AdGFP-
treated failing hearts displayed no significant difference in functional parameters and were combined to heart failure control 
group (HF-control; n=14). Data were obtained in isoflurane-anesthetized animals 7 days after intracoronary gene transfer or 
saline injection. Sham-OP; n=7, HF-AdS100A1; n=7. * P<0.05 HF-AdS100A1 vs. HF control. 
AdS100A1 gene transfer recovers contractile function of failing hearts in vivo
To gain further insight into the physiological consequences of restored cardiac S100A1 
protein levels in failing myocardium in vivo, we re-examined LV contractile properties by 
cardiac catheterization via the right carotid artery 7 days after gene transfer to 12 week 
post-infarcted rat hearts. Since saline- and AdGFP-treated failing hearts displayed no sig-
nificant difference in functional parameters, both groups were pooled and further refered 
to as HF-control (n=14).  As shown in Figure 3.11H, heart rate (HR) was not significantly 
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different among groups 7 days following gene delivery. However, cardiac S100A1 gene 
transfer significantly enhanced systolic function of failing hearts in vivo, reflected by a nor-
malized peak rate of LV pressure rise (+dp/dtmax) (+mmHg/sec: HF-AdS100A1; 6640±149, 
HF-control; 4634±267, sham-OP; 6777±209, P=n.s. HF-AdS100A1 vs. sham-OP, P<0.05 
HF-AdS100A1 vs. HF-control) and increased LV end-systolic pressure (LVESP) (mmHg: 
HF-AdS100A1; 101±4, HF-control; 88±4, sham-OP; 113±11, P=n.s. HF-AdS100A1 vs. 
sham-OP, P<0.05 HF-AdS100A1 vs. HF-control) (Figure 3.11I/J).  In addition, the peak 
rate of LV pressure decline (-dp/dtmin) (-mmHg/sec: HF-AdS100A1; 4501±129, HF-con-
trol; 3808±121, sham-OP; 5887±282, P<0.05 HF-AdS100A1 vs. HF-control), an index of 
diastolic function, was also significantly improved in response to S100A1 gene delivery 
(Figure 3.11K).  LV end-diastolic pressure (LVEDP) was also normalized after AdS100A1 
delivery (mmHg: HF-AdS100A1; 8.5±0.5 mmHg, HF-control; 16.1±2.4 sham-OP; 8.3±0.8, 
P=n.s. HF-AdS100A1 vs. sham-OP, P<0.05 HF-AdS100A1 vs. HF-control) (Figure 3.11L). 
Importantly, the S100A1-mediated in vivo gain in cardiac function was preserved after b-
adrenergic stimulation. As shown in Figure 3.11M, the isoproterenol-stimulated increase 
in heart rate was not significantly different between AdS100A1-treated and control failing 
hearts, however, AdS100A1-treated failing myocardium displayed improved systolic con-
tractile function in response to isoproterenol (Figure 3.11N/O). In line with these findings, 
LV cardiomyocytes isolated from AdS100A1-infected hearts displayed increased contrac-
tility (FS%: HF-AdGFP; 4.2±0.13, HF-AdS100A1; 8.1±0.51, P<0.05 HF-AdS100A1 vs. 
HF-AdGFP, n=60 cells; isolated from three different animals in each group) and intracellular 
Ca2+-transients (nM: HF-AdGFP; 188±10, HF-AdS100A1; 309±37, P<0.05 HF-AdS100A1 
vs. HF-AdGFP, n=60 cells; isolated from three different animals in each group) compared 
with failing cardiomyocytes derived from AdGFP-treated hearts. 
Cardiac AdS100A1 gene delivery in vivo reverses fetal gene expression
RT-PCR analysis of in vivo AdS100A1-treated failing rat hearts revealed a significant 
attenuation of elevated mRNA levels for ANF , NCX and α-sk-actin mRNA levels 7 days af-
ter gene transfer (Figure 3.12A). Moreover, Western blot analysis of failing rat myocardium 
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after AdS100A1 intracoronary delivery yielded a significant decrease in elevated NCX pro-
tein levels (arbitrary units: sham-OP; 1.3±0.4, HF-control; 2.4±0.3, F-AdS100A1; 1.6±0.3, 
n=4, P<0.05 HF-S100A1 vs. HF-control) and a significant increase in SERCA2 (sham-OP; 
3.5±0.8, HF-control; 1.4±0.6, F-AdS100A1; 2.9±0.3, n=4, P<0.05 HF-S100A1 vs. HF-con-
trol) and PLB (sham-OP; 4.1±0.5, HF-control; 2.3±0.7, F-AdS100A1; 3.6±0.2, n=4, P<0.05 
HF-S100A1 vs. HF-control) protein amount compared with HF-control (Figure 3.12B). Pro-
tein data are given as relative arbitrary units normalized to CSQ that did not change among 
the groups (data not shown).  
Figure 3.12: Intracoronary adenoviral S100A1 gene delivery reverses fetal gene expression and aberrant 
protein expression in failing myocardium in vivo. (A) Reversed fetal gene expression after S100A1 gene 
delivery in failing myocardium in vivo (* P<0.05 HF-AdS100A1 vs. HF-control, n=4, samples were obtained 
from 3 different animals in each group). (B) Impact of S100A1 gene addition on SERCA2, PLB and NCX pro-
tein amount in failing myocardium in vivo compared with saline-treated and AdGFP-treated failing myocardi-
um (n=4, samples were obtained from 3 different animals in each group). Data are presented as mean±SEM. 
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3.5 Discussion
S100A1 has recently been identified by our group as a novel positive regulator of cardi-
ac contractility as its cardiac-restricted overexpression improves cardiac contractile perfor-
mance in vitro and in vivo in a cAMP-independent manner (7, 8). Since S100A1 protein has 
been shown to be down-regulated in human and animal HF models (5, 6), we undertook this 
study to address whether S100A1 gene addition may reverse ventricular contractile dysfunc-
tion in failing myocardium. Using a post-infarct HF model in the rat, we provide evidence, 
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for the first time, that adenoviral-mediated myocardial S100A1 gene delivery can restore 
S100A1 protein expression in failing myocardium and rescue contractile dysfunction both 
in vitro and in vivo.  Restored S100A1 protein levels normalized dysfunctional intracellular 
Ca2+- and Na+-handling, reversed fetal gene expression associated with HF and restored en-
ergy supply in failing myocardium. These results strongly support the hypothesis that altered 
expression of S100A1 in HF significantly contributes to Ca2+-signaling abnormalities and 
cardiac dysfunction and S100A1 is a key factor in the regulation of cardiac excitation-con-
traction coupling. 
Adenoviral-mediated S100A1 gene transfer in vitro increased contractile performance 
of isolated failing cardiomyocytes to levels observed in non-failing ventricular cells. More-
over, S100A1 gene addition almost totally normalized b-adrenergic contractile response in 
failing ventricular myocytes, which was significantly attenuated under control conditions. 
This response was independent of any S100A1-mediated change in post-bAR signaling. 
For example, S100A1 overexpression did not alter serine-16 phosphorylation of PLB after 
isoproterenol addition.  This lack of altered bAR signalling in failing myocardium after 
S100A1 gene addition is similar to previous findings in transgenic mouse hearts overexpres-
sing S100A1 protein (8). Thus, normalized S100A1 protein levels in failing cardiomyocytes 
appear to have cAMP-independent and additive positive inotropic effects with b-adrenergic 
stimulation. This is also supported by previous findings in S100A1 deficient mouse hearts, 
which had impaired contractility despite normal b-adrenergic signalling (12).
Depressed contractility in HF is inherently linked to abnormal intracellular Ca2+-homeo-
stasis.  To gain further insight into the mechanisms by which S100A1 restores contractility 
in failing myocardium, we explored the impact of S100A1 gene addition on dysfunctional 
Ca2+-cycling in failing cardiomyocytes.  S100A1 gene delivery was found to normalize Ca2+-
transients and decreased diastolic Ca2+-overload in failing cardiomyocytes. Overall, it seems 
that normalized S100A1 expression in failing cardiomyocytes enhances contractility by re-
storing cytosolic Ca2+-handling, which was suggested by previous studies in normal myo-
cardium (7-9).  Since impaired SR Ca2+-load is a major hallmark of HF (16) and contributes 
to depressed cytosolic Ca2+-cycling (2), we were interested in whether S100A1 restoration 
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after gene delivery improved this aspect of SR Ca2+-signaling in failing cardiomyocytes. 
Importantly, S100A1 restores SR Ca2+-load in failing cardiomyocytes, which may account, 
at least in part, for reconstituted f-transients and improved cardiac contractile performance 
in AdS100A1-treated failing cardiomyocytes.  
Using confocal laser microscopy we found a colocalization in the SR between S100A1 
and SERCA2 after AdS100A1 treatment and also found a Ca2+-dependent association bet-
ween these two proteins in failing cardiomyocytes. Accordingly, we assessed the influence 
of normalized S100A1 levels on SERCA2 activity in failing myocardium since the abo-
ve results with increased SR Ca2+-load may be due to increased Ca2+-uptake. Importantly, 
S100A1 was found to enhance SERCA2 activity indicating that restored SR Ca2+-content 
seen in AdS100A1-treated failing cardiomyocytes might be the result of this mechanism 
enhancing SR Ca2+-uptake.  This was further supported by the finding that inhibition of 
SERCA2 abrogated this functional gain in S100A1 overexpressing failing cardiomyocytes. 
Moreover, testing of distinct S100A1 oligopeptides revealed that the carboxyl terminus of 
S100A1 is responsible for its enhancement of SERCA2 activity. Interestingly, this result is 
consistent with previous studies showing that this domain of S100A1 is involved in modu-
lating the activity of target proteins such as RyR1 in skeletal muscle (11). S100A1 was also 
found both to enhance Ca2+-dependent SERCA2 activity and to interact with the SR Ca2+-
pump in the context of a non-cardiac cellular environment. Therefore, normalized S100A1 
protein expression in HF appears to enhance SR Ca2+-load in failing myocardium by incre-
asing SERCA2 activity through a Ca2+-dependent interaction with the carboxyl domain of 
this S100 family member. Further studies are needed to determine the specific mechanism 
responsible for this domain of S100A1 to enhance SERCA2 activity in myocardial SR.
SR Ca2+-load is balanced both by diastolic Ca2+-uptake and Ca2+-leak and enhanced di-
astolic Ca2+-leakage in failing myocardium can contribute to impaired SR Ca2+-content (2, 
16).  Interestingly, normalized S100A1 protein levels after AdS100A1 treatment lead to a 
decrease in the SR Ca2+-leak in failing cardiomyocytes.  This could be due to an effect of 
S100A1 on RyR2 as we found a colocalization between these two SR proteins as well as a 
Ca2+-dependent association. This notion is further supported by the finding that S100A1 ap-
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parently reduces RyR2 activity at diastolic Ca2+-concentrations as indicated by reduced [3H]-
ryanodine binding. Overall, these results suggest that restored SR Ca2+-load in response to 
S100A1 gene addition is caused both by enhanced Ca2+-uptake and decreased Ca2+-leakage. 
This is significant as it could mean that this mechanism is responsible for the decreased dia-
stolic [Ca2+]
i 
in AdS100A1-treated failing cardiomyocytes. However, our results suggest that 
S100A1 apparently influences RyR2 activity in a biphasic manner. Increasing free Ca2+-con-
centrations ≥ 300 nM resulted in enhanced [3H]-ryanodine binding suggesting that S100A1 
enhances RyR2 activity at supra-diastolic Ca2+-concentrations. Given the fact that S100A1 
has previously shown to enhance Ca2+-induced SR Ca2+-release in non-failing myocardium 
(8), enhanced RyR2 activity might also contribute to normalized excitation-contraction cou-
pling in failing cardiomyocytes after S100A1 gene addition. Further studies are required to 
detail the biphasic mechanisms of S100A1 on diastolic and systolic SR Ca2+-release channel 
function in failing and normal myocardium. 
Since abnormal intracellular Na+-handling has also been associated with HF (17), we 
addressed the impact of S100A1 gene transfer on [Na+]
i
 overload in failing cardiomyocytes 
in vitro. Importantly, this defect that can cause pro-arrythmogenic actions and ventricular 
remodeling (17) was also normalized by S100A1 gene transfer. Since suppressed SR func-
tion in HF can favor diastolic Ca2+-efflux via the NCX forward-mode (17), this SR dysfunc-
tion might essentially contribute to increased [Na+]
i
 in failing myocardium. Considering 
normalized SR Ca2+-load after S100A1 gene transfer, it is possible that S100A1-mediated 
enhancement of Ca2+-uptake enables the SR to better compete with NCX for diastolic [Ca2+]
i 
elimination.  In turn, this effect might therefore reduce sarcolemmal [Na+]
i
-influx and cont-
ribute to reduction in [Na+]
i
.  However, with regard to the complex network of ion channels 
and transporters regulating both cardiac Ca2+- and Na+-homeostasis (17), elucidating the ex-
act mechanisms underlying S100A1 beneficial effects on Ca2+- and Na+-handling in failing 
cardiomyocytes warrants further investigation.
Decreased energy reserve via the creatine kinase reaction is also a characteristic finding 
both in human and experimental HF (18). Normalization of S100A1 protein in failing cardi-
omyocytes restored the depressed PCr/ATP ratio to normal values. Since SERCA2 activity is 
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the most vulnerable reaction to a decrease in free energy released from ATP hydrolysis (19), 
normalized energy transfer might also account for improved SR Ca2+-uptake in our experi-
mental setting despite sustained suppression of the Ca2+-pump.  Thus, S100A1 gene addition 
also appears to normalize impaired energy supply in failing cardiomyocytes. With regard to 
diastolic [Ca2+]
i 
overload that essentially contributes to impaired mitochondrial function in 
failing myocardium, the S100A1-mediated decrease of diastolic [Ca2+]
i 
might in part cont-
ribute to the correction of the decreased PCr/ATP ratio. Since S100A1 has previously been 
shown to also reside in the outer membrane of mitochondria within cardiomyocytes (20), 
this finding strongly supports the notion that this Ca2+-binding protein might also support mi-
tochondrial function, which is the subject of current investigations.  Moreover, we speculate, 
that the increase of free energy released from ATP hydrolysis might also restore, at least in 
part, depressed Na+/K+-ATPase activity in failing cardiomyocytes (17) that might also cont-
ribute to the S100A1-mediated normalized [Na+]
i
 discussed above.
Our in vitro results indicate that S100A1 normalization via gene transfer to the heart may 
represent a novel therapeutic strategy for HF.  However, the ultimate question is whether 
similar results may occur in vivo after myocardial gene delivery of S100A1.  To test this, 
we delivered AdS100A1 via the coronary arteries to post-infarcted rat hearts that were in 
overt HF.  Importantly, 7 days after intracoronary S100A1 gene delivery S100A1 protein 
was normalized in failing myocardium and this resulted in markedly improved contractile 
function of failing hearts in vivo. Although gene delivery to the rat heart was shown to be 
global in nature it was not entirely homogenous and regional overexpression may account 
for the overall normalization of S100 in failing rat hearts.  Important however, this norma-
lized myocardial S100A1 protein levels essentially restored to almost normal both the peak 
rate of LV pressure rise and LV end-systolic pressure, reflecting a rescue of in vivo cardiac 
systolic function.  This is significant due to the continued presence of a large LV infarct. 
Similarly, S100A1 gene transfer subsequently decreased elevated LV end-diastolic filling 
pressure to levels seen in non-failing hearts demonstrating improved diastolic function as 
well.  In contrast, delivery of the control AdGFP (or saline) did not alter the diminished 
cardiac levels of S100A1 nor was there any improvement in cardiac function in vivo of the 
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failing rat hearts.  This in vivo rescue of myocardial function due to S100A1 restoration was 
also preserved after b-adrenergic stimulation and importantly, S100A1 gene treatment did 
not alter heart rate.  
In addition to in vivo hemodynamics, we also isolated ventricular myocytes from Ad100A1 
or AdGFP treated failing hearts.  Importantly, we found that AdS100A1 positive cells had 
enhanced cellular contractility and intracellular Ca2+-cycling both under basal conditions 
and in response to β-AR stimulation (data not shown) supporting the hypothesis that that 
S100A1-mediated HF rescue in vivo is due to an increase in myocyte contractile function. 
Overall, this in vivo rescue appears to be due to similar mechanisms of restored SR function 
as found above in our in vitro study.  
As in the failing cardiac myocytes in vitro, in vivo HF rescue via S100A1 gene delivery 
was associated with a reversal of up-regulated fetal gene expression. Further, there was an 
apparent normalization of aberrant SERCA2/PLB ratios and NCX protein expression. These 
results are consistent with previous findings in non-failing cardiomyocytes in vitro where 
S100A1 addition prevented fetal gene expression in response to a1-adrenergic stimulation 
(6).  Thus, the down-regulation of S100A1 protein in HF might be permissive for the in-
duction of genes that underlie myocardial hypertrophy and failure, whereas restoration of 
S100A1 protein both participates in thwarting expression of fetal genes and may maintain 
the genetic program that defines normal cardiac function. However, attenuated fetal gene ex-
pression may also be simply a secondary result to normalized Ca2+-cycling and end-diastolic 
pressure by S100A1 gene transfer. 
Overall, we have shown for the first time that restoring S100A1 protein expression can 
rescue defective contractile performance of failing myocardium in vitro and in vivo due to 
improved cytosolic and SR Ca2+-cycling. The apparent mechanism involves enhancement 
of SERCA2 activity and modulation of RyR2 function. Importantly, the therapeutic effects 
of S100A1 normalization was not limited to improved Ca2+-cycling and contractile function 
since normalized protein levels also restored impaired Na+-homeostasis, cardiac energetic 
and attenuation of fetal gene expression occuring in HF.  Since S100A1 protein is down-re-
gulated in end-stage human HF, the present study clearly validates this Ca2+-sensor as a key 
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regulator of cardiac function and its normalization appears to be a novel therapeutic target. 
Moreover, targeting S100A1 and SR Ca2+-cycling differ in many ways from conventional 
positive inotropic agents that increase chronotropy and energy consumption of failing myo-
cardium counterbalancing the positive effects on contractile strength.  Our study does have 
its limitations including the use of a first-generation adenoviral vector that limits our study 
duration as it will be important to examine the chronic effects of HF rescue by S100A1 gene 
delivery, and studies with improved vectors (i.e. AAV) may translate these findings into fu-
ture S100A1 HF gene therapy clinical trials.
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4.1 Abstract
Calcium is a key regulator of cardiac function and is modulated through the Ca2+-sensor 
protein S100A1. S100 proteins are considered to exert both intracellular and extracellu-
lar functions on their target cells. Here we report the impact of an increased intracellular 
S100A1 protein level on Ca2+-homeostasis in neonatal ventricular cardiomyocytes in vitro. 
Specifically, we compare the effects of exogenously added recombinant S100A1 to tho-
se resulting from the overexpression of a transduced S100A1 gene. Extracellularly added 
S100A1 enhanced the Ca2+-transient amplitude in NVCMs through a marked decrease in 
intracellular diastolic Ca2+-concentrations ([Ca2+]
i
). The decrease in [Ca2+]
i  
was independent 
of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity and was likely the result of an 
increased sarcolemmal Ca2+-extrusion through the sodium-calcium exchanger (NCX). At 
the same time the Ca2+-content of the sarcoplasmic reticulum (SR) decreased. These effects 
were dependent on the uptake of extracellularly added S100A1 protein and its subsequent 
routing to the endosomal compartment. Phospholipase C and protein kinase C that are tight-
ly associated with this subcellular compartment, were found to be activated by endocytosed 
S100A1.
In contrast, adenoviral-mediated intracellular S100A1 overexpression enhanced the Ca2+-
transient amplitude in NVCMs mainly through an increase in systolic [Ca2+]
i.
 The increased 
Ca2+-load in the SR was based on an enhanced SERCA2a activity while NCX function was 
unaltered. Overexpressed S100A1 co-localized with SERCA2a and other Ca2+-regulatory 
proteins at the SR, whereas recombinant S100A1 protein that had been endocytosed did 
not co-localize with SR proteins. This study provides the first evidence that intracellular 
S100A1, depending on its subcellular location, modulates cardiac Ca2+-turnover via different 
Ca2+-regulatory proteins. 
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4.2 Introduction
S100A1 belongs to a multigenic family of small (Mr 9-13 x 103), non-ubiquitous Ca2+-
sensing proteins of the EF-hand type. S100 proteins, which exhibit a cell- and tissue-specific 
expression pattern, play a major role in intracellular Ca2+-homeostasis. In addition, they have 
been linked to the Ca2+-dependent regulation of a variety of intracellular activities such as 
cell proliferation and differentiation or the dynamics of cytoskeletal constituents (for review 
see (Donato, 2003; Heizmann and Cox, 1998; Zimmer et al., 1995). S100A1 is the most ab-
undant S100 protein in striated muscle and predominantly expressed in the adult heart (Hai-
moto and Kato, 1988; Kato and Kimura, 1985). Recent gain-of function experiments have 
shown that increasing intracellular S100A1 protein levels in the adult heart and skeletal mu-
scle resulted in enhanced Ca2+-cycling and contractile function in vitro and in vivo (Most et 
al., 2001; Most et al., 2003b; Most et al., 2003c; Remppis et al., 2002; Remppis et al., 2004). 
The identification of S100A1 as a novel intracellular regulator of cardiac and skeletal muscle 
contractility may provide new impulses in the field of excitation-contraction coupling. 
Although S100 proteins apparently lack the classic signaling sequences required for secre-
tion, some S100 proteins seem to reach the extracellular space through secretory pathways 
that neither involve the common endoplasmic reticulum/Golgi nor the alternative inter-
leukin-1 route (Rammes et al., 1997). From here, S100 proteins may exert an increasing 
number of downstream functions. For instance, S100B, S100A4 and S100A12 have been 
shown to promote differentiation of embryonic neurons (Mikkelsen et al., 2001; Novitskaya 
et al., 2000; Selinfreund et al., 1991). Moreover, S100B that had been secreted by astrocy-
tes, was found to be internalized by neurons, where it influenced intracellular Ca2+-levels 
([Ca2+]
i
) and cellular excitability (Barger and Van Eldik, 1992; Kubista et al., 1999). Some 
extracellular activities of S100 proteins such as S100A12 and S100B are apparently medi-
ated through interaction with the multiligand receptor for advanced glycation end products 
(RAGE) (Hofmann et al., 1999; Huttunen et al., 2000). Indeed, Roth and coworkers have 
shown that the S100A12/RAGE interaction plays an important role in the pathology of chro-
nic inflammatory diseases such as bowel disease (Foell et al., 2003c), cystic fibrosis (Foell 
et al., 2003d), rheumatoid arthritis (Foell et al., 2003b), and vascular disorders (Foell et al., 
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2003a). Importantly, Donato and colleagues have demonstrated that both RAGE-dependent 
and -independent extracellular effects of S100B are involved in the regulation of cell survi-
val (Huttunen et al., 2000) and muscle development (Sorci et al., 2003; Sorci et al., 2004a; 
Sorci et al., 2004b). Although there is no evidence for S100A1 secretion from cardiac cells 
so far, a release into the extracellular space during myocardial damage has been reported 
(Kiewitz et al., 2000). We have recently shown that extracellularly added S100A1 is endocy-
tosed by neonatal ventricular cardiomyocytes (NVCMs) in a RAGE-independent manner via 
a Ca2+-dependent clathrin-mediated pathway (Most et al., 2003a). Subsequently, internalized 
S100A1 protected NVCMs from apoptosis via the specific activation of the extracellular 
signal-regulated kinase (ERK1/2) prosurvival pathway. Thus, similar to other S100 family 
members, S100A1 may act ‘outside-in’ and its extracellular presence may indicate a func-
tion as a paracrine factor in protecting the heart. 
Since intracellular S100A1 plays an essential role in cardiac Ca2+-handling we examined, 
whether extracellularly added S100A1 has a similar effect on myocardial Ca2+-homeostasis. 
The present study compares the consequences of extracellularly added S100A1 to those of 
virally transduced S100A1 overexpression on Ca2+-cycling in NVCMs in vitro. 
4.3 Materials and Methods 
Reagents
Thapsigargin (T-9033), tetracaine (T-7645), monodansylcadaverine (MDC) (M-4008) and 
caffeine (C-0750) were purchased from Sigma. Inhibitors for protein kinase A (PKA) (myr-
PKI, 476485), protein kinase C (PKC) (calphostin-c, 208725) and phospholipase C (PLC) 
(U-73122, 662035) were obtained from Calbiochem. NCX inhibitor myr-FRCRCF was cus-
tom-made by Eurogentec (Belgium).
Expression and purification of human recombinant S100A1 protein
Human recombinant S100A1 was produced by an isopropylthiogalactosid (IPTG)-driven 
expression system in Escherichia coli and purified as described previously (Most et al., 
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2003c). The coupling of S100A1 to tetramethyl-rhodamine (Rh-S100A1) was carried out 
by Eurogentec.
Generation of S100A1 adenovirus
The S100A1 adenovirus (AdS100A1) was generated by the use of the pAdTrack-CMV/pA-
dEasy-1 system as recently reported (Most et al., 2001). To facilitate identification of infec-
ted cells, AdS100A1 carried the green fluorescent protein reporter gene (GFP) in addition to 
the human S100A1 cDNA (accession number X58079). Each transgene was independently 
expressed under the control of a cytomegalovirus promotor sequence. To rule out that the 
infection procedure in itself had an effect on the amount of S100A1 in the cell, NVCM were 
infected with a corresponding adenovirus carrying GFP cDNA alone as a control (Adcon-
trol). Both replication-deficient adenoviruses were amplified in human embryonic kidney 
293 cells (HEK 239), purified and enriched by cesium chloride centrifugation. Activity was 
tested by plaque assay. 
Isolation and primary culture of neonatal rat ventricular cardiomyocytes
Ventricular cardiomyocytes from 1-2 day old neonatal hearts (NVCMs) were prepared as 
published in detail elsewhere (Most et al., 2003a). NVCMs were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Biochrom) supplemented with penicillin/streptomycin 
(100 units/ml), L-glutamine (2 mM), and 1% fetal calf serum (FCS Gold; PAA Laboratories 
GmbH; DFCS) at 37°C in a 95% air/5% CO2 humidified atmosphere for 2-3 days. Ade-
noviral infection of NVCMs was carried out in serum-free HEPES-modified medium 199 
(M199) with a multiplicity of infection (MOI) of 8 plaque forming units (pfu) per cell. After 
4 hours incubation at 37°C in a 95% air/5% CO2 humidified atmosphere, medium was chan-
ged to DFCS. Efficiency of adenoviral gene transfer was monitored 24 hours later by GFP 
fluorescence. Approximately 95% of NVCMs were infected. 
Incubation of NVCMs with recombinant S100A1 (1 µM) was performed in DFCS for 24 
hours and mock-treated cells served as control. 
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Indirect immunofluorescence
Imaging of NVCMs was carried out as described (Most et al., 2003a). Briefly, 3-day old 
NVCMs grown on glass coverslips were either treated with Rh-S100A1 (1 µM) or S100A1 
and GFP adenovirus (MOI 8 pfu/cell) as described above. After 24 hours cells were fixed, 
permeabilized and labeled with a polyclonal anti-S100A1 (SA 5632, Eurogentec; 1/300), 
a monoclonal anti-S100A1 (Sigma, 1/200), a monoclonal anti-SERCA2a (ABR; 1/500) or 
anti-RyR2 (ABR; 1/500) antibodies, followed by the corresponding Cy3-conjugated (Jack-
son Immuno Research Lab; 1/3000), Cy5-conjugated (Jackson Immuno Research Lab; 
1/400) and ALEXA Fluor 488-conjugated (Alexis; 1/800) secondary antibodies. Polyclonal 
rabbit anti-SERCA2a antibody (1/1000) was a kind gift from Dr. F. Wuytack (Department of 
Molecular Cell Biology, Leuwen). Confocal images (CLSM) were obtained using a 100 x oil 
objective on a Leica TCS SP laser scanning confocal microscope. Digitized confocal images 
were processed by Leica software and Adobe Photoshop.
Intracellular Ca2+-calibration and Ca2+-imaging in field-stimulated cardiomyocytes
Calibration and measurement of intracellular Ca2+-transients in field-stimulated NVCMs 
using the Ca2+-fluorescent dye FURA2-AM was carried out as described in detail by (Most 
et al., 2003b). Analysis of steady state Ca2+-transients at 1 Hz, 37°C and 2 mM [Ca2+]
e
 was 
performed with T.I.L.L Vision software (version 4.01). Baseline data from five consecutive 
steady-state transients were averaged for analysis of transient amplitude (Ca2+ amplitude; 
[nM]), diastolic Ca2+-levels ([nM]) and transient decay (t; [ms]). The sarcoplasmic reticulum 
(SR) Ca2+-load and sodium-calcium exchanger (NCX) activity were assessed by changes 
in the transient amplitude ([nM]) and decay (t; [ms]), respectively, of quiescent NVCMs in 
modified Tyrode solution (mM: 140 NaCl, 6 KCl, 1 MgCl
2
, 2 CaCl
2
, 10 glucose, 5 HEPES), 
subjected to rapid caffeine application (10 mM) after 5 seconds rest. Exchange against sodi-
um- and calcium-free Tyrode solution (choline chloride and EGTA replaced NaCl and CaCl
2
, 
respectively) was used to block NCX current during the decay of the caffeine-induced tran-
sient. Myr-FRCRFC (30 µM) was used to inhibit NCX current in field-stimulated NVCMs. 
Free intracellular Ca2+ concentration [Ca2+]
i
 was calculated by the equation of Grynkiewicz 
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et al; [Ca2+]
i
 = Kd x ß x ((R - Rmin)/(Rmax – R)). The Ca2+-transient amplitude was calcu-
lated as the difference between calibrated systolic and diastolic [Ca2+]
i
. Data sets represent 
analysis of 50 cells from three different preparations.
Protein expression analysis
To assess protein expression of S100A1 (Sigma, S-2407, 1/500), sarcoplasmic reticulum 
Ca2+-ATPase (SERCA2a; Biomol SA209, 1/5000), sodium-calcium exchanger (NCX; ABR 
MA3-926, 1/5000), and cardiac actin (Progen Ac1-20.4.2, 1/10000), Western blotting from 
whole cell homogenates of NVCMs was carried out as previously described (Most et al., 
2003b). Briefly, cells were washed three times with EGTA/EDTA buffer (PBS, pH 7.4, con-
taining 2 mM EGTA/EDTA), scraped off the dish, and immediately homogenized in EGTA/
EDTA buffer. Homogenates were centrifuged for 10 min at 15.000 g and the supernatant was 
used for biochemical analysis. S100A1 protein was concentrated by sequential size exlusion 
centrifugation columns (Amicon; Microcon YM-100 and -3). 
Statistical analysis
Data are presented as mean ± s.e.m. Unpaired two-tail student´s t-test and a two way re-
peated ANOVA analysis was performed to test for differences between groups. A value of 
P<0.05 was accepted as statistically significant. 
4.4 Results
Adenoviral-mediated S100A1 overexpression and endocytosis of extracellular S100A1 
yield a distinct subcellular location of S100A1 in neonatal ventricular cardiomyocytes 
To examine the effects of an increased S100A1 protein level on the cycling of cytosolic 
Ca2+ in neonatal rat ventricular cardiomyocytes (NVCMs), we employed two different proce-
dures (Figure 4.1): the NVCMs were either transduced by means of an adenoviral S100A1-
expression construct, (AdS100A1 cells, Figure 4.1A) or incubated for 24 hours with DFCS 
containing 1 µM recombinant human S100A1 protein (Figure 4.1C). As illustrated in Figure 
4.1, overexpressed S100A1 mainly displayed a fine granular network-like pattern. In addi-
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tion, small amounts were detected in the nucleus. This pattern corresponds to the distribu-
tion of endogenous S100A1 observed in control cells (Figure 4.1B). Westernblotting using 
an antibody that reacts with both human and rat S100A1 showed that adenoviral-mediated 
S100A1 gene delivery to NVCMs resulted in approximately 3-fold higher amounts of total 
S100A1 protein compared to the level of endogenous S100A1 in control cells infected with 
an adenoviral construct lacking the S100A1 gene (panel Figure 4.1A). Equivalent protein 
loadings were confirmed by comparable cardiac actin levels. 
Figure 4.1: Subcellular location of overexpressed, internalized and endogenous S100A1. 
A, Overexpressed S100A1 (AdS100A1; blue) is detected by an antibody that specifically reacts with S100A1. 
Western blot analysis comparing levels of S100A1 (upper panel) and cardiac actin (lower panel) expression in 
homogenates of Adcontrol and AdS100A1-transduced NVCMs. B, Immunostaining of endogenous S100A1 
(green) in untreated NVCMs reveals a fine granular network-like pattern (control). C, Vesicular accumulation 
of internalized Rh-S100A1 protein (red) in the perinuclear region and in the cytosol of S100A1-treated cells. 
Western blot analysis comparing levels of S100A1 (upper panel) and cardiac actin  (lower panel) in homoge-
nates from S100A1-treated and control NVCMs. D,E,F AdS100A1-transduced cells were incubated for 1 hour 
with Rh-S100A1 twenty-four hours post infection, and then immunolabeled with an antibody that specifically 
reacts with human S100A1. 
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D, The anti-human S100A1/Cy5-anti-rabbit antibody detects internalized Rh-S100A1 as well as overexpressed 
S100A1 protein (total exogenous S100A1). E, Vesicular accumulation of internalized Rh-S100A1 protein in 
the perinuclear region and in the cytosol. F, Overlay of both D and F shows that internalized Rh-S100A1 (vio-
let) exhibits a distinct distribution compared to overexpressed S100A1 (blue). Bar, 10 µm.
As an alternative approach to achieve an increase of the intracellular S100A1 level in 
NVCMs, we incubated cells for 24 hours in medium containing 1 µM rhodamine-coupled 
recombinant human S100A1 (Rh-S100A1). The CSLM image shown in Figure 4.1C reveals 
an intracellular perinuclear accumulation of Rh-S100A1. This finding is consistant with our 
recently published data, which shows that following endocytosis via a Ca2+-dependent cal-
thrin-mediated process, the extracellularly added S100A1 is routed to the endosomal com-
partment (Most et al., 2003a). The uptake of S100A1 caused an almost 4-fold increase of in-
tracellular S100A1 in NVCMs compared to mock-treated control cells (panel Figure 4.1C). 
To directly correlate the distribution of exogenous S100A1 resulting from the two different 
procedures, we incubated AdS100A1 cells for 1 hour with Rh-S100A1 protein (1 µM) 24 
hours after adenoviral infection (Figure 4.1D to F). As in the individually treated cells, the 
internalized recombinant human Rh-S100A1 (red, Figure 4.1E) displayed a vesicular-like 
endosomal localization in AdS100A1 cells. When immunolabeld with a polyclonal antibody 
that specifically recognizes the hinge region of human S100A1, both S100A1 populations 
were recognized in the S100A1-treated AdS100A1 cells (blue, Figure 4.1D). Superimposing 
the CSLM image of total exogenous S100A1 with the internalized Rh-S100A1 (Figure 4.1F) 
confirmed that the localization of internalized Rh-S100A1 (violet) was clearly distinct from 
the fine granular network-like pattern of overexpressed human S100A1 (blue).
Elevated S100A1 enhances cytosolic Ca2+-turnover in neonatal ventricular cardiomy-
ocytes
As illustrated by the Ca2+-transients in Figure 4.2, the overexpression of S100A1 in 
AdS100A1-transduced NVCMs gave rise to an enhanced cytosolic Ca2+-cycling compared 
to control cells. The overall enhanced Ca2+-cycling was reflected by an increased amplitude 
of Ca2+-transients in AdS100A1 cells (Figure 4.2B). The larger amplitude was predomi-
nantly due to an S100A1-induced rise of systolic [Ca2+]
i
 as indicated by the higher peak in 
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AdS100A1-transduced NVCMs (Figure 4.2A, bar). Concomitantly, S100A1 overexpression 
also decreased diastolic [Ca2+]
i
 (Figure 4.2C), which was associated with a reduction in the 
Ca2+-transient decay-constant t (Figure 4.2D). 
Figure 4.2: Overexpressed and in-
ternalized S100A1 enhance cytoso-
lic Ca2+-turnover in neonatal vent-
ricular cardiomyocytes.
A to D, Adenoviral-transduced NV-
CMs overexpressing S100A1. A, 
Superimposed tracings of calibra-
ted Ca2+-transients in S100A1-ove-
rexpressing (AdS100A1, solid line) 
and control (Adcontrol, dashed line) 
NVCMs. Note the gain in systolic 
[Ca2+]
i
 in S100A1-overexpressing 
NVCMs (bar). B, C and D, Effects 
of increased S100A1 protein level on 
Ca2+-transients. Compared to control 
cells expressing endogenous levels 
of S100A1, S100A1 overexpression 
significantly increases the Ca2+-tran-
sient amplitude (AdS100A1 454±22 
nM vs. Adcontrol 311±11 nM; 1B), 
lowers diastolic [Ca2+]
i
 (AdS100A1 
181±14 nM vs. Adcontrol 219±12 
nM; 1C), and accelerates the decay 
of the Ca2+-transient (t, AdS100A1 
172±14 ms vs. Adcontrol 223±11 ms; 
1D). n=150 cells from three different 
cell preparations. Data are given as 
mean±S.E.M. 
 A’to D’, NVCMs treated with 1 µM 
human recombinant S100A1. A’, 
Superimposed tracings of calibrated 
Ca2+-transients in S100A1-treated 
(S100A1, solid line) and mock-tre-
ated (control, dashed line) NVCMs. 
The decrease in diastolic [Ca2+]
i
 in 
S100A1-treated NVCMs is indicated 
by the bar. B’, S100A1-uptake in-
creases the Ca2+-transient amplitude 
(S100A1-treated 442±23 nM vs. con-
trol 324±15 nM). C’, The effects of an 
increased S100A1 level are a reduc-
tion of diastolic [Ca2+]
i
 (S100A1-tre-
ated 143±13 nM vs. control 236±14 
nM) and D’, an accelerated decay 
of the Ca2+-transient (t, S100A1-tre-
ated 182±16 ms vs. control 232±10 
ms). Preincubation with monodan-
sylcadaverine (MDC, an inhibitor of 
clathrin-mediated endocytosis) ab-
olished the effects of extracellularly 
added S100A1 on the Ca2+-turnover 
(* P<0.01 vs. no inhibitor). 
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Similar to S100A1 overexpression in AdS100A1 cells, uptake of S100A1 also had an 
effect on the Ca2+-transients recorded in S100A1-treated cells (Figure 4.2A’). Accordingly, 
they exhibited an increased amplitude (Figure 4.2B’), indicating that the rise in intracellular 
S100A1 caused an increased cytosolic Ca2+-turnover in S100A1-treated NVCMs. However, 
in contrast to Ca2+-transients of cells with adenoviral-mediated S100A1 overexpression, the 
amplitude of S100A1-treated cells was primarly increased by a marked reduction of diasto-
lic [Ca2+]
i
, and to a lesser extent by elevated systolic [Ca2+]
i
 (Figure 4.2A’, bar and 4.2C’). 
For both, overexpression and uptake from the extracellular environment, increased S100A1 
levels accelerated diastolic Ca2+-elimination as indicated by a decrease in the Ca2+-transient 
decay-constant t (Figure 4.2D and 4.D’). 
To test whether binding of extracellular S100A1 to NVCMs was sufficient to induce an 
improved cytosolic Ca2+-cycling or whether endocytosis was required, NVCMs were treated 
with recombinant S100A1 in the presence of monodansylcadaverine (MDC, 50 µM), which 
was shown to effectively prevent S100A1 uptake (Most et al., 2003a). As illustrated by the 
Ca2+-transients, the presence of MDC precluded changes in the amplitude (Figure 4.2B’) and 
diastolic [Ca2+]
i
 (Figure 4.2C’) as well as in the decay of the Ca2+-transient (Figure 4.2D’). 
Together these results show that an augmented intracellular S100A1 protein level in NV-
CMs increase cytosolic Ca2+-turnover. More specifically, we observe a differential effect of 
adenoviral-mediated S100A1 overexpression versus increased S100A1 following endocyto-
sis: higher systolic Ca2+-peaks are responsible for the increased amplitude of Ca2+-transients 
in NVCMs overexpressing S100A1 while a marked decrease in diastolic [Ca2+]
i
 largely ac-
counts for the increased amplitude of Ca2+-transients in cells after endoyctosis of extracel-
lular S100A1.
Overexpressed but not endocytosed S100A1 colocalizes with sarcoplasmic Ca2+-regula-
tory proteins 
We next examined whether the differential effect of overexpressed and internalized 
S100A1 on Ca2+-turnover was associated with the distinct subcellular location of S100A1. 
Since S100A1 protein has previously been shown to co-immunoprecipitate with cardiac 
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SR Ca2+-regulatory proteins in human myocardium (Kiewitz et al., 2003), we examined the 
distribution of the SR Ca2+-ATPase (SERCA2a) and its potential association with S100A1 
in NVCMs with an increased level of S100A1 compared to control cells by immunolabeling 
with anti-SERCA2a antibodies (Figure 4.3). 
Figure 4.3:  Overexpressed but not internalized S100A1 colocalizes with SERCA2a at the SR.
Immunolocalization of S100A1 and SERCA2a. A, Endogenous S100A1 labeled with a monoclonal anti-
S100A1/Cy5-anti-mouse antibody in control cells. A’, Overexpressed S100A1 detected with a polyclonal anti-
human S100A1/Cy5–anti-rabbit antibody in AdS100A1-transduced NVCMs. A’’, Internalized Rh-S100A1. 
B, Immunolabeling of SERCA2a in control, B’, AdS100A1-infected, B’’, and Rh-S100A1-treated NVCMs. 
C, Overlay of panels A and B, and C’, A’ and B’ depicts colocalization of endogenous and overexpressed 
S100A1 with SERCA2a (violet). C’’, Internalized Rh-S100A1 does not co-localize. Bar, 10 µm (C ’) and 5 
µm (C,C’’).
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To rule out that the adenoviral transduction procedure by itself caused a translocation of 
SERCA2a, we first established that its distribution in cells infected with a control virus 
was similar to that in uninfected NVCMs expressing only endogenous S100A1 (data not 
shown). Subsequently, the distribution of S100A1 in control cells (blue, Figure 4.3A,C), 
in AdS100A1 NVCMs (blue, Figure 4.3A’,C’) and in S100A1-treated cells (red, Figure 
3A’’,C’’) was compared to the location of immunolabeled SERCA2a (Figure 4.3B,B’,B’’). 
Merging the corresponding confocal images clearly showed that overexpressed S100A1 and 
endogenous S100A1 partially colocalized with the SR Ca2+-pump (violet, Figure 4.3C,C’). 
Conversely, as illustrated in Figure 4.3A’’ to C’’, internalized Rh-S100A1 protein (red) did 
not colocalize with the reticular distribution of SERCA2a (green).
In conclusion, the immuno-localization studies revealed that depending on the experi-
mental procedure employed to increase S100A1 levels, S100A1 was routed to a different 
cellular compartment. Consequently, an association of S100A1 with the SR was only obser-
ved in AdS100A1-transduced NVCMs.
Enhanced Ca2+-turnover in AdS100A1-transduced NVCMs is based on SR Ca2+-
cycling
Because overexpressed S100A1 was associated with SERCA2a at the SR, we tested the 
influence of SERCA2a antagonists on the efficiency of Ca2+-cycling in AdS100A1- as well 
as in S100A1-treated NVCMs. Because Ca2+-cycling in infected control cells and mock-tre-
ated NVCMs was indistinguishable, the two groups were pooled and are hereafter referred 
to as control NVCMs. As documented in Figure 4.4A, a reduced amplitude in Ca2+-tran-
sients of control NVCMs indicated that the SERCA2a-mediated Ca2+-uptake into the SR 
was inhibited by thapsigargin (1 µM). Incubation of AdS100A1-cells with this SERCA2a 
inhibitor completely abolished the S1000A1-induced gain in the Ca2+-transient amplitude 
(Figure 4.4A). The Ca2+-transients in thapsigargin-treated NVCMs did not significantly dif-
fer with respect to the diastolic Ca2+-load or the decay rate between AdS100A1-transduced 
and control NVCMs: thapsigargin inhibition of SERCA2a equally raised diastolic [Ca2+]
i
 
(Figure 4.4B) and prolonged SR resequestration (Figure 4.4C). In contrast, the enhancement 
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of the Ca2+-transient amplitude in S100A1-treated NVCMs was not affected by thapsigargin 
(Figure 4.4A). 
Figure 4.4:  Inhibition of SR Ca2+-fluxes 
abolishes enhanced Ca2+-cycling in S100A1 
overexpressing but not in S100A1-treated 
NVCMs.
A, Addition of the SERCA2a inhibitor thap-
sigargin (1 µM) abolishes the S100A1-indu-
ced increase in the Ca2+-transient amplitude in 
overexpressing (AdS100A1) but not S100A1-
treated NVCMs. B, Thapsigargin reduces di-
astolic [Ca2+]
i
 in control and S100A1 overex-
pressing cells whereas S100A1-treated cells 
are not significantly affected. C, SERCA2a 
inhibition raises the decay-constant t in cont-
rol and AdS100A1-infected NVCMs but does 
not significantly alter t in S100A1-treated 
NVCMs. D, Tetracaine (100 µM), an inhibi-
tor of the SR Ca2+-release channel (RyR), ab-
rogates the increased Ca2+-transient amplitude 
in S100A1 overexpressing NVCMs but does 
not significantly reduce the augmented amp-
litude of the Ca2+-transient in S100A1-treated 
NVCMs relative to tetracaine-treated control 
cells. * P<0.01 vs. control. Measurements rep-
resent n=150 cells from three independent cell 
preparations. Data are given as mean±S.E.M.
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Moreover, inhibition of SERCA2a had virtually no effect on the decreased diastolic 
[Ca2+]
i
 (Figure 4.4B) and accelerated cytosolic Ca2+-elimination (Figure 4.4C) in S100A1-
treated NVCMs. Like thapsigargin, inhibition of SR Ca2+-release by tetracaine (100 µM), a 
blocker of the SR Ca2+-release channel/ryanodine receptor (RyR2), decreased the amplitude 
of the Ca2+-transient in control NVCMs and completely abolished the gain in the Ca2+-tran-
sient amplitude in S1000A1 overexpressing NVCMs (Figure 4.4D). However, tetracaine 
had no effect on the augmented Ca2+-transient amplitude in S100A1-treated NVCMs (Figure 
4D). Consistent with these findings, immunofluorescence studies indicated that internalized 
S100A1 did not colocalize with SERCA2a (Figure 4.3) or RyR2 (data not shown).
Since the data suggested that the increased efficiency of Ca2+-turnover in S100A1 overex-
pressing but not in S100A1-treated NVCMs depended on SR Ca2+-fluxes, we next investiga-
ted the SR Ca2+-load in both groups. To address this issue, AdS100A1-infected and S100A1-
treated NVCMs were exposed to caffeine (10 mM) and the amplitude of caffeine-releasable 
SR Ca2+ served as an indirect measure of the SR Ca2+-content. As depicted in Figure 4.5A, 
S100A1 overexpression caused an increase in the caffeine-induced Ca2+-transient amplitude 
while internalized S100A1 apparently reduced the SR Ca2+-load compared to the control. 
Changes in NCX activity might be involved in modulating sarcolemmal Ca2+-fluxes in 
response to S100A1 
Cytosolic Ca2+-turnover in NVCMs not only invokes the SR, but is simultaneously regu-
lated by sarcolemmal Ca2+-fluxes. The sodium-calcium exchanger (NCX) is a major regu-
lator of sarcolemmal Ca2+-fluxes. Analysis of the decay-constant t of the caffeine-induced 
Ca2+-transients, which served as a measure for NCX-mediated sarcolemmal Ca2+-extrusion, 
revealed unchanged kinetics in AdS100A1-transduced NVCMs compared to cells infected 
with a control construct (Figure 4.5B). Thus, it appears that overexpressed S100A1 does 
not affect NCX activity. Conversely, in S100A1-treated NVCMs t of the caffeine-induced 
Ca2+-transients was decreased compared to mock-treated NVCMs (control, Figure 4.5). This 
finding indicated that the increased S100A1 level in the endosomal compartment could be 
responsible for the accelerated decay of the caffeine-mediated rise in cytosolic [Ca2+]
i
.
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Since the NCX forward-mode mainly accounts for trans-sarcolemmal Ca2+-efflux, the 
influence of NCX inhibition in S100A1-treated cells was studied. Selective NCX inhibition 
was achieved by rapidly replenishing the medium with sodium/calcium-free medium (Bas-
sani et al., 1994; Despa et al., 2002). As documented by the caffeine-induced Ca2+-transients 
in Figure 4.5C, this regimen effectively abrogated the S100A1-mediated acceleration of the 
Ca2+-transient decay.
This finding suggests that endocytosed S100A1 decreases diastolic [Ca2+]
i
 through en-
hanced sarcolemmal Ca2+-extrusion, possibly involving an increased NCX forward-mode 
activity.
Figure 4. 5: Sarcolemmal Ca2+-regulatory proteins modulate 
Ca2+-cycling in S100A1-treated NVCMs.
A, Caffeine-induced Ca2+-transient amplitudes reveal that ove-
rexpressed S100A1 (AdS100A1) enhances SR Ca2+-content, 
whereas SR Ca2+-level are reduced in S100A1-treated cells com-
pared to control cells exposed to caffeine. B, The elimination of 
caffeine-releasable SR Ca2+ indicated by the decay-constant t is 
similar in caffeine-treated control cells and S100A1-overexpres-
sing cells. However, the decay of the Ca2+-transient is accelerated 
in S100A1-treated NVCMs compared to control cells. C, Swit-
ching to sodium/calcium-free medium abrogates decay accele-
ration in S100A1-treated cells. * P<0.01 vs. control. n=50 cells 
in AdS100A1 and S100A1-treated cells, control (mock- and Ad-
control-treated NVCMs) n=100 cells, cells from each group were 
obtained from three independent cell preparations. Data are given 
as mean±S.E.M.
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To further explore the influence of endocytosed S100A1 protein on NCX activity, we stu-
died the impact of myristylated (myr)-FRCRCFa, a specific NCX blocker on diastolic [Ca2+]
i
 
in S100A1-treated field-stimulated NVCMs. Myr-FRCRCFa is a novel, cell-permeable 
peptide inhibitor of NCX that alters neither L-type Ca2+-channel/dihydropyridine receptor 
(LCC) nor Na+- or K+-channel activity, and appears to exhibit a higher degree of selectivity 
compared to other widely used NCX-inhibitors such as KB-R7943 or SEA0400 (Convery et 
al., 1998; Hobai et al., 1997; Khananshvili et al., 1995; Reuter et al., 2002). Administration 
of 30 µM myr-FRCRCFa caused a large rise in diastolic [Ca2+]
i
 in control cells and abrogated 
the S100A1-mediated decrease in diastolic [Ca2+]
i
 treated cells (Figure 4.6A).
Figure 4.6: Ca2+-cycling in S100A1-treated NVCMs 
is regulated via PLC-PKC activation of NCX.
A, Inhibition of NCX activity by myr-FRCRCFa 
(30µM) abrogated the S100A1-mediated decline in di-
astolic [Ca2+]
i
 in NVCMs. B and C, The S100A1-me-
diated decrease in diastolic [Ca2+]
i
 is abolished trough 
inhibition of phospholipase C and protein kinase C 
by U-73122 and calphostin-c, respectively. * P<0.01 
vs. control, Measurements represent n=50 cells from 
three independent cell preparations. Data are given as 
mean±S.E.M.
Given that endocytosed S100A1 activates the PLC-PKC-p44/42 pathway (Most et al., 2003a) 
and PKC is known to stimulate NCX function (Iwamoto et al., 1996), we investigated whe-
ther triggering a corresponding pathway may be involved in increasing NCX activity in 
S100A1-treated NVCMs. Incubation with U73122 (5 µM), an inhibitor of PLC, resulted in 
a significant increase in diastolic [Ca2+]
i
 in S100A1-treated NVCMs (Figure 4.6B). Similar 
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results were obtained after addition of calphostin-c (1 µM), a PKC-inhibitor (Figure 4.6C) 
indicating that enhanced cyotosolic [Ca2+]
i
 removal by endocytosed S100A1 might involve 
PLC and PKC. Notably, PD98095 (10 µM) as well as myr-PKI (5 µM), specific inhibitors 
of MEK1 and PKA, respectively, failed to inhibit the S100A1-mediated decrease in diastolic 
[Ca2+]
i
 (data not shown). 
Increased S100A1 protein levels do not affect abundance of Ca2+-regulatory proteins 
Because increased S100A1 levels in NVCMs impinged on Ca2+-regulatory proteins we 
assessed the abundance of NCX and SERCA protein in S100A1-treated and AdS100A1-
transduced NVCMs. As shown by representative immunoblots in Figure 4.7, neither endo-
cytosis nor overexpression of S100A1 altered the levels of NCX and SERCA2a compared 
to control cells. 
These findings suggest that the changes in Ca2+-cycling seen in response to an increase of 
intracellular S100A1 are based on the altered activity of Ca2+-regulatory proteins rather than 
their amounts. 
Figure 4. 7:  Increased level of S100A1 does not alter expression of Ca2+-regulatory proteins.
A, Western blots of extracts from control, S100A1-treated, AdS100A1- and Adcontrol-transduced cells pro-
bed with specific antibodies. Levels of NCX and SERCA2a remain constant despite the increased levels of 
S100A1.
Discussion
S100 Ca2+-binding proteins have been associated with a variety of intracellular Ca2+-
mediated processes (Heizmann and Cox, 1998). Binding of Ca2+ induces a conformational 
change in the three-dimensional structure and enables these proteins to interact with target 
proteins thereby transducing the intracellular Ca2+-signal (Wang et al., 2001). Recent fin-
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dings involving S100A1 gene transfer into ventricular cardiomyocytes have demonstrated 
that S100A1 overexpression enhances cytosolic Ca2+-cycling and contractile properties both 
in vitro and in vivo (Most et al., 2001; Most et al., 2003b; Most et al., 2003c; Remppis et al., 
2002; Remppis et al., 2004). Consistently, S100A1-deficient mice display an impaired cardi-
ac contractility in response to hemodynamic stress (Du et al., 2002). These studies promote 
S100A1 as a novel key regulator of cardiac function. In addition, recent studies from our la-
boratory provide evidence that S100A1 may also act on ventricular cardiomyocytes through 
an unrelated mechanism: uptake of S100A1 from the extracellular environment protects cells 
from apoptosis induced by reactive oxygen species or 2-deoxyglucose (Most et al., 2003a). 
This downstream effect apparently relies on RAGE-indepedent endocytosis of extracellular 
S100A1 and involves the activation of the PLC-PKC-ERK1/2 prosurvival pathway. A num-
ber of studies support the notion that extracellular S100 proteins may have distinct functions 
in cellular physiology and pathology. For example, S100A4 was reported to stimulate the 
outgrowth of neurite cells (Novitskaya et al., 2000), whereas S100B has been shown to be 
involved in the regulation of cell differentiation and survival (Huttunen et al., 2000; Sorci et 
al., 2003; Sorci et al., 2004a; Sorci et al., 2004b). Another example is S100A12, which has 
been implicated as an important pro-inflammatory regulator in numerous chronic inflamma-
tory diseases (Foell et al., 2003a; Foell et al., 2003b; Foell et al., 2003c; Foell et al., 2003d). 
Notably, release of S100A1 into the extracellular space in reponse to ischemic cadiac injury 
has been reported (Kiewitz et al., 2000) but it is unclear whether extracellular S100A1 might 
affect Ca2+-homeostasis in ventricular cardiomyocytes. In the present study we addressed 
this issue by comparing the effects of S100A1 added to the extracellular environment to the 
effects of adenoviral-mediated S100A1 overexpression on cardiac Ca2+-cycling in vitro.
The model illustrated in Figure 4.8 summarizes the data presented in this paper. First, 
we show that recombinant S100A1 added to the extracellular environment is internalized 
and subsequently modulates cytosolic Ca2+-cycling in ventricular cardiomyocytes (Figure 
4.8B). Second, compared to the effects of adenoviral-mediated S100A1 overexpression on 
Ca2+-turnover (Figure 4.8C), internalized S100A1 modulates Ca2+-homeostasis in a different 
manner, that is likely to involve the NCX.
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Figure 4. 8: Model of differential effects of endocytosed and overexpressed S100A1 on sarcolemmal and 
sarcoplasmic Ca2+-cycling. 
A, Simplified scheme of intracellular Ca2+-fluxes in a ventricular cardiomyocyte. Endogenous S100A1 (hat-
ched circle) is located at the SR where it interacts with SERCA2a and RyR2. (1) Electrical depolarization of the 
transverse tubule membrane (T-tubulus) activates inward Ca2+-flux through L-type voltage-gated Ca2+-channels 
(LCC), which (2) triggers the release of Ca2+ from SR stores via ryandine receptors (RyR2). As a result, con-
tractile filaments are activated. (3) For relaxation to occur, the cytosolic [Ca2+]
i
 must decline. This process is 
mainly mediated by the SR Ca2+-ATPase (SERCA2a), which resequesters cytosolic Ca2+ in the SR. (4) At the 
sarcolemma, Ca2+ is extruded primarily via the sodium-calcium exchanger (NCX). B, Extracellularly added 
S100A1 is internalized and subsequently routed to the endosomal compartment, where it increases the activity 
of PLC and PKC (both associated with the endosomal compartment). Through activation of this signaling 
pathway, internalized S100A1 eventually modulates intracellular Ca2+-flux through an enhanced sarcolemmal 
Ca2+-extrusion via NCX. The increased Ca2+-extrusion leads to a decreased SR Ca2+-load. C, Effects of overex-
pressed S100A1 on the intracellular Ca2+-cycling. Overexpressed S100A1 is located at the SR, where it asso-
ciates with the SR-regulatory proteins SERCA2a and RyR2. As a result, intracellular Ca2+-cycling is enhanced 
leading to an increased SR Ca2+-uptake and SR Ca2+-load. This, in turn, gives rise to an enhanced Ca2+-induced 
SR Ca2+-release (CICR).
The immunofluorescence studies suggest that this mechanistic difference is related to a dis-
tinct subcellular location of internalized versus overexpressed S100A1. Both experimental 
regimens, endocytosis of extracellularly added S100A1 and intracellular S100A1 overex-
pression led to a 3- to 4-fold increase of intracellular levels of the Ca2+-sensor protein. Be-
cause the increase in intracellular S100A1 is comparable, we can largely rule out that the 
total amount of S100A1 is responsible for the differential effects on cytosolic Ca2+-turnover. 
S100A1 uptake was found to enhance the cytosolic Ca2+-transient amplitude by a marked 
decrease in diastolic [Ca2+]
i
 while systolic [Ca2+]
i
 were mostly unchanged. In contrast, ove-
rexpression of S100A1 enhanced the Ca2+-transient amplitude mainly by a marked increase 
in systolic [Ca2+]
i
 in combination with a slight decrease in diastolic [Ca2+]
i
. The downstream 
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effect of extracellularly added S100A1 on cardiac Ca2+-handling together with the previous-
ly demonstrated cardioprotective effects argue that S100A1 could act as paracrine cardiac 
factor which also acts on other cardiac cells, such as fibroblasts, smooth muscle and endo-
thelial cells. 
Along with a differential Ca2+-handling, we also observed a different location of S100A1 
that was taken up from the extracellular environment compared to overexpressed S100A1. 
The latter is associated with the SR since it colocalized with the SR Ca2+-regulatory proteins 
SERCA2a (Figure 4.8C) and RyR2 (data not shown). These findings are in line with recently 
published data showing Ca2+-dependent co-immunoprecipitation of endogenous S100A1 
protein with RyR2 and SERCA2a in murine and human myocardium (Kiewitz R et al., 2003; 
Most et al., 2003b). Like Kiewitz et al., who were able to show a colocalization of endoge-
nous S100A1 and SERCA2a in neonatal cardiomyocytes from mouse (Kiewitz et al., 2003), 
our data reveal a colocalization in rat neonatal cardiomyocytes. Consistently, when RyR2 
and SERCA2a activities were inhibited in S100A1 overexpressing cells, the amplitude of 
Ca2+-transients display a marked decrease, also diastolic [Ca2+]
i
 are noticeably increased and 
the decay of Ca2+-transients is decelerated (Figure 4.8C). In contrast, inhibitors of SERCA2a 
or RyR2 neither affected the S100A1-induced increase in the Ca2+-transient amplitude nor 
lowered diastolic [Ca2+]
i
 in cardiomyocytes following uptake of extracellular S100A1. Thus, 
enhanced Ca2+-cycling in cardiomyocytes overexpressing S100A1 is presumably based on 
SR Ca2+-cycling. These findings are consistent with previous studies showing that overex-
pressed S100A1 increased both, SR Ca2+-uptake and Ca2+-load as well as Ca2+-release from 
the SR (Most et al., 2001; Most et al., 2003b; Remppis et al., 2002). Since the levels of 
SERCA2a were unaltered, we conclude that overexpressed S100A1 enhances SR Ca2+-load 
by an increased SERCA2a activity rather than protein abundance.
Internalized S100A1 on the other hand, does not co-localize with SR Ca2+-regulatory 
proteins (Figure 4.3) and was also not detected at the sarcolemmal membrane of cardiomy-
ocytes (Most et al., 2003a). Instead, it displays a vesicular-like perinuclear distribution that 
has recently been identified as part of the endosomal compartment (Most et al., 2003a). Con-
sistent with the distinct location of S100A1, Ca2+-handling by S100A1-treated cells appears 
Chapter 4: S100A1 differentially affects cardiac Ca2+-cycling  
96
to be independent of SR Ca2+-regulatory proteins (Figure 4.8B). However, since S100A1 
uptake decreased the SR Ca2+-levels, another mechanism must be affected that accounts for 
an enhanced cytosolic Ca2+-elimination. Accordingly, we measured an accelerated decay of 
the caffeine-induced Ca2+-transient amplitude, which indicates that the enhanced cytosolic 
Ca2+-elimination is likely to involve a trans-sarcolemmal Ca2+-efflux via NCX. In addition, 
inhibition of NCX by switching to sodium/calcium-free medium abolished this effect which 
supports the notion that internalized S100A1 stimulates cytosolic Ca2+-extrusion through the 
NCX forward-mode rather than through the slow Ca2+-removal systems such as the plasma 
membrane Ca2+-ATPase (PMCA) and the mitochondrial uniporter (Bassani et al., 1994). Si-
milar effects were seen in S100A1-treated field-stimulated cardiomyocytes in the presence 
of the specific NCX inhibitor myr-FRCRCFa. The inhibitory cell-permeable hexapeptide 
abolished the S100A1-mediated decrease in diastolic [Ca2+]
i
. Based on these results, we 
propose a mechanism where endocytosed S100A1 decreases diastolic [Ca2+]
i
 by activating 
sarcolemmal Ca2+-extrusion via NCX. 
Since endocytosed S100A1 was not present at the sarcolemmal membrane, the questi-
on arose, how an increased S100A1 protein level confined to the endosomal compartment 
could trigger NCX activity. However, it has been shown that PKC and PLC play a role in 
the regulation of NCX in neonatal cardiomyocytes (Iwamoto et al., 1996). Moreover, we 
have demonstrated that internalized S100A1 activates the ERK1/2 signaling pathway th-
rough activation of PLC and PKC (Most et al., 2003a). These findings and our Ca2+-transient 
measurements in the presence of specific inhibitors of PLC and PKC prompted us to suggest 
that a S100A1-mediated activation of NCX forward mode might occur through the PLC and 
PKC signalling pathway. 
In conclusion, our data indicates that the enhanced Ca2+-cycling observed in S100A1 
overexpressing cardiomyocytes predominantly involves SR Ca2+-fluxes (Figure 4.8C), whe-
reas endocytosed S100A1 apparently alters intracellular Ca2+-turnover through sarcolemmal 
modulation (Figure 4.8B). According to the model, accumulation of internalized S100A1 in 
the endosomal compartment somehow triggers endosome-associated PLC and PKC, which 
then activate NCX to increase sarcolemmal Ca2+-efflux.
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This study provides the first insight into the mechanisms through which S100A1 differen-
tially modulates sarcolemmal and sarcoplasmic Ca2+-handling in ventricular cardiomyocytes 
depending on the subcellular location of this protein. Endosomal S100A1 protein appears to 
modulate Ca2+-cycling through an enhanced NCX forward-mode activity, whereas cytosolic 
S100A1 increases Ca2+-cycling by enhancing SR Ca2+-fluxes. The latter is likely to underlie 
the positive inotropic and lusitropic effects seen in S100A1 overexpressing myocardium 
(Most et al., 2001; Most et al., 2003b; Remppis et al., 2002; Remppis et al., 2004). In ad-
dition, we have very recently shown that cardiac adenoviral S100A1 gene delivery rescues 
failing myocardium in vitro and in vivo (Most et al., 2004), which warrants further studies 
on the impact of decreased diastolic [Ca2+]
 
 and SR Ca2+-load resulting from S100A1 endo-
cytosis on cardiac function in vivo.
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5.1 Abstract
    S100A1, a Ca2+-sensing protein of the EF-hand family that is predominantly expressed 
in cardiac muscle plays a pivotal role in cardiac contractility in vitro and in vivo. It has re-
cently been demonstrated that by restoring Ca2+-homoestasis, S100A1 was able to rescue 
contractile dysfunction in failing rat hearts. Myocardial contractility is not only regulated by 
Ca2+-homoestasis, but also by the energy metabolism, in particular the production of ATP. 
Here we report a novel interaction of S100A1 with the mitochondrial F
1
-ATPase, which 
affects F
1
-ATPase activity and cellular ATP production. In particular, cardiomyocytes that 
overexpress S100A1 exhibited a higher ATP content than control cells, whereas knockdown 
of S100A1 expression decreased ATP levels. In pulldown experiments, we identified the α- 
and β-chain of F
1
-ATPase to interact with S100A1 in a Ca2+-dependent manner. The interac-
tion was confirmed by colocalization studies of S100A1 and F
1
-ATPase and the analysis of 
the S100A1-F
1
-ATPase complex by gel filtration chromatography. The functional impact of 
this association is highlighted by an S100A1-mediated increase of F
1
-ATPase activity. Con-
sistently, ATP-synthase activity is reduced in cardiomyocytes from S100A1 knockout mice. 
Our data indicate that S100A1 might play a key role in cardiac energy metabolism.
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5.2 Introduction
S100 proteins are a family of soluble, EF-hand Ca2+-binding proteins, which exhibit a remar-
kable cell- and tissue-specific expression pattern. They are involved in numerous intracel-
lular activities such as cell proliferation and differentiation or the dynamics of cytoskeletal 
constituents (reviewed in references 4, 9 and 30). The most abundant S100 protein in the 
heart is S100A1 (12; reviewed in reference 4). It has been recognized recently as a positive 
inotropic intracellular regulator of cardiac as well as skeletal muscle Ca2+-homeostasis and 
contractility (15, 16, 18, 19, 20). Accordingly, S100A1-deficient mice exhibited an impaired 
cardiac contractility response to hemodynamic stress (5). Notably, the absence of S100A1 
significantly accelerates the development of contractile dysfunction after myocardial infarc-
tion with a rapid onset of cardiac remodeling and transition to heart failure combined with 
excessive mortality (21). Normal contractile function and Ca2+-homeostasis, on the other 
hand, could be restored in failing myocardium in postinfarcted rat hearts by S100A1 gene 
delivery (19). 
     In addition to Ca2+-homeostasis, myocardial workload depends on cardiac metabolism. 
As the energy demand changes, the flux through the mitochondrial ATP-synthase (F
1
F
o
-AT-
Pase), which is responsible for the bulk of ATP synthesis in the myocardium must change so 
that ATP-synthesis matches ATP consumption (reviewed in references 6 and 10). To sustain 
cardiac function in all possible situations there has to be a strict correlation between energy 
production, energy transfer and energy utilization (reviewed in reference 29). In this regard, 
Ca2+ has emerged as a major factor for adapting mitochondrial ATP production to the con-
stantly varying energy demand of the cell. Consistently, several studies provided evidence 
that F
1
F
o
-ATPase dependent ATP synthesis correlates with Ca2+ levels in heart cells (review-
ed in reference 1). Furthermore, metabolic pathway abnormalities that result in an imbalance 
of several metabolic reactions, for example, a decreased PCr (phosphocreatine)/ATP ratio 
indicative of an increase in ADP, an alteration of oxidative phosphorylation or a decreased 
ATP/ADP ratio, lead to abnormal contraction and relaxation and eventually result in the fai-
ling of the heart. Thus, it is conceivable that energy starvation may contribute to heart failure 
(reviewed in reference 11).
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Because S100A1 is able to restore a reduced PCr/ATP ratio and Ca2+-homeostasis in failing 
cardiomyocytes (19), we examined whether S100A1 has an influence on cardiac energy 
homeostasis in neonatal rat ventricular cardiomyocytes (NVCMs). Here, we demonstrate 
a Ca2+-dependent interaction of S100A1 with the α- and β-chain of the F
1
-ATPase in NV-
CMs and isolated mitochondria. Moreover, this interaction is consolidated by colocalization 
in immunofluorescence and immunoelectron microscopy studies, and the isolation of an 
S100A1-F
1
-ATPase complex by gel filtration chromatography. Furthermore, the physiologi-
cal significance of S100A1 in energy metabolism is validated through the effects of S100A1 
overexpression and knockdown on ATP production in NVCMs and its influence on F
1
-AT-
Pase activity.
Based on the data presented, a new role for S100A1 in cardiac energy metabolism emerges. 
5.3 Materials and Methods
Reagents 
ATP (disodium salt), phosphoenolpyruvate, NADH, pyruvate kinase, lactate dehydrogenase 
and isoproterenol were purchased from Sigma. 
Generation of S100A1 adenovirus
The generation of an S100A1 adenovirus (AdS100A1) by the pAdTrack-CMV/pAdEasy-
1 system has been described elsewhere (15). To facilitate identification of infected cells, 
AdS100A1 carried the green fluorescent protein reporter gene (GFP) in addition to the hu-
man S100A1 cDNA (accession number X58079). Each transgene was independently ex-
pressed under the control of a cytomegalovirus promotor sequence. To rule out the possi-
bility that the infection procedure itself had an effect on the amount of S100A1 in the cell, 
cells were infected with a corresponding adenovirus carrying GFP cDNA alone as a control 
(Adcontrol). tested by plaque assay. 
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Isolation and primary culture of ventricular cardiomyocytes from neonatal rats (NV-
CMs) and adult mice
Ventricular cardiomyocytes from 1-2 day old neonatal hearts (NVCMs) were isolated as 
published in detail elsewhere (17). NVCMs were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with penicillin/streptomycin (100 units/ml), L-glutamine 
(2 mM), and 1% fetal calf serum (FCS Gold; PAA Laboratories GmbH; DFCS) at 37°C in a 
95% air/5% CO
2
 humidified atmosphere for 2-3 days. Adenoviral infection of NVCMs was 
carried out in serum-free M199 medium with a multiplicity of infection (MOI) of 8 plaque 
forming units (pfu) per cell. After 4 hours of incubation at 37°C, M199 medium was chan-
ged to DFCS. Efficiency of adenoviral gene transfer was monitored 24 hours later by GFP 
fluorescence. Accordingly, approximately 95% of NVCMs were infected. 
S100A1-deficient (SKO) mice have been previously described (5). Adult ventricular cardi-
omyocytes from C57/Bl6 wild type (WT) and SKO mice (2-3 months of age) were enzy-
matically isolated using a pressure and temperature controlled retrograde coronary perfusi-
on protocol as reported elsewhere (24). Subsequently, WT and SKO cardiomyocytes were 
pelleted and sonicated in ice-cold EGTA-buffered sonication solution (20 mM HEPES, 1.0 
MgCl
2
, 2.0 mM EGTA, pH 7.2) with a free [Ca2+] of 0.2 mM. Samples were kept on ice until 
measurements. Free [Ca2+] was calculated applying the program REACT.
S100A1 RNA interference 
Custom-designed synthetic S100A1 siRNA and negative control (scrambled) siRNA were 
purchased from Eurogentec (Seraing, Belgium). S100A1 siRNA is target-specific 20-25 nt 
siRNA to knockdown gene expression of S100A1 in NVCM’s (sense: 5’-UGG-AGA-CCC-
UCA-UCA-AUG-UdTdT-3’, antisense: 5’-ACA-UUG-AUG-AGG-GUC-UCC-AdTdT-3’). 
NVCM were transfected with S100A1 and control siRNA (100nM) oligonucleotides using 
Effectene Transfection Reagent according to the manufature’s instructions (Qiagen Inc, Va-
lencia, CA, USA). After incubation at 37°C for 24h, cells were lysed and subjected to Wes-
tern blotting.
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Indirect immunofluorescence
Immunofluoresence labeling of NVCMs was carried out as previously described (17). Fres-
hly isolated NVCMs were cultured for 2 days on glass coverslips and incubated with the 
fluorescent dye MitoTracker Red (1 µM; Molecular Probes) for 30 min. Cells were fixed, 
permeabilized and labeled with a monoclonal anti-S100A1 (diluted 1:200; Sigma) and a 
polyclonal F
1
-ATPase antibody (diluted 1:400). The latter was a kind gift from Dr. Pfan-
ner (Institute for Biochemistry and Molecular Biology, Freiburg, Germany). The secondary 
antibodies used were ALEXA Fluor 488-conjugated anti mouse Ig (diluted 1:800; Alexis) 
and Cy5-conjugated anti rabbit Ig (diluted 1:400; Jackson Immuno Research Lab). Confo-
cal images (CLSM) were obtained using a 100x oil objective lens on a Leica TCS SP laser 
scanning confocal microscope. Digitized confocal images were processed by Leica software 
and Adobe Photoshop.
Immunoelectron microscopy
Isolated mitochondria and pieces of heart tissue from 3-day old neonatal rats were fixed as 
previously described (25). Ultrathin sections were cut and mounted on carbon/parlodion-
coated copper grids. Specimens were blocked with 2% BSA in PBS two times 5 min prior to 
incubation with S100A1 antibody (diluted 1:100, Sigma) for 2 hours at room temperature. 
Grids were washed in PBS, blocked in 2% BSA in PBS for two times 5 min, and then incu-
bated with 10 nm gold conjugated goat anti-mouse secondary antibody (BBInternational) 
for 1 hour at RT.
For double immuno-labeling, sections were sequentially incubated with the primary antibo-
dies and the corresponding gold conjugated secondary antibody (10 nm and 5 nm, respec-
tively) for 2 hours at room temperature (RT). After washing in PBS and water, grids were 
stained with a mixture of 6% uranyl acetate for 1 hour, rinsed with water and then post-stai-
ned for two min with lead-citrate. Electron micrographs were recorded on a Hitachi 7000 at 
80 kV.
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Isolation of mitochondria:
Mitochondria were isolated from the hearts of adult male rats by differential centrifugation 
steps as described previously (3). Briefly, minced heart tissue was homogenized with appro-
ximately 10 ml/g tissue homogenization buffer (0.1 M KCl, 0.05 M MOPS, 5 mM MgSO
4
, 1 
mM EDTA, 1 mM ATP, 0.2% BSA, pH 7.4) using a Teflon-glass homogenizer with a loose 
fitting piston. The homogenate was centrifuged at 300 g at 4°C for 10 min. The supernatant 
was poured through a double layered cheese cloth and centrifuged again at 5,000 g at 4°C 
for 10 min. Pelleted mitochondria were resuspended in 1 ml homogenization buffer and 
centrifuged again at 5,000 g at 4°C for 10 min. The pellet was resuspended in 0.15 ml KME 
buffer (0.1 M KCl, 0.05 M MOPS, 0.5 mM EGTA, pH7.4). The protein concentration in the 
mitochondrial suspension was determined by the Bradford method (Sigma) using bovine 
albumin Fraction V as a standard. 
Purification of F
1
-ATPase/S100A1-F
1
-ATPase complex and F
1
-ATPase activity
Purification of the bovine F
1
-ATPase was carried out as previously described (22). The 
S100A1-F
1
-ATPase complex was prepared as follows: purified F
1
-ATPase (15 mg), stored as 
an ammonium sulfate precipitate, was collected by centrifugation (16,000 g), re-dissolved 
in complex buffer (CB: 20 mM TRIS, pH 7.4; 100 mM NaCl, 1 mM MgCl
2
, 2 mM CaCl
2
) 
and desalted on a Micro Bio-Spin column (Amersham Pharmacia Biotech). The enzyme was 
then mixed with a 12.5-fold molar excess of S100A1 over F
1
-ATPase and incubated for 30 
min at 37°C. 1 mM MgATP was added at 1 and 15 min to yield a final concentration of 2 
mM. ATPase activity was measured at 37°C with an ATP-regenerating system as reported by 
following the oxidation of NADH to NAD+ at 340 nm in a Hewlett Packard spectrophoto-
meter (2). The assay was carried out in 1 ml assay buffer (50 mM Tris, pH 7.4, 50 mM KCl, 
2 mM MgCl
2
) containing 2 mM ATP, 2 mM phosphoenolpyruvate, 0.4 mM NADH, 12.5U 
pyruvate kinase, 12.5U lactate dehydrogenase. The reaction was started by adding 10 ml of 
F
1
-ATPase or the S100A1-F
1
-ATPase complex in the presence of 2 mM or 0.2 mM CaCl
2
. 
The decline of NADH absorbance at 340 nm allows monitoring the rate of ATP hydrolysis 
(OD/min).
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Determination of mitochondrial ATP-synthase activity 
The enzymatic activity of the mitochondrial ATP-synthase complex was measured using a 
spectrophotometric assay as described elsewhere with minor modifactions (7). Briefly, ali-
quots of cardiomyocyte homogenates from adult WT and SKO mice were added to EGTA-
buffered activity solution (mM: 60 sucrose, 50 triethanolamine-HCl, 50 KCl, 4 MgCl
2
, 2 
ATP, 1.5 phosphoenolpyruvate, 2 EGTA, 1 KCN, 0.001 thapsigargin, pH 7.4 with KOH) 
supplemented with 200 mM NADH, 5 U pyruvate kinase and 5 U lactate dehydrogenase. 
Thapsigargin was used to block activity of the Ca2+-sensitive sarcoplasmic reticulum Ca2+-
ATPase. Free [Ca2+] were adjusted either to 0.2 mM or 0.2 mM determined by the program 
REACT. The conversion of NADH to NAD+ was followed spectrophotometrically at 340 nm 
at 37°C for 3 min. Recombinant human S100A1 protein was added 10 min prior to measure-
ment as indicated. Oligomycin (10 mg/ml) was used to block the mitochondrial ATP-syntha-
se. Mitochondrial ATP-synthase activity was calculated as the difference between total and 
oligomycin-insensitive conversion of NADH to NAD+.
      
Gel filtration chromatography
Upon preparation of the S100A1-F
1
-ATPase complex as described above, it was chroma-
tographed at RT at a flow rate of 0.3 ml/min on a HiLoad Superdex 200 column that was 
pre-equilibrated in CB. The absorbance of the eluant was monitored at 280 nm. Individual 
fractions (0.3 ml) were analyzed by SDS-PAGE.
Measurement of ATP production
The ATP content of NVCMs was determined by the luciferin-luciferase system according to 
the manufacturer’s protocol (ATP Bioluminescence Assa KIT HS II, Roche).
Recombinant proteins
A human S100A1 cDNA (accession number X58079) was subcloned into the expression 
vector pGEX-6P1 containing glutathione S-transferase (GST) cDNA. S100A1 was produ-
ced as a fusion protein with a 26 kDa glutathione S-transferase (GST) at the NH2-terminus 
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(GST-S100A1) by an isopropylthiogalactosid (IPTG)-driven expression system in E. coli. 
The fusion protein was purified using glutathione-Sepharose 4B (Amersham Pharmacia Bi-
otech) and dialyzed against PBS.
 The GST fusion constructs of palpha3 and pbeta1 were generated by PCR overlap exten-
sion using cDNAs of the α- and β-chain of mitochondrial bovine heart F
1
-ATPase (palpha3 
and pbeta1). The two external primers for the palpha3 construct used were the following: 5’-
EcoRI primer 5’-GAATTCCAGAAACCGGCACT, and 3’-XhoI primer 5’-CTCGAGAG-
CTTC AAATCCAGC. The PCR product was digested with EcoR and XhoI and inserted into 
the pGEX-6P1 vector at the corresponing restriction sites. For the GST-pbeta1 expression 
construct the two external primers were the following: 5’-Sal1 primer 5’-CGGTCGACT-
CATGGCCGCTCAAGCATCTCC and 3’-Not1 primer 3’-CCCGCCGGCCGCTCAT-
GAGTGCTCTTCAGCCAAC. The PCR product was digested with Sal1 and Not1 and in-
serted into the pGEX-6P1 vector at the respective sites. GST-fusion proteins of the a-chain 
and b-chain of the F
1
-ATPase were expressed and purified as described for GST-S100A1. 
 A recombinant human S100A1 cDNA (accession number X58079) was also subcloned 
into the expression vector pHis-TRX-1 containing a thrombin cleavage side. S100A1 was 
produced as a fusion protein with a histidine tag at the NH2-terminus by an isopropylthi-
ogalactosid (IPTG)-driven expression system in E. coli. The fusion protein was purified 
using a HiTrap Chelating HP column (Amersham Pharmacia Biotech) according to the 
manufacturer’s protocol. Subsequently, the histidine-tag was removed by thrombin cleavage 
and purified S100A1 was dialysed against 25 mM Tris, pH 7.45.
GST pull-down assays
0.02 mg/ml GST-fusion proteins (GST-S100A1, GST-α-F
1
-ATPase, GST-β-F
1
-ATPase) or 
GST alone were bound to glutathione S-Sepharose slurries in an incubation buffer (IB2: 100 
mM NaCl, 20 mM Tris, pH 7.4, 0.05% Triton X-100, containing 2 mM CaCl
2
, 0.2 mM CaCl
2
 
or 2 mM EDTA) for 1.5 hours at 4°C. Isolated neonatal rat cardiomyocytes (5x106 cells) 
and 1 mg/ml isolated heart mitochondria were homogenized in a homogenization buffer 
(100 mM NaCl, 20 mM Tris, pH7.4, 1 mM MgCl
2
, 1 mM PMSF, 1 µl DNAse, 0.2% Triton 
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X-100, supplemeted with a Mini complete EDTA free protease inhibitor tablet, Roche) con-
taining either 2 mM CaCl
2
, 0.2 mM CaCl
2
 or 2 mM EGTA. Homogenates of neonatal car-
diomyocytes, isolated mitochondria, and recombinant S100A1 (1 mM) were incubated with 
GST-S100A1, GST-α-F
1
-ATPase, GST-β-F
1
-ATPase or GST slurries for 2.5 hours at 4°C. 
Incubation of purified F
1
-ATPase with GST-S100A1 or GST slurries was carried out at RT 
for 1 hour. Mixtures were washed 6 times with IB2, applied to spin columns, and centrifuged 
at 400 g for 1 min. The columns were spin-washed twice with IB2. Unbound protein was re-
moved by spin-wash steps for 3 min at 2,300 g. Bound proteins were eluted with SDS-PAGE 
sample buffer (5% SDS) and analyzed by SDS-PAGE and mass spectrometry. 
Mass spectrometry analysis
For mass spectrometry, gel slices were excised from silver stained SDS-PAGE gels and di-
gested with 0.25 mg trypsin (Promega) in 50 mM ammonium bicarbonate (pH 8.0) at 37°C 
for 16 h. The resulting peptides were analysed by capillary liquid chromatography (LC/MS/
MS) using a Magic C18 100 mm x 10 cm HPLC column (Spectronex) connected to a Finnig-
an TSQ7000 tandem mass spectrometer (ThermoFinnigan). A linear gradient from 2 to 75% 
B (0.1% acetic acid and 80% (v/v) acetonitril in water) in A (0.1% acetic acid in water) was 
generated with a Rheos 2000 HPLC system (Flux) at 100 ml/min. A precolumn flow splitter 
reduced the flow to approximately 500 nl/min. The eluting peptides were ionized by elec-
trospray ionization, detected, and the peptides were automatically selected and fragmented 
by collision-induced dissociation (MS/MS). Individual MS/MS spectra were searched in the 
data bank using the Mascot software (www.matrixscience.com).
Western blotting
To reveal the presence of S100A1 in the SDS-PAGE separated protein mixtures of pulldown 
experiments, standard Western blotting using a specific polyclonal anti-S100A1 antibody 
(SA 5632, diluted 1:10,000; Eurogentec) was performed. Blots were developed with the 
Avidix chemiluminescence detection system (Tropix, Applied Biosystems). To detect the 
presence of S100A1 on the SDS-PAGE separated protein mixtures of siRNA experiments, 
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standard Western blotting using an epitope affinity purified anti-S100A1 antibody (SP5355P, 
diluted 1:5000; Acris) were performed (19). Proteins were visualized with a LI-COR infra-
red imager (Odyssey), and quantitative densitometric analysis was performed by applying 
the Odyssey version 1.2 infrared imaging software. Signals were normalized to CSQ densi-
tometric levels that were not different between groups. 
Statistical analyses
Data are presented as mean ± SEM. Unpaired student´s t-test and a two-way repeated ANO-
VA analysis was performed to test for differences between groups. A value of P < 0.01 was 
accepted as statistically significant.
5.4 Results
S100A1 enhances ATP production in neonatal rat cardiomyocytes 
To examine the effects of an increased S100A1 protein level on the ATP production in ne-
onatal rat ventricular cardiomyocytes (NVCMs), cells were transduced by means of an 
adenoviral construct that independently drives the expression of human S100A1 and GFP 
(AdS100A1). As a control, NVCMs were infected with a corresponding adenovirus carrying 
only GFP cDNA (Adcontrol). Twenty-four hours postinfection, AdS100A1, Adcontrol and 
non-transfected (NT) cells were processed for ATP quantification using a luciferase based 
luminometry reaction. 
Figure 5.1: S100A1 raises the ATP content in neonatal cardiomyocytes.
(A) In resting cardiomyocytes, adenovirus-mediated S100A1 overexpression (AdS100A1) leads to a signi-
ficantly higher ATP content (nM/mg protein) than in control transfectants (Adcontrol) and non-transfected 
(NT) cells. Upon electrical stimulation (1 Hz), AdS100A1 cells are able to increase ATP levels to a greater 
extent than Adcontrol and NT cells. Data are given as mean ± S.E.M. of five different experiments. 
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Under resting conditions (without electrical stimulation), the amount of ATP was raised by 
~67% in AdS100A1 cells compared to control cells expressing endogenous S100A1 only 
(Fig. 5.1; Adcontrol and NT cells). In response to electrical stimulation at 1Hz, the ATP 
production was increased by ~110% in cells overexpressing S100A1. This data suggests that 
S100A1 is involved in the regulation of the energy metabolism in NVCMs.
Calcium-dependent interaction of S100A1 with mitochondrial proteins
To identify possible target proteins of S100A1 implicated in the ATP increase observed in 
S100A1 overexpressing cells, we performed GST-S100A1 pulldown assays with different 
heart homogenates in the presence of 2 mM CaCl
2
 or 2 mM EGTA (Fig. 5.2). Silver-stained 
protein bands that were specific to GST-S100A1 pulldown assays in the presence of 2 mM 
CaCl
2
 were analyzed by mass spectrometry. In homogenates of isolated NVCMs (Fig. 5.2A), 
five different mitochondrial proteins, hydroxyl-Coenzyme A dehydrogenase (1), the α-chain 
of F
1
-ATPase (2), isocitrate dehydrogenase 2 (3), annexin V (4) and adenine nucleotide 
translocase (5), were identified as potential binding partners of S100A1. The corresponding 
proteins were also pulled down from adult rat heart homogenates (data not shown).
Figure 5.2: GST-S100A1 pulldown as-
says with different homogenates
Protein eluates from different GST-
S100A1 pulldown assays were separa-
ted on denaturing SDS-polyacrylamide 
gels and individual proteins identified 
by mass spectrometry. (A) Five mito-
chondrial proteins from a homogenate of 
NVCMs that interact with GST-S100A1 
were identified: hydroxyl-Coenzyme A 
dehydrogenase (1), α-chain of F
1
-AT-
Pase (2), isocitrate dehydrogenase 2 (3), 
annexin V (4) and adenine nucleotide 
translocase (5). (B) Similar proteins were 
pulled down from isolated mitochondria 
by GST-S100A1 in the presence of 2 mM 
CaCl
2
. In addition, the β-chain of the F
1
-
ATPase (2a) and the hydroxyacyl dehy-
drogenase (6) were identified. The band 
representing GST-S100A1 is indicated 
by an arrowhead.
To substantiate the finding that S100A1 interacts with a number of mitochondrial proteins, 
we isolated mitochondria from adult rat hearts and prepared corresponding mitochondrial 
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extracts for pulldown assays with GST-S100A1 (Fig. 5.2B). Analyses by mass spectrometry 
revealed that the same S100A1-interacting proteins were identified in isolated mitochondria 
as were detected in isolated NVCMs. In addition, the β-chain of the F
1
-ATPase (2a) was 
identified in mitochondrial extracts.
S100A1 colocalizes with the F
1
-ATPase in mitochondria
We used immunofluorescence and immunoelectron microscopy to probe the cellular dis-
tribution of S100A1 and its association with the F
1
-ATPase in situ. Indirect immunofluo-
rescence labeling of NVCMs with an S100A1 antibody revealed a punctate distribution of 
S100A1 (green) throughout the cytoplasm (Fig. 5.3A and D) and to a lesser extent in the 
nucleus. Because NVCMs were incubated in parallel with MitoTracker Red, mitochondria 
(red) could be identified as ‘bullet-shaped’ structures (Fig. 5.3B). Merging the two confocal 
images revealed a partial colocalization of S100A1 with mitochondria (Fig. 5.3C, yellow). 
Figure 5.3: S100A1 is present in mitochondria where it colocalizes with the F
1
-ATPase
(A and D) S100A1 is labeled with a monoclonal S100A1/Alexa488-mouse antibody in NVCMs (green). (B) 
Mitochondria are recognized by MitoTracker Red uptake (red). (C) Overlay of panels (A) and (B) reveals a 
partial colocalization of S100A1 with mitochondria (yellow). (E) F
1
-ATPase labeled with a polyclonal F
1
-AT-
Pase/Cy5-anti-rabbit antibody (blue). (F) Superposition of panels (D) and (E) reveals a partial colocalization of 
S100A1 and F
1
-ATPase (turquoise). Bar, 10 mm. (G) Ultrastructural colocalization of S100A1 and F
1
-ATPase 
in mitochondria from neonatal rat heart revealed by double immunogold staining. Electron micrograph depicts 
colocalization of S100A1 and F
1
-ATPase as indicated by 10 nm and 5 nm gold particles that are less than 30 
nm apart (marked as red circles). Bar, 150 nm
To analyze the interaction of S100A1 and F
1
-ATPase at the subcellular level, we perfor-
med double-immunolabeling experiments of NVCMs with a monoclonal antibody against 
S100A1 and a polyclonal antibody that reacts with all 5 subunits of the F
1
-ATPase. As 
Chapter 5: S100A1 interacts with F
1
-ATPase
114
illustrated in Fig. 5.3E, the F
1
-ATPase antibody typically revealed ‘bullet- shaped’ structures 
(blue), which were similar to mitochondria stained by MitoTracker. Merging the respective 
confocal images (Fig. 5.3D and E) clearly showed that S100A1 partially localized to the 
same confocal volume as the F
1
-ATPase (Fig. 5.3F, turquoise).
To obtain more detailed information on this colocalization, we used double immunogold 
labeling of S100A1 and F
1
-ATPase on ultrathin sections of a 3-day old neonatal rat heart. As 
indicated by the red circles in the electron micrograph displayed in Fig. 5.3G, we observed 
numerous cases where 10 nm gold particles (S100A1) and 5 nm gold particles (F
1
-ATPase) 
appeared in close proximity. Taking the dimensions of the two antibody complexes into 
account, a spacing of approximately 30 nm between 10 nm and 5 nm gold particles is indi-
cative of a physical interaction between the two binding sites. In conclusion, these immuno-
localization studies substantiated the localization of S100A1 in mitochondria and its direct 
interaction with the F
1
-ATPase.
The interaction of S100A1 with the α-and β-chain of the F
1
-ATPase depends on calcium 
and pH
To confirm the direct interaction of S100A1 with the α- and β-chain of the F
1
-ATPase, we 
performed reverse pulldown assays. For this purpose, recombinant GST-α-chain, GST-β-
chain fusion proteins or GST alone were coupled to glutathione-Sepharose beads in the 
presence of 2 mM CaCl
2
, 0.2 mM CaCl
2
 or 2 mM EGTA and subsequently incubated with 
recombinant S100A1 protein. Bound protein was eluted and analyzed by SDS-PAGE and 
Western-blotting using an S100A1 antibody (Fig. 5.4A). 
In the presence of 2 mM CaCl
2
 and 0.2 mM CaCl
2
, both the GST-α-chain and the GST-β-
chain fusion protein each pulled down two bands with an apparent molecular weight of 10 
and 20 kDa, respectively, which were recognized by the S100A1 antibody. The migration 
behavior of these two bands corresponds to that of the monomeric and dimeric form of re-
combinant S100A1. Both bands were absent when pulldown assays were carried out in the 
presence of EGTA or with GST-control beads. 
Furthermore, when GST-S100A1 pulldown assays with purified bovine heart F
1
-ATPase 
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were performed under different pH conditions, a pH sensitive interaction was observed (Fig. 
5.4B and C). At pH 7.4, the α- and β-chain of F
1
-ATPase were pulled down by GST-S100A1 
in the presence of 2 mM CaCl
2
. However, in the presence of 2 mM EGTA the two respective 
bands were significantly diminished. When the pH was lowered to 6.8, the binding of F
1
-AT-
Pase to GST-S100A1 was barely detectable even in the presence of 2 mM CaCl
2
. In control 
pulldown assays carried out in the presence of 2 mM EGTA or with immobilized GST alone, 
no bands were visible (data not shown). 
These data confirmed that at pH 7.4 there is a direct interaction between S100A1 and the 
α-and β-chains of F
1
-ATPase in the presence of 2 mM or 0.2 mM CaCl
2
. 
Figure 5.4: Pulldown assays indicate an interaction between S100A1 and the F
1
-ATPase
(A) Western blot of eluates of GST-F
1
-ATPase α-and β-chain pulldown assays performed with recombinant 
human S100A1 in the presence of 2 mM CaCl
2
, 0.2 mM CaCl
2
 or 2 mM EGTA. Probing with an anti-human 
S100A1-specific antibody revealed a 10 (monomeric) and 20 kDa (dimeric) S100A1 species which were pulled 
down by GST-F
1
-ATPase α-and β-chain in the presence of 2 mM CaCl
2
 and 0.2 mM CaCl
2
. GST alone (con-
trol) does not pull down S100A1. (B and C) Pulldown assays with GST-S100A1 and purified F
1
-ATPase at 
different pH. (B) At pH 7.4 in the presence of 2 mM CaCl
2
, two bands migrating at approximately 55 and 51 
kDa are detected. Comparison with purified F
1
-ATPase (lane on the right) indicates that these bands represent 
the α-and β-chain subunits. 2 mM EGTA largely abolishes the interaction between GST-S100A1 and the α-and 
β-chain of the F
1
-ATPase. (C) At pH 6.8, F
1
-ATPase subunits are not pulled down by GST-S100A1 even in the 
presence of 2 mM CaCl
2
.
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S100A1 forms a complex with the F
1
-ATPase and increases its activity
To analyze the interaction of S100A1 and the F
1
-ATPase in molecular detail, we isolated 
the S100A1-F
1
-ATPase complex by gel filtration chromatography. For complex formation, 
purified F
1
-ATPase was incubated at pH 7.4 with a 12.5-fold molar excess of S100A1 in the 
presence of 2 mM CaCl
2
 or 2 mM EGTA for 30 min at 37°C. To maintain F
1
-ATPase activity, 
1 mM MgATP was added to the mixture at 1 and 15 min. After incubation, the mixture was 
subjected to gel filtration chromatography on a Superdex 200 HiLoad column and individual 
fractions were analyzed by SDS-PAGE. In the presence of CaCl
2
, two prominent peaks were 
identified in the elution profile (Fig. 5.5A). Based on the apparent molecular masses of the 
proteins that eluted in the first peak (fractions 36-42), this peak contained the five subunits of 
the F
1
-ATPase (α-, β-, γ-, δ-, and ε-chains) and, as suggested by their electrophoretic mobili-
ty, monomeric and dimeric S100A1 (Fig. 5.5A; 10 and 20 kDa bands, respectively, framed in 
black). The presence of S100A1 was confirmed by Western blotting using an S100A1-spe-
cific antibody and by mass spectrometry (data not shown). The elution profile of peak I also 
displayed a small shoulder (fractions 40-42) that possibly represents aggregation products of 
S100A1 and F
1
-ATPase subunits. SDS-PAGE of the second, smaller peak (fractions 50-54) 
contained predominantly free S100A1 mono- and dimmers and only traces of the F
1
-ATPase 
subunits.
In the presence of 2 mM EGTA, gel filtration chromatography of the S100A1-F
1
-ATPase 
complex (Fig. 5.5B) produced an elution profile that was clearly distinct from that obtai-
ned with 2 mM CaCl
2
. SDS-PAGE analysis of the first peak (fractions 36-40) revealed the 
five subunits of the F
1
-ATPase but no monomeric or dimeric S100A1 protein (black fra-
mes). S100A1 only eluted in fractions corresponding to the second peak (fractions 49-53). 
This peak, which predominantly contains the free S100A1, was increased by approximately 
150% compared to the corresponding peak obtained in the presence of 2 mM CaCl
2
 (Fig. 
5.5A, peak II). Together, the data indicate that S100A1 forms a complex with the F
1
-ATPase 
in the presence of calcium at pH 7.4.
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Figure 5.5. Gel filtration chromatography of the S100A1-F
1
-ATPase complex and determination of the 
F
1
-ATPase activity
(A) Analysis of the S100A1-F
1
-ATPase complex in the presence of 2 mM CaCl
2
. The absorbance of the eluant 
was monitored at 280 nm. The elution profile shows two major peaks of different height. Analysis of individual 
column fractions (X axis) on a 12-22% gradient SDS-PAGE gel reveals that peak I (fractions 36-42) contains 
the 5 subunits of the F
1
-ATPase, as well as S100A1 in form of a dimer and monomer (framed in black). Peak II 
(fractions 50-54) comprises the excess of recombinant S100A1. Only residual amounts of the F
1
-ATPase subu-
nits are detected in this peak. (B) In the presence of 2 mM EGTA, the elution profile of the S100A1-F
1
-ATPase 
complex displays two symmetric peaks of comparable height. The 5 subunits of the F
1
-ATPase are eluted in 
peak I (column fractions 36-40) whereas S100A1 protein appears only in peak II in form of a monomer and 
dimer (fractions 49-53). S100A1 monomer is indicated by an arrowhead. (C) S100A1 increases F
1
-ATPase 
activity. F
1
-ATPase activity was measured with an ATP-regenerating system by following the oxidation of 
NADH to NAD+ at 340 nm in the presence of either 2 mM or 0.2 mM calcium. Results are reported as relative 
change of F
1
-ATPase activity in the presence of 1 mM S100A1 compare to control (F
1
-ATPase alone). Data are 
represented as mean ± S.E.M. of 25 experiments. P<0.01, indicated by asterisks.10 µm.
To determine the functional effects resulting from the interaction of S100A1 with the F
1
-
ATPase we measured the activity of isolated F
1
-ATPase incubated with S100A1 (Fig. 5.5C). 
Accordingly, S100A1 caused an ~18% increase of the F
1
-ATPase activity in the presence of 
2 mM CaCl
2
 and a ~28% increase in the presence of 0.2 mM CaCl
2
. 
In conclusion, these studies substantiate the direct interaction of S100A1 with the F
1
-ATPase 
and its effects on the F
1
-ATPase activity. 
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S100A1 protein levels affect ATP-synthase activity, ATP content and Ca2+-transient 
amplitudes in cardiomyocytes
To address the functional significance of an S100A1-F
1
-ATPase interaction in cells, we ex-
amined the consequences of S100A1 knockdown on both ATP-synthase activity and F
1
-AT-
Pase-mediated ATP production in cardiomyocytes. 
To examine the relationship between S100A1 levels and ATP-synthase activity we used 
adult ventricular cardiomyocytes from wild type (WT) and S100A1-deficient (SKO; (5) 
mice. The significantly higher conversion rate of NADH to NAD+ observed in WT compared 
to SKO cardiomyocyte homogenates at 0.2 mM and 0.2 mM free [Ca2+] indicated a higher 
mitochondrial ATP-synthase activity in WT cardiomyocytes (Fig. 5.6A). Because cardiomy-
ocyte homogenates were prepared in Ca2+ buffered solution, which prevented loss of endo-
genous S100A1 protein in WT as confirmed by immunblotting (data not shown), the higher 
ATP-synthase activity could be attributed to S100A1. Consistently, addition of recombinant 
S100A1 protein to SKO cardiomyocyte homogenates significantly increased mitochondrial 
ATP-synthase activity both at 0.2 mM and 0.2 mM free [Ca2+]. 
To analyze the ATP content in cardiomoycytes expressing different S100A1 protein levels, 
NVCMs were transfected with S100A1 small interfering RNA (siRNA) or scrambled con-
trol RNA. Efficient suppression of S100A1 protein by the specific siRNA in transfected 
NVCMs was confirmed by Western blotting (Fig. 5.6B). Parallel NVCM cultures were lysed 
seventy-two hours post transfection, and subsequently ATP levels were assayed by a luci-
ferase based luminometry reaction. As illustrated in Fig. 5.6B, knockdown of S100A1 ex-
pression in unstimulated NVCMs (S100A1 siRNA, basal conditions) caused ATP levels to 
decrease by an average of 48% compared to control cells transfected with scrambled siRNA 
or untransfected NVCMs (NT). Consistent with the notion that S100A1 levels influence ATP 
production, overexpression of S100A1 in NVCMs (Fig. 5.6C; AdS100A1) increased ATP 
levels by 82% compared to control cells expressing endogenous S100A1 (Adcontrol, NT). 
Qualitatively similar results were obtained after stimulation of cells with 1 mM isoprotere-
nol, a beta adrenergic receptor agonist, or 10 mM CaCl
2
: S100A1-deficient NVCMs exhibi-
ted a significantly reduced ATP level (approximately 65% for isoproterenol-treated and 53% 
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for CaCl
2
-treated knockdown NVCMs compared to control cells) whereas overexpression of 
S100A1 consistently led to an enhanced ATP level (approximately 118% for isoproterenol-
treated, and 127% for CaCl
2
-treated AdS100A1 NVCMs compared to control cells). 
Figure 5.6.S100A1 protein levels affect ATP-Synthase activity, ATP content and Ca2+-transient amplitu-
des cardiomyocytes 
(A) Mitochondrial ATP-synthase activity assessed by monitoring conversion of NADH to NAD+ in WT and 
SKO cardiomyocyte homogenates. Compared to WT, mitochondrial ATP-synthase activity is significantly lo-
wer in SKO cardiomyocyte homogenates at 0.2 mM and 0.2 mM free [Ca2+]. Preincubation with S100A1 
protein (0.1 mM) for 10 min restored mitochondrial ATP-synthase activity in SKO cardiomyocyte homogena-
tes at 0.2 mM and 0.2 mM free [Ca2+]. Values are mean±S.E.M. * P < 0.05 vs WT, † P < 0.05 vs SKO. n = 4 
cell preparations, each experiment was carried out in triplicates. (B) Western Blot of S100A1 or calsequestrin 
(CSQ, loading control) of extracts from cells transfected with scrambled or S100A1 siRNA and non-transfec-
ted (NT) cells. (C) Comparison of the ATP content in NT, adenovirus transduced (AdS100A1 and Adcontrol) 
and siRNA-treated cells. Under basal conditions, S100A1 overexpression (AdS100A1) results in a signifi-
cantly higher ATP content compared to control (Adcontrol) and NT cells. In contrast, knockdown of S100A1 
protein (S100A1 siRNA) leads to a significant reduction of ATP compared to control cells (scrambled siRNA). 
Upon isoproterenol stimulation, AdS100A1 cells exhibit a two-fold higher ATP content compared to Adcontrol 
and NT cells whereas S100A1 suppression caused a two-fold reduction of ATP compared to scrambled siR-
NA treated cells. Addition of 10 mM calcium also yields to a two-fold increase of ATP content in AdS100A1 
cells and likewise to a two-fold reduction in S100A1 siRNA cells. (D) Effects of S100A1 protein levels on 
Ca2+-transients. Compared to control cells expressing endogenous levels of S100A1, S100A1 overexpression 
(AdS100A1) significantly increases the Ca2+-transient amplitude under basal conditions as well as when stimu-
lated with isoproterenol or 10 mM calcium. Suppression of S100A1 protein leads to decreased Ca2+-transient 
amplitude. Data are represented as mean ± S.E.M. of five different experiments in (C), and of 150 cells from 
the different cell preparations in (D). P<0.01, indicated by asterisks.
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Furthermore, compared to control or AdS100A1 cells, S100A1-deficient NVCMs were not 
able to respond with an adequate ATP increase after isoproterenol or CaCl
2
 stimulation.
 To examine the effects of reduced and increased levels of S100A1 on Ca2+-cycling, we 
recorded Ca2+-transients in NVCMs under basal and stimulated conditions (Fig. 5.6D). In 
AdS100A1 cells overexpressing S100A1 the increased ATP content was accompanied by 
an increase in the Ca2+-transient amplitudes compared to control cells (approximately 38% 
increase for basal, 35% for isoproterenol-treated, and 47% for CaCl
2
-treated AdS100A1). 
Consistently, suppression of S100A1 protein by S100A1 siRNA led to decreased Ca2+-tran-
sient amplitudes (approximately 14% for basal, 30% for isoproterenol-treated, and 12% for 
CaCl
2
-treated AdS100A1 compared to control cells), concomitant with a reduced ATP pro-
duction.
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5.5 Discussion
S100A1 has recently been recognized to act as a regulator of Ca2+-cycling and contractility 
in the heart (15, 20, 23). However, efficient performance of the myocardium, in particular 
cardiac contractility, is based not only on Ca2+-homeostasis but to a large extent also on ener-
gy metabolism (reviewed in references 6 and 10). Thus, the increase in cardiac contractility 
brought about by S100A1 overexpression strongly argued for a role of S100A1 in energy 
metabolism in addition to its role in Ca2+-cycling. Indeed, we found that the ATP content 
measured in cardiomyocytes overexpressing S100A1 (AdS100A1) was 67% higher in res-
ting AdS100A1 and even 110% higher in electrically stimulated AdS100A1 cells compared 
to control cells. This ATP increase substantiates the notion that S100A1 is involved in the 
regulation of the energy metabolism in cardiomyocytes. 
Pulldown experiments with GST-S100A1 provided the first clues as to the molecular mecha-
nism underlying the increase in ATP induced by S100A1. Interestingly, several mitochond-
rial proteins were pulled down by GST-S100A1, and virtually all of these potential S100A1 
target proteins are involved in the cell’s energy metabolism. In support of our findings, gel 
overlay experiments revealed glycogen phosphorylase and phosphoglucomutase, which, th-
rough their role in glycogenolysis, are also involved in energy production, as potential target 
proteins of S100A1 (31). In addition, S100A1 was shown to interact in a Ca2+-dependent 
manner with fructose-1,6-bisphosphate aldolase, thereby increasing its enzymatic activity 
(32). Fructose-1,6-bisphosphate aldolase is a key regulator of glycolysis and thus essential 
for energy production. Our data provide the first evidence that S100A1 interacts in a Ca2+-
dependent manner with the F
1
-ATPase in heart tissue. F
1
-ATPase is part of the F
1
F
o
-ATPase, 
which is responsible for the ATP synthesis
in the cell. Hence, it is tempting to speculate that the interaction of S100A1 with the F
1
-AT-
Pase is responsible for the increased ATP content in cardiomyocytes overexpressing S100A1. 
At this point, we cannot rule out that any of the other mitochondrial proteins pulled down by 
GST-S100A1, for example the Ca2+-sensitive dehydrogenase isocitrate or the adenine nucle-
otide translocase, could also play a role in regulating the ATP content of the cell.
Because we were able to demonstrate a direct interaction of S100A1 with the α- and β-chain 
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of the F
1
-ATPase by reverse pulldown assays using GST-F
1
-ATPase α- and β-chain as bait 
proteins for recombinant S100A1, we have focused our studies on the S100A1-F
1
-ATPase 
interaction. The specificity of this interaction was corroborated by the Ca2+-dependence and 
pH sensitivity of S100A1 binding to the α- and β-chain of F1-ATPase. The most convincing 
piece of evidence that S100A1 biochemically interacts with the F
1
-ATPase has been provi-
ded by the isolation of a S100A1-F
1
-ATPase-complex by gel filtration chromatography.
For a physical interaction of S100A1 and the F
1
-ATPase to occur in the cell, the spatial pro-
ximity of these proteins is required. While the localization of the F
1
-ATPase in mitochondria 
has been known for quite some years (13), there are only a limited number of studies that re-
port a mitochondrial localization of S100A1. For example, electron microscopy studies have 
shown that S100A1 is present in the mitochondria of mouse slow-twitch fibers (8) as well 
as in mitochondria of the human heart (14). Similarly, our data document the presence of 
S100A1 at the inner and outer mitochondrial membrane, as well as in the matrix of rat heart 
mitochondria. Furthermore, double immunolabeling experiments, both from confocal light 
and electron microscopy studies reveal that S100A1 and the F
1
-ATPase indeed colocalize in 
mitochondria, indicating that a physical interaction between S100A1 and the F
1
-ATPase is 
likely to occur in vivo. 
A first indication of the functional significance of such an interaction has been reported by 
Simonian et al., who showed that S100A1 stimulated the ATPase activity in mitochondria 
isolated from gerbil brain (26). The increased level of ATP we observed in cardiomyocytes 
that overexpress S100A1 extends the notion of a functional interaction between S100A1 
and the F
1
-ATPase. Moreover, the effect of S100A1 knockdown on the ATP level conso-
lidates the association of S100A1 with mitochondrial ATP production. Further evidence is 
provided by the diminished mitochondrial ATPase activity observed in cardiomyocytes from 
S100A1 knockout mice. A direct indication of the influence of S100A1 on the function of 
the F
1
-ATPase is provided by the determination of the F
1
-ATPase activity. Indeed, incubati-
on of S100A1 with isolated F
1
-ATPase causes an 18% increase of the F
1
-ATPase activity in 
the presence of 2 mM CaCl
2
 and a 28% increase at 0.2 mM calcium. The direct impact of 
S100A1 protein on F
1
-ATPase activity is also demonstated by restoring decreased mitochon-
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drial ATP-synthase activity in SKO cardiomyocytes through exogenous S100A1. 
A potential interaction between the Ca2+-binding protein S100A1 and the F
1
-ATPase raises 
the question of how energy production, as well as cardiac work, and Ca2+-homeostasis are 
connected. In their recent work, Ventura-Clapier et al. have suggested that Ca2+ is one of the 
main candidates for coupling energy metabolism and cardiac work (reviewed in reference 
29). Furthermore, work by Territo and Balaban has shown that cytosolic Ca2+ plays an im-
portant role in the regulation of cardiac energy metabolism. Of particular interest is their 
finding that Ca2+ activates several steps in oxidative phosphorylation, including F
1
F
o
-ATPase 
(27, 28; reviewed in reference 1). It has been proposed that Ca2+ as an intermediary may 
concomitantly control both energy metabolism and cardiac work (28). Because S100A1 not 
only improves cardiac Ca2+-handling and heart muscle contractility (19) but also increases 
energy production, we speculate that the Ca2+-sensor might be involved in coupling Ca2+-cy-
cling with Ca2+-dependent regulation of cardiac metabolism. This notion is supported by the 
finding that Ca2+-transient amplitudes and ATP levels were concomitantly increased when 
S100A1 levels were raised, whereas knockdown of S100A1 reduced both ATP levels and 
Ca2+-transient amplitudes. The important question whether improved energy supply is cru-
cial to S100A1 Ca2+-dependent inotropic actions in healthy and diseased myocardium will 
need to be addressed in future studies.   
In conclusion, our data have unveiled a novel role of S100A1 in cardiac metabolism. Und-
oubtedly, a more detailed knowledge of the molecular interaction between F
1
-ATPase and 
S100A1 and also the other mitochondrial target proteins identified by pulldown assays is 
needed to more rationally understand the molecular mechanism by which S100A1 participa-
tes in the cardiac energy metabolism. Elucidation of this molecular mechanism will ultima-
tely provide insight into the failing heart where the cardiac pump is no longer able to meet 
the energy requirements of the body.
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6.1 Extracellular S100A1 inhibits apoptosis in ventricular cardiomyocytes
      via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2)
Growing evidence indicates that members of the S100 protein family exert intracellular but 
also extracellular effects on their target cells (Donato, 2003). Moreover, it has been shown 
that S100A1 protein is released into the extracellular space in considerable amounts during 
ischemic myocardial injury (Kiewitz et al., 2000). This observation prompted us to explore 
the extracellular effect of S100A1 on neonatal ventricular cardiomyocytes (NVCMs).
By directly coupling human recombinant S100A1 protein with rhodamine we were 
able to trace the uptake of extracellulary added S100A1 into the cytosolic compartment of 
cultured NVCMs (Chaper 2). Using confocal laser scanning microscopy, we have shown 
for the first time that S100A1 is internalized by NVCMs via a Ca2+-dependent pathway. The 
colocalization studies documented that the pathway of S100A1 internalization is clathrin-
dependent. By using several inhibitors that are specific for different steps along the intracel-
lular signal transduction pathway, we could identify that S100A1-mediated activation of the 
ERK1/2 signaling involves activation of PLC and PKC, both of which have been closely 
linked to the endosomal compartment. 
Taken together this part of our study demonstrated extracellular S100A1 to act as a 
novel anti-apoptotic factor that enhances survival of neonatal cardiomyocytes in vitro via 
activation of the PLC-PKC-MAP kinase kinase1-ERK1/2 pathway. 
So far, the receptor for S100A1 internalization is still unknown. Previous studies identified 
the cell surface receptor for advanced glycosylated end products (RAGE) as possible recep-
tor for S100 proteins (Hofmann et al., 1999; Huttunen et al., 2000). This was shown for the 
isoforms S100B and S100A12 (Donato, 2003). Because our results suggest that RAGE is 
not involved in the endocytosis of S100A1 in NVCM, we predict that another cell surface 
receptor is responsible for S100A1 uptake in NVCMs (Figure 6.1)
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Figure 6.1: Model of S100A1 interna-
lization and involvement in ERK1/2. 
signaling. The model suggests endocytosis 
of extracellular S100A1 by NVCM via an 
unknown receptor (red). PLC, phospholi-
pase C; PKC, phosphokinase C; MEK1, 
MAPkinase kinase1; ERK1/2, extracellular 
signal-regulated kinase 1/2. 
In future studies we will attempt to identify a possible receptor for S100A1 by employing 
GST-S100A1 fusion protein pull-down assays of plasma membranes. In addition, the cardi-
oprotective effect of internalized S100A1 in vitro warrants further research into the release 
of S100A1 during heart failure. Moreover, our findings should initiate new perspectives on 
the pathophysiological relevance of the cardioprotective effect of S100A1 protein on cardiac 
cells in vivo. 
6.2 Adenoviral-mediated S100A1 gene delivery rescues failing myocard
Since S100A1 protein has been shown to be downregulated in human and animal heart 
failure (HF) model  (Remppis et al., 1996; Tsoporis et al., 2003), we undertook this study 
to address whether S100A1 gene addition might reserve ventricular contractile dysfunction 
in failing myocardium (Chapter 3). Using a postinfarct HF model in the rat, we provided 
evidence that adenoviral-mediated myocardial S100A1 gene delivery can restore S100A1 
protein expression in failing myocardium. As a result of restored S100A1 levels, a normali-
sation of previously dysfunctional intracellular Ca2+- and Na+-handling occured. In additon 
S100A1 expression abolished aberrant fetal gene expression associated with HF, and most 
intringuely restored energy supply in failing myocardium. 
Overall, we have shown for the first time that restoring S100A1 protein expression can 
rescue defective contractile performance of failing myocardium in vitro and in vivo due to 
improved cytosolic and SR (sarcoplasmic reticulum) Ca2+-cycling. This effect is 
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caused by both enhanced activity of SERCA (sarco(endo)plasmic reticulum Ca2+-ATPase) 
and modulation of RyR (ryanodine receptor).
Our studies provide ample vidence that S100A1 is a key-regulator of cardiac function in 
vitro and in vivo. The effects of restored S100A1 protein level in failing myocardium argue 
for a novel clinical approach in the regimen of HF. Athough the study described first results 
on the application of adenoviral S100A1 expression in failing myocardium, there exist also 
limitations and open questions. For instance, we have used a first-generation adenoviral vec-
tor that limits study duration. Thus, we will analyze chronic effects of HF rescue by S100A1 
gene delivery with improved vectors. However, in the future S100A1 HF gene therapy might 
proof to be a promising clinical treatment. 
6.3 Distinct subcellular location of S100A1 differentially modulates Ca2+-cycling in 
      ventricular rat cardiomyocytes
Because S100A1 is a Ca2+-sensor, we investigated the effect of an increasing S100A1 
levels on the cycling of cytosolic Ca2+ in NVCMs by two different procedures: NVCMs were 
either transduced by an adenoviral S100A1-expression construct (AdS100A1) or incuba-
ted with recombinant human S100A1 protein (S100A1-treated) (Chapter 4). Ca2+-transient 
measurements revealed an increase on Ca2+-turnover for both procedures. By using different 
inhibitors of Ca2+-cycling, we have demonstrated that cells overexpressing S100A1 and cells 
treated with S100A1 use different mechanisms to increase the intracellular Ca2+-cycling. 
AdS100A1 cells arrived at an enhanced Ca2+-transient amplitude mainly through an increase 
in systolic [Ca2+]
i
. In contrast, a marked decrease in diastolic Ca2+-concentrations ([Ca2+]
i
) 
was the main cause for the enhanced Ca2+-transient amplitude in S100A1-treated NVCMs. 
The decreased diastolic [Ca2+]
i
 in S100A1-treated cells was likely the result of increased 
sarcolemmal Ca2+-extrusion through the Na+/Ca2+-exchanger (NCX). Moreover, uptake of 
S100A1 into the endosomal compartment triggered endosome-associated PLC and PKC, 
which then activate NCX to increase sarcolemmal Ca2+-efflux.
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The enhanced systolic [Ca2+]
i 
in AdS100A1 cells was brought about by an increased activity 
of RyR and SERCA. Consistently, immunofluorescence documented a colocalization of in-
tracellular overexpressed S100A1 and these two Ca2+-regulatory proteins.
In conclusion, we demonstrated that intracellular S100A1, depending on its subcellular loca-
tion, modulates cardiac Ca2+-turnover via different Ca2+-regulatory proteins.
After having shown that internalized S100A1 has a pro-survival effect on cultured cardi-
omyocytes and that adenoviral S100A1 gene delivery rescues failing myocardium in vitro 
and in vivo (Most et al., 2004), we are now facing the challenge of elucidating the effects of 
internalized S100A1 on cardiac function in vivo.
6.4 The Ca2+-dependent dependent interaction of S100A1 with the F
1
-ATPase leads to    
      an increased ATP content in cardiomyoctes
Reports on the involvement of S100A1 in energy metabolism (Zimmer et al., 1995; Zimmer 
and Dubuisson, 1993), have prompted us to examine the effect of S100A1 overexpression 
on cardiac energy metabolism (Chapter 5). We found that AdS100A1 cells exhibited a sig-
nificantly higher ATP content compared to control cells (Adcontrol). By using GST-S100A1 
fusion protein pull-down assays we were able to identify several mitochondrial proteins, 
which are all involved in energy metabolism. Based on the relationship between S100A1 
and ATP content, we primarily focussed on the interaciton of S100A1 with the F
1
-ATPase. 
Confocal and electron microscopy studies provided further evidence that S100A1 interacts 
with the mitochondrial F
1
-ATPase. Interestingly, several groups have reported the localizati-
on of S100A1 in mitochondria, but so far the functional consequence of this localization has 
not been addressed (Haimoto and Kato, 1988; Maco et al., 2001). In order to fill this gap, we 
dissected the S100A1-F
1
-ATPase complex using different biochemical assays. We found the 
interaction to be dependent on the presence of Ca2+ and on the pH. At physiological pH 
(7.4 ) and in the presence of Ca2+, S100A1 and F
1
-ATPase form a stable complex. 
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For further  structural analysis of the complex, we initialized a collaboration with the labora-
tory of Sir John Walkers in Cambridge. In a first step we have isolated an S100A1-F
1
-ATPase 
complex by gel filtration chromatography. To unravel the molecular interactions of S100A1 
and F
1
-ATPase, we ultimately plan to crystallize the complex.
This part of the projekt  unveiled a novel mechanism of S100A1 on cardiac function. The 
high metabolic demand of the heart requires a close coordination of energy production (ATP) 
and workload (Cortassa et al., 2003). Approximately 2% of the cellular ATP is consumed 
with each heartbeat and almost all of this energy is replenished by mitochondrial oxidative 
phosphorylation under normoxic conditions (Das and Harris, 1991; Harris and Das, 1991). 
The fact that not only the F
1
-ATPase but also other mitochondrial proteins that participate 
oxidative phosphorylation associate with GST-S100A1 in pull-down experiments, convin-
cingly argues for further investigations of these interactions (Figure 6.2). 
Figure 6.2: Schematic model of S100A1 and its target protein. The model demonstrates a cardiac cell and 
the energy metabolism of fatty acids and glucose.Identified target proteins of S100A1 are marked in red. TCA, 
tricarboxylic cycle.
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6.5 Conclusions
The work presented in this thesis provides essential insights into the molecular mechanisms 
of S100A1 on cardiac function.
First it reveals novel mechanisms of S100A1. By combining different localization techni-
ques and biochemical assays, the internalization of S100A1 via a Ca2+-dependent, clathrin-
mediated process was discovered. Moreover, it is shown that internalized S100A1 exhibits 
anti-apoptotic effects on cardiomyocytes and increases Ca2+-turnover. Different molecular 
mechanisms were implicated in Ca2+-handling depending on the localization of the exoge-
nous S100A1. In addition, the rescue of failing myocardium in response to S100A1 gene 
delivery holds promise for a treatment of heart failure by S100A1 gene therapy.  Finally, the 
identification of new target proteins for S100A1 gives rise to new perspectives on the invol-
vement of S100A1 in the energy metabolism.   
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